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Abstract 
 
Density functional theory (DFT) and combined quantum mechanics/molecular 
mechanics (QM/MM) calculations have been used to model inter- and intra-molecular 
non-covalent interactions of transition metal complexes and where applicable their 
interactions with DNA. Two DFT functionals, BHandH and B97-D, which have shown 
to be efficient in modelling systems containing non-covalent interactions, have been 
tested against high level ab initio calculations on test transition metal complexes, 
designed to represent the intermolecular interactions present in the benzene dimer and 
methane benzene systems. The DFT functionals above show good agreement with the 
benchmark calculations and have been used to study ruthenium arene 'piano stool' type 
complexes, of the general form [6(arene)Ru(en)Cl]+, which have shown potential as 
anticancer agents. The intramolecular interactions of these ruthenium complexes 
through coordination to guanine and adenine through the N7 nitrogen, has been 
explored using a selection of pure DFT, hybrid DFT, and post Hartree-Fock approaches 
against benchmark correlated wavefunction methods, where the best methods were 
found to be BHandH, B97-D2, and MP2(0.25). The B97-D2 functional was used to 
model these ruthenium complexes, with a selection of extended aromatic ligands with 
potential to act as intercalators, interacting with base pair steps. Calculated binding 
energies show a sensitivity to the nature of the arenes, where the more flexible ligands 
form more non-covalent interactions with DNA, as demonstrated by QTAIM analysis. 
Conformations and binding energies of a relatively new platinum anticancer drug, 
kiteplatin, with small single strand fragments of DNA, have been studied using B97-D 
and semi-empirical methods and compared to established drugs cisplatin and 
oxaliplatin. Isotropic shielding values and J coupling constants have also been 
calculated for these systems to relate these values to conformational data. Extended dual 
strand kiteplatin-DNA adducts have been studied using the QM/MM method ONIOM, 
combining BHandH with AMBER, to calculate binding energies and optimised 
structures. These results show that as the DNA adduct increases in size the values of the 
kiteplatin energies start to converge and comparison of base pair parameters show that 
around the site of coordination all fragments show comparable geometrical distortions. 
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Chapter 1: Introduction 
 
1.1 Overview 
 
This thesis aims to present the work carried out, using a variety of quantum chemical 
and hybrid quantum mechanics / molecular mechanics methods, on modelling non-
covalent interactions within transition metal complexes and modelling ruthenium and 
platinum anticancer drugs interacting with differing sizes of DNA adducts. The 
literature review presented in this chapter gives the background into non-covalent 
interactions, how they affect the structures of biological macromolecules, and the 
computational approaches that can be taken to model systems that contain these 
interactions. Also an overview of platinum and ruthenium anticancer drugs, with a focus 
on cisplatin and some of its newer analogues and ruthenium based 'piano stool' 
complexes is presented. This will not only look at the history of such molecules but how 
they have been modelled previously, as isolated molecules and within DNA adducts. 
 
1.2 Non-Covalent Interactions 
 
Much of the work presented within this thesis focuses on calculating properties of 
systems that contain non-covalent interactions, particularly at parts the energy of these 
interactions, which for some have shown to be a particular challenge for computational 
chemistry, due to their origin in electron correlation. These interactions can be defined 
as intermolecular or intramolecular interactions between atoms that are not 
characterised as covalent bonds; they are also sometimes referred to as weak 
interactions as their strength can be significantly less than that of covalent bonds. In 
spite of their relative weakness they have an additive nature that allows them to play an 
important role in many areas such as biological systems, material science, and 
molecular recognition.1-9 
 
1.2.1 Origin of Non-Covalent Interactions 
 
Non-covalent interactions are of great importance in many areas of science, particularly 
hydrogen bonding and van der Waals forces. However the ones of greatest interest 
within this work are those that arise due the correlated motion of electrons, this focuses 
on interactions such as π...π stacking and CH...π interactions. In contrast, hydrogen 
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bonding is a result of a charge-charge interaction of an electronegative atom with a 
hydrogen atom that is directly bonded to another electronegative atom, as well as orbital 
overlap effects and charge transfer which contribute to the overall strength of these 
interactions. As a result this makes hydrogen bonding mainly electrostatic in nature and 
they also can be significantly stronger than dispersion based interactions.10 The π...π 
type of non-covalent interactions are a result of two induced dipoles, which occur 
instantaneously, they are also known as London dispersion forces. 
 
The nature of π...π type interactions wasn't fully understood until Hunter et al. devised a 
model based on observations of porphyrin ring systems.2 In this model the σ framework 
and π electrons are treated separately and postulates that the favourable π...π interaction 
is resultant of the π...σ attraction being greater than the repulsion of the π electron 
systems, giving a net attractive force. 
 
A key feature in systems containing π...π interactions is how different relative 
orientations of species results in differing interaction strengths. This is especially 
prevalent in one of the key examples of this interaction, the benzene dimer, which 
exhibits three possible conformations, as shown in figure 1.2.1.1. The parallel displaced 
and T-shaped systems exhibit much more favourable energetic interactions than that of 
the sandwiched conformation.11 
 
 
Parallel Displaced T-Shaped Sandwiched 
 
Figure 1.2.1.1 Three conformations of the benzene dimer. 
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The Hunter model attempts to explain this result using three charges to represent the π 
systems and arrives at three rules. Rule 1, π...π repulsion dominates in a sandwiched π-
stacked geometry; rule 2, π...σ attraction dominates in a T-shaped geometry; and rule 3, 
π...σ attraction dominates in an parallel displaced π-stacked geometry, as shown in 
figure 1.2.1.2.2 
 
Figure 1.2.1.2 The interactions between two idealised π systems as a function of 
orientation and distance of parallel displacement.2 
 
Although this model is generally considered as the standard explanation for π...π 
interactions it is not without flaws, the main noticeable one being that the model claims 
that two overlapping π systems, such as the sandwiched benzene dimer conformation, 
would result in an unfavourable interaction and therefore repulsion, whilst this is not the 
case. The benzene dimer preferentially exists in either the parallel displaced or T-shaped 
conformations but if the two benzenes are forced into the sandwich conformation the 
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interaction is still favourable, albeit of reduced stabilisation energy. Hill et al.11 
calculated these energies using CCSD(T) (cf. section 2.4.3) giving the parallel displaced 
dimer an interaction energy of -2.51 kcal/mol, the T-shaped dimer an energy of -2.49 
kcal/mol, and the sandwiched complex an energy of -1.56 kcal/mol. This model does 
explain the geometrical preference observed in the benzene dimer, however to be able to 
calculate final binding energies dispersion is vital, which can be shown from errors that 
stem from computational approaches that do not account for electron correlation. 
 
The CH...π interaction is another class of non-covalent interaction comprising of an 
energetically stable conformation arising when a C-H bond within a molecule is 
orientated towards a π system, such as one of the simplest examples the methane 
benzene system. This interaction can be validated by Hunter's rule 2 and the T-shaped 
benzene dimer can be thought of as somewhat analogous to a methane...benzene 
interaction where a CH points toward the centre of the benzene ring. However, the 
interaction energy of methane...benzene is less than the T-shaped benzene dimer, with 
CCSD(T) values of -1.45 kcal/mol12 and -2.49 kcal/mol11 respectively. 
 
1.2.2 Non-Covalent Interactions in DNA 
 
As mentioned above, non-covalent interactions are of great importance within 
biological systems, as they are crucial in defining the structures of many biological 
macromolecules, particularly DNA and proteins. DNA, or deoxyribonucleic acid, is a 
fundamentally important biological molecule with a double helix of nucleic acid 
polymer chains, as shown in figure 1.2.2.1. 
 
 
Figure 1.2.2.1 Double helical structure of DNA. 
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DNA can be characterised by its primary, secondary, and tertiary structure. The primary 
structure relates to the individual building blocks that make up the nucleic acid chain. 
These are formed from a deoxyribose sugar and one of four nucleobases, adenine, 
thymine, guanine, and cytosine (A, T, G, and C respectively) as shown in figure 1.2.2.2. 
Each of these units is termed a nucleoside and they are linked through phosphate 
groups, at the 3’ and 5’ oxygen atoms, to form nucleotides which make up the nucleic 
acid chains. In models of DNA the structures of the individual strands are usually 
terminated at the 3’ and 5’ oxygens, leading to definition of the term 3’ and 5’ end. 
 
 
  
Deoxyadenosine Deoxythymidine 
 
  
Deoxyguanosine Deoxycytidine 
 
Figure 1.2.2.2 Structures of the four possible nucleosides of DNA, with the Crick and 
Watson numbering. 
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The secondary structure of DNA relates to the double helical structure that two nucleic 
acid chains form, as initially discovered by Crick and Watson.13 The two chains run in 
anti-parallel directions and the pyrimidine nucleobases form stabilising hydrogen bonds 
with their complimentary purine bases, G to C and A to T. Nucleobases on the same 
strand also form additional stabilising interactions as a result of their stacked nature 
along that strand. As a result of the helical structure of DNA there are grooves present 
between the strands, adjacent to the nucleobases. These have the ability to act as a 
binding site, but due to the unsymmetrical nature of the two strands, as a result of the 
base pairs not being directly opposite, it is possible to form different size grooves, 
which are termed the minor and major grooves, as shown by figure 1.2.2.3. 
 
 
 
Figure 1.2.2.3 Minor and major groove of a DNA molecule.14 
 
The tertiary structure of DNA relates to the form of the double helix, of which the most 
common are the A, B, and Z forms, as shown by figure 1.2.2.4. The B form of DNA is 
the one which is usually found within cells but the others can be observed depending on 
factors such as the level of hydration and through the binding of drugs. 
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A-DNA B-DNA Z-DNA 
 
Figure 1.2.2.4 The three most common forms of DNA.15 
 
The structure of DNA owes a lot to non-covalent interactions, especially the hydrogen 
bonds formed between base pairs and the π stacking occurring between adjacent 
nucleobases on a strand. Each base pair forms multiple hydrogen bonds, G-C forms 
three and A-T forms two, between the most favoured donor and acceptor atoms on the 
present bases, as shown by figure 1.2.2.5. This donor/acceptor pattern also allows for 
effective recognition of G for C and A for T. The multiple hydrogen bonds allow for 
extra stabilisation between the two nucleobases and this effect is greatly increased 
across all the consecutive base pairs in a DNA molecule. 
 
  
 
GC 
 
AT 
 
Figure 1.2.2.5 Hydrogen bonds formed between the GC and AT base pairs. 
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The hydrogens bonds are considered the strongest non-covalent interaction contributing 
to the structure of DNA but the π stacking occurring between adjacent nucleobases also 
gives significant stabilisation. There are also some electrostatic interactions occurring in 
the DNA molecule, the phosphate groups on the backbone are negatively charged and to 
balance this positive sodium and magnesium counter ions are present. 
 
1.2.3 Modelling Non-Covalent Interactions 
 
Accurately modelling non-covalent interactions presents an issue for many 
computational chemistry techniques. With their origin arising from the correlated 
motion of electrons any technique that approximates this incorrectly, will not result in a 
quantitatively accurate result and techniques that neglect it usually do not yield 
qualitatively accurate results. Ideally, to model systems containing these interactions 
high level correlated wavefunction methods are required, such as coupled cluster 
techniques. In addition, usually large basis sets of at least an augmented triple-ζ are also 
required, limiting applicability drastically.16 At present the most accurate method that is 
applicable to more than a few atoms is termed CBS(T),17 which combines an 
extrapolation of the second order Møller-Plesset correlation energy (MP2), to the basis 
set limit with a correction using coupled cluster, with single and double excitations and 
pertubative triples (CCSD(T)), at a smaller basis set, usually of double-ζ quality, as 
shown by equation 1.1. The extrapolation of the MP2 energy is usually carried out by 
the method of Helgaker et al.18 where systematically improved basis sets are utilised, 
most commonly augmented double-ζ to augmented triple-ζ. This approach is believed to 
yield results within a small fraction of l kcal/mol of the true interaction energies.19-22 
 
E(CBS(T)) = E(HF) + Ecorr(MP2)CBS + ΔCCSD(T)VDZ (eq. 1.1) 
 
Systems containing hydrogen bonding do not give as much problem computationally as 
π...π and CH...π systems, as hydrogen bonding is a mainly electrostatic interaction. As a 
result of this it is possible to model these systems with Hartree-Fock (HF) and density 
functional theory (DFT) methods with relatively small sized basis sets and still calculate 
geometries and binding energies to a reasonable level of accuracy. However using these 
approaches on systems containing CH...π or π stacking often results in unfavourable 
interaction energies as a result of not properly describing the London dispersion 
forces,23 which arise from electron correlation. The HF method is a prime example of 
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this, as it ignores dispersion by construction, cf. section 2.2, and therefore incorrectly 
models any system that contains stacking interactions. 
 
As mentioned above the post Hartree-Fock methods, which account for electron 
correlation, are the ideal approach to treat non-covalent interactions, although some of 
the more inexpensive correlated wavefunction methods can still result in major errors. 
What could be considered the simplest of these is MP2 and it has been well established 
that this approach overestimates stacking energies, in some cases up to 100% 
overestimation can occur.24,25 Riley et al.26 attributed this failure of MP2, particularly in 
stacked complexes, to a loss in balance of the factors that compensate for error. Usually 
these compensating factors, that arise from overestimation in energy due to the failure to 
describe intramolecular correlation effects and the underestimation of total binding 
energy as a result of basis set deficiency, are balanced, yielding reasonable binding 
energies. However in the case of stacked complexes the balance between the two factors 
shifts resulting in less accurate values, which can explain the overestimations shown 
above. As a result of the errors within MP2, coupled cluster techniques, such as 
CCSD(T), and techniques that correct using coupled cluster, such as CBS(T), are widely 
regarded as those that will give the most accurate results for dispersion based systems. 
 
The drawbacks to these high level methods mean they cannot be realistically used for 
many systems, as calculation time and therefore cost scales unfavourably with 
increasing system sizes, for example whilst Hartree-Fock and DFT generally scale at 
N4, where N is the number of basis functions, MP2 scales at N5 and CCSD(T) scales at 
N7. As a result of this, an area which has garnered great interest is creating new methods 
which are computationally inexpensive but can still model non-covalent interactions, as 
well as modifying current approaches to make them more feasible without significantly 
losing accuracy. 
 
To evaluate new approaches they are usually compared with benchmark datasets and 
one that is regularly used is that of Hobza's JSCH-2005 set.27 This dataset uses 
CCSD(T) and MP2 to calculate the binding energies of a selection of non-covalently 
bound nucleobase and amino acid pairs, exhibiting a variety of H-bonding and stacking 
interactions. This set of over one hundred complexes was also reduced to a smaller set, 
termed the S22 set, which contains seven hydrogen bonding complexes, eight dispersion 
based complexes, and seven complexes containing mixed interactions. As this S22 
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dataset contains a variety of non-covalent interactions, it is often the set to which newly 
developed methods are benchmarked against. This set has however recently been 
superseded by the newer S66 dataset,28,29 which uses CBS(T) to calculate interaction 
energies, equilibrium geometries, and dissociation curves of sixty six intermolecular 
complexes at nine distinct geometric configurations. 
 
One direction in which research has been taken to accurately modelling dispersion 
based systems is to attempt to reduce the computational cost of the post Hartree-Fock 
methods. Not only does this aid in modelling non-covalent interactions but also allows 
these correlated wavefunction methods to be used on a wider range of systems, that 
previously would have been too computationally expensive. One such approach is the 
use of local correlation methods that exploit the short range nature of electron 
correlation, which decays as a function of r-6.30-32 This has been applied to MP2 to give 
the LMP2 method, cf. section 2.4.4. This approach uses localised orbitals to restrict 
excitations to a set of virtual orbitals, termed domains, which are spatially close to the 
occupied orbitals, resulting in an overall decrease in computational cost.33,34 As an 
additional bonus, by construction these local correlation methods give results which are 
free of basis set superposition error when used with triple-ζ or larger basis sets, which 
further reduces cost as other methods such as counterpoise corrections don't need to be 
made. These methods can also be paired with the density fitting approximation (DF), 
also called resolution of identity (RI), which attempts to approximate the expensive 4-
index-2-electron integrals with a cheaper combination of 2- and 3-index integrals. In 
some instances this has reduced the time of an MP2 calculation by an order of 
magnitude.35-37 When these two approximations are paired with MP2, the resulting DF-
LMP2 approach yields a method that in favourable cases has approached linear scaling 
with system size.38,39 
 
DF-LMP2 has been shown to significantly reduce the computational effort when 
compared to a normal MP2 calculation, but this still does not alleviate the 
overestimation of stacking interactions. To improve on this it is possible to use an 
approach that separately scales the correlation energy of parallel and anti-parallel spin 
electron pairs, termed spin-component scaling (SCS).40 In the initial form, proposed by 
Grimme, the scaling parameters were optimised to improve MP2 for a range of 
thermodynamic, kinetic, and geometrical properties. Different scaling parameters have 
also been published to account for specific interactions, such as SCSN,41 SCS(MI),42 
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and SCSC.43 SCSN has been optimised to improve binding energies of stacked nucleic 
acid base pairs, SCS(MI) has been optimised against the S22 dataset, and SCSC has 
been optimised to study catalysis and account for total energies as well as interaction 
energies. Both SCSN and SCS(MI) give errors of approximately 0.3 kcal/mol when 
compared to CBS(T) values over a set of representative intermolecular interactions. 
 
Another approach in reducing the computational cost of MP2 calculations is to modify 
the basis set used. Combining MP2 with small basis sets such as 6-31G* or SVP, but 
using more diffuse polarization functions than normal yields results of similar accuracy 
to those carried out with larger basis sets.44,45 Hobza et al.46-50 used this approach in 
early electron correlation studies of nucleic acid base stacking, combining MP2 with the 
6-31G* basis set but using diffuse d-functions with an exponent of 0.25 instead of the 
standard 0.8. This approach is sometimes termed MP2(0.25). Hobza and Ŝponer have 
however noted that this unbalanced basis set could not be used for other calculations, 
such as geometry optimisation, but this method does allow for a description of base 
stacking at a lower computational cost as a result of a decreased number of basis 
functions, compared to a basis set which would normally be deemed acceptable for 
calculating dispersion based interactions.46  
 
Traditionally DFT methods do not accurately describe stacking interactions, but usually 
perform well for hydrogen bonding systems.51 As with Hartree-Fock theory there is a 
lack of dispersion in the construction of standard Kohn-Sham DFT, cf. section 2.5. 
Although, as these methods are less computationally expensive than the correlated 
wavefunction methods, research has been directed into making DFT methods that can 
model systems containing dispersion based interactions. Some DFT approaches have 
been proposed that have been shown to model stacking interactions, these include time 
dependent DFT,52 an inclusion of an empirical dispersion correction,53 and modifying 
the exchange-correlation functional to model dispersion based interactions.54,55 
 
The improvement of the exchange-correlation functional has led to a selection of 
functionals including KT1 and KT2 developed by Tozer et. al,55 and the Minnesota 
family of functionals developed by Truhlar.56-61 Truhlar's functionals include M05, 
M05-2X, M06, and M06-2X and have shown good performance in modelling non-
covalent interactions,62-66 which has been ascribed to an improved description of 
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correlation energy at the typical ranges of interacting molecules in van der Waals 
complexes. 
 
The inclusion of an empirical dispersion correction to standard Kohn-Sham DFT is a 
method termed DFT-D.53,67-72 This approach utilises the r-6 distance relationship of 
dispersion based interactions by correcting the Kohn-Sham DFT energy using an atom 
pairwise sum over r-6 potentials. The most common type of this correction takes the 
form known as D2 but has been refined for a broader range of applicability and higher 
accuracy in the form of D3, which includes r-8 terms as well as r-6.73 One of these 
methods that has been used extensively throughout this work is that of B97-D, which 
includes the D2 correction on the generalised gradient approximation method B97 
which was developed by Grimme.74 
 
Whilst many DFT approaches do not model stacking interactions, which as mentioned 
above is not unexpected due to a lack of dispersion in Kohn-Sham DFT, it is possible 
for methods to work surprisingly well due to what is usually attributed to cancellation of 
errors. One such approach, which has been used throughout this work, is that of Becke's 
half and half functional, BHandH.75 Tests carried out on the benzene dimer show that 
BHandH performs better than MP2 at describing stacking interactions, whilst the 
similar hybrid DFT functional B3LYP does not give a favourable interaction at all.76 
This functional has been successfully applied to many systems by our group, including 
binding of platinum and ruthenium anticancer drugs to DNA and modelling stacking 
interactions within transition metal complexes.76-83 However BHandH does consistently 
overestimate hydrogen bonding, which can lead to issues modelling systems containing 
a mix of non-covalent interactions.80 
 
1.3 Anti-Cancer Drugs 
 
It is possible to utilise the non-covalent interactions mentioned above in the design of 
anti-cancer drugs. Planar aromatic systems can be designed to act as intercalators, which 
effectively slot in between two nucleobases such that π...π stacking interactions stabilise 
this drug DNA adduct.84-90 Molecules can also be designed to bind to the minor groove 
of DNA, whilst using non-covalent interactions to stabilise the overall complex.90-96 
Another class of anti-cancer drugs rely on formation of covalent bonds between 
nucleophilic sites on DNA bases and transition metal centres, as exemplified by 
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cisplatin and related drugs.97-107 These are the class of drugs that are of focus here as it 
is generally believed that the distortion of the natural DNA structure induced by drug 
binding is significant enough to induce recognition by repair proteins, which leads to a 
cascade of biological responses ultimately ending in apoptosis, or programmed cell 
death.108-110 
 
1.3.1 Cisplatin 
 
Out of all the transition metal anticancer drugs the ones containing platinum are 
probably the most well known and out of these cisplatin or (cis-[PtCl2(NH3)2]) is one of 
the best selling. Even though this complex was first synthesised in the 19th century,111 
the true possibility of using platinum to treat cancer wasn't fully realised until the 
1960's, when Rosenberg discovered cytotoxicity, or that platinum metal inhibited cell 
division.112,113 Although it is now widely used to treat many types of cancer, including 
testicular, ovarian, cervical, and colorectal cancer, it is not without drawbacks, which 
include nephrotoxicity and neurotoxicty when doses are exceeded.114 
 
As a result of the drawbacks to cisplatin much work has been carried out into improving 
platinum based anti-cancer drugs as well as attempts to understand the mechanisms 
occurring when these complexes bind to DNA within tumour cells.115 This research has 
led to the discovery of several platinum based drugs, two of which have seen global 
approval alongside cisplatin, namely carboplatin and oxaliplatin, whilst others such as 
heptaplatin, nedaplatin, and lobaplatin have been approved locally,116 as shown in figure 
1.3.1.1. 
 
Carboplatin and nedaplatin have a similar proposed mode of action compared to 
cisplatin, which is attributed to the formation of the same active species when the 
anionic ligand is lost. Oxaliplatin, heptaplatin, and lobaplatin replace the NH3 carrier 
ligands with bulkier chelating amines with an aim to increase cell uptake due to 
increased hydrophobicity. One of the main differences with these drugs is the observed 
toxicity, for example carboplatin exhibits less toxicity within cells when compared to 
cisplatin but has shown to be less efficient due to the chelating effect of the anionic 
ligand. Oxaliplatin, which is mainly used in treatment of colorectal cancer,117 forms 
more hydrophobic adducts compared to both cisplatin and carboplatin and as a result 
different effects occur within cells.118 It is also possible for toxicity issues to arise, such 
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that oxaliplatin treatment can result in severe peripheral neuropathy114 and with any of 
these drugs there is also a possibility of tumour cells becoming resistant, through means 
such as reduced accumulation and repair of the drug DNA adducts. 
 
Pt
ClH3N
ClH3N  
 
Cisplatin Oxaliplatin 
 
 
Carboplatin Heptaplatin 
 
 
Nedaplatin Lobaplatin 
 
Figure 1.3.1.1 Structures of platinum based anti-cancer drugs 
 
The reason for these complexes acting as anti-tumour agents is a result of formation of 
cytotoxic lesions on platinum DNA adducts, but there is still debate over how these 
drugs work. The currently accepted thesis for the mode of action of cisplatin is based 
around the drug entering cells intact, where there has also been debate between passive 
diffusion and active transport routes. Once in the cytoplasm, cisplatin is hydrolysed 
through displacement of the chloride ligands with water molecules, resulting in a 
positively charged complex. This can then interact with nucleophilic molecules within 
cells, with DNA a prime target. Cytotoxicity is induced through binding to N7 nitrogen 
sites on the purine nucleobases, guanine and adenine, which results in a combination of 
monoadducts and crosslinks causing distortion of the DNA helix. Whilst the 1,2-
intrastrand crosslinks are usually associated with the cytotoxicity, it is also possible to 
form 1,3-intrastrand and interstrand crosslinks. 
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As there is no confirmed mode of action for these drugs, there is still great interest 
within this area of research. Computational studies can offer insight that can sometimes 
not be obtainable through experimental study. As a result of this cisplatin has been 
extensively studied using computational techniques to probe structure, activation, and 
the interactions which form DNA adducts. With the size of biomolecules, studying 
DNA drug adducts with molecular mechanics or semi-empirical methods would seem 
the ideal approach, as more accurate and computationally expensive approaches are 
impractical for large system sizes. However within this work there is a focus on using 
quantum chemical techniques to study DNA fragments where metal binding is 
occurring at a high level of accuracy, as such the literature here mainly represents 
studies using ab initio and density functional theory. 
 
Some or the earliest attempts at calculations were carried out by Basch et al.,119 to 
compare cisplatin with its geometrical isomer, transplatin, using Hartree-Fock and 
double-ζ Gaussian type basis sets, with pseudopotentials on platinum, to find that the 
trans form is approximately 19 kcal/mol more stable than the cis form, which was 
attributed to reduced repulsion from the chloride ligands. With the need to account for 
electron correlation, Carloni et al.120 used gradient corrected exchange correlation DFT 
with plane wave basis sets and reproduced structural data for cis- and trans-platin, 
within an estimated error margin of crystal structure data. This DFT study also 
confirmed the extra stability of transplatin, but by a reduced value of 8 kcal/mol. 
Pavankumar et al.121 continued this work on the structure and bonding of cisplatin using 
Møller-Plesset perturbation theory with a variety of basis sets and pseudopotentials, as 
well as exploring conformations of different symmetry. They found that calculated 
geometries improved, compared to experimental data, with an increase in number of 
basis functions and the order of the perturbation theory, up to fourth. Vibrational 
frequency analysis was used to confirm that found geometries were true minima, but as 
there was variation with calculated values between the methods and basis sets used, the 
authors proposed the most suitable approach as MP2/6-311++G(2d,2p). 
 
Whilst extensive studies have shown that structural data and energetic properties can be 
reproduced within good accuracy, a lot of current interest has been on the activation of 
cisplatin through hydration. This has focused not only reactions between the complex 
and water to form the hydrolysed complex through loss of chloride ligands, but also the 
effect of water within a solvation shell around an intact cisplatin molecule. 
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Kozelka et al.122 calculated potential energy surfaces for cisplatin with a single water 
molecule and found favoured conformations and distance dependence. There was also 
an indication that dispersion forces were in play, as results calculated at Hartree-Fock, 
DFT, and MP2 levels of theory exhibited significant differences. Lopes et al.123 also 
calculated similar potential energy surface curves but with a larger number of possible 
orientations for cisplatin water complexes. Robertazzi et al.124 used the DFT functional 
mPW1 to calculate optimum geometries of complexes containing cisplatin and a single 
water, reporting only three stable minima and then characterised the interactions at the 
minima by examining the electron density.  
 
Not only is the effect of water as a solvent around cisplatin of interest but also the 
mechanism of hydrolysis to the aqua complex, as well as barriers to ligand substitution, 
and the energies associated with processes. Zhang et al.125 used a range of pure and 
hybrid DFT methods with implicit solvent models to study the hydrolysis reaction of 
cisplatin. They found the reaction went through a 5-coordinate transition state, with a 
barrier of approximately 23 kcal/mol, with the reported experimental value at 20 
kcal/mol. They also found that when comparing the gas phase and solvated data that 
inclusion of a solvent model greatly affected the barriers, by affecting the geometrical 
parameters of the transition state and concluded that a solvent model was essential. 
 
Lau and Deubel used the B3LYP DFT functional with a continuum dielectric model to 
study all three hydrolysis reactions of cisplatin.126 They calculated similar activation 
barriers of 25-27 kcal/mol and reaction free energies of 0-2 kcal/mol for the three 
reactions, in good agreement with experimental values. However the results for the 
second and third hydrolysis barriers are in strong disagreement with previous 
computational studies.127,128 They attribute the differences to the other studies choice of 
reference states, along the reaction coordinate, to calculate barriers as well as estimating 
the free solvation and entropic effects. This study is also the first theoretical study to 
support the diaqua species being the active form of cisplatin, which is in agreement with 
previous experimental observations. 
 
Mentioned above is that a hydrated cisplatin molecule will interact with DNA and 
preferentially bind to the nucleophilic oxygen and nitrogen sites on nucleobases, which 
is generally accepted as the reason for cisplatin's observed cytotoxicity. As a result of 
this the interaction of cisplatin with DNA, or individual nucleobases, is another area that 
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has garnered great interest. One of the first studies was carried out by Basch et al.,129 
using Hartree-Fock to model the binding of the [Pt(NH3)3]2+ complex to the four 
nucleobases A, G, C and T. This showed the preference to bind to the N7 position on 
guanine (see figure 1.2.2.2), which was approximately 19 kcal/mol more stable than the 
next most stable site. There is still reasonably strong binding to the other nitrogen and 
oxygen sites, with the calculated binding strength series as G(N7) > C(N3) > C(O2) > 
G(O6) > A(N3) > A(N1) > A(N7) > G(N3) > T(O4) > T(O2). 
 
Baik et al.130 carried out studies using B3LYP and implicit solvent models, attempting 
to explain the reason for cisplatin preferentially binding to guanine over adenine, when 
these sites are electronically similar in DNA. Hydrogen bonds were observed from the 
NH moeities on cisplatin to the O6 on guanine and N6 on adenine, with calculated 
strengths of 7 kcal/mol and 5 kcal/mol respectively, significantly too small to account 
for the stability difference. Examination of the kinetics of formation of the platinum 
nucleobase adducts through vibrational frequency data also found that the reaction 
barrier was smaller for guanine than adenine, with calculated values of 24.6 kcal/mol 
and 30.2 kcal/mol respectively. 
 
The research outlined above has utilised accurate computational techniques to model 
cisplatin and small fragments of DNA. There is however still interest in accurately 
modelling interactions of drugs, where there is more than just small fragments or single 
nucleobases. To be able to carry out studies of these interactions where the presence of 
larger biological molecules is desired hybrid quantum mechanics / molecular mechanics 
(QM/MM) methods are used. These schemes treat a small region of the system, such as 
the drug and coordinated nucleobase, with a high level method, such as MP2 or DFT, 
and the remainder of the complex with more approximate and faster molecular 
mechanics methods. 
 
Robertazzi and Platts77 used the ONIOM QM/MM approach to combine the DFT 
functional BHandH and AMBER forcefield to study cisplatin binding to systems of 
DNA, including small single strand adducts. In this scheme the platinum complex and 
nucleobases were treated with BHandH, chosen to account for any dispersion 
interactions present, and the sugar phosphate backbone was treated with AMBER. 
Inclusion of the backbone was found to not alter trends in binding energies, when 
compared to isolated nucleobases, but differences in energies and geometries were 
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observed. A similar approach was taken to model a larger cisplatin adduct, with the 
octamer of form d(CCTG*G*TCC). This BHandH/AMBER approach was found to 
satisfactorily reproduce the experimental structure for this, obtained from NMR studies. 
 
Gkionis and Platts83 carried out studies using QM/MM to test variants of the ONIOM 
method, by studying cisplatin adducts of a DNA dimer and octamer where BHandH was 
used for the QM region and AMBER forcefield for the MM region. By comparing 
optimised structures obtained by different strategies the authors concluded that 
electrostatic embedding is essential for proper descriptions of the complex and inclusion 
of an explicit solvent model in the form of water molecules further improves 
performance. This approach led to good agreement with experimentally obtained 
structures. 
 
1.3.2 Carboplatin, Oxaliplatin, and Nedaplatin 
 
Whilst there has been significant research into cisplatin, in part due to its small size, 
well defined geometry, and its significance in the area of anti-cancer agents, other 
analogous platinum based drugs have not garnered as much interest. In spite of this 
there is still literature, especially when focusing on comparisons between the newer 
drugs and cisplatin. One of the first such studies was carried out by Tornaghi et al.,131 
comparing carboplatin with cisplatin against experimental crystal structures. Using DFT 
methods there was relatively small discrepancies between bond lengths and angles, 
attributed to the inherent errors in the chosen methods. 
 
Giese et al. used the B3LYP functional with the LANL2DZ basis set to calculate 
structures and vibrational spectra of cisplatin, carboplatin, and a variety of novel 
platinum complexes that exhibited anti-cancer activity.132 The computational studies 
were to aid experimental data obtained by Raman spectroscopy and where available the 
calculations were useful in interpreting experimental results, but due to computational 
limitations at the time, the chosen methodology was not applicable to the larger 
complexes. 
 
Wysokiński et al. evaluated the performance of several DFT functionals at calculating 
geometries and vibrational spectra of cisplatin and carboplatin.133,134 The hybrid 
functional mPW1PW91 was found to best reproduce the experimental crystal structure 
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and good agreement with experimental Raman spectroscopy validated the accuracy of 
this method. Pavelka et al.135 used B3LYP with implicit solvent models to study the 
hydrolysis reactions of carboplatin as the chelating anionic ligand means that it 
undergoes slower activation than cisplatin. The calculated initial barrier was found to be 
approximately 31 kcal/mol and found to proceed through a similar transition state and 
mechanism to that of cisplatin. 
 
Sarmah and Deka used DFT methods to compare cisplatin and carboplatin with the third 
generation anti-cancer drug oxaliplatin.136 Optimised geometries for carboplatin and 
cisplatin showed good agreement with results discussed above, whilst oxaliplatin was in 
good agreement with experimental crystal structure, exhibiting the cyclohexane ring in 
the chair conformation. Parameters, indicative of reactivity, were also calculated for all 
three drugs, including hardness and electrophilicity, which were in good agreement with 
the observed experimental trend in reactivities. 
 
Gao137 used several different DFT functionals with a variety of basis sets to calculate 
the molecular structure and vibrational spectra of carboplatin, with the aim of 
investigating performance and determining the most suitable methodology. The author 
suggests the most suitable approach is LSDA with either the SDD or LANL2DZ basis 
sets to calculate geometries, indicating this approach is better than the mPW1PW91 
functional. For vibrational spectra calculations the PBE0/SDD approach was deemed 
most suitable. 
 
Tyagi et al.138 used the GGA functional PW91 to study structure and vibrational spectra 
of oxaliplatin and compare against experimental infra-red spectroscopy. With a focus on 
the conformation of the diaminocyclohexane ligand, the trans form was found to be 
more stable than the cis form. Out of the two equally stable trans enantiomers the trans-
(1R,2R) form was found to be more biologically potent, which they attributed to chiral 
recognition by DNA. They also found good comparison between calculated gas-phase 
geometries and experimental structures to validate the chosen methodology. 
 
The hydrolysis reactions of oxaliplatin have also been studied, by Russo et al.139 using 
B3LYP with an implicit solvent model, to study the mechanisms in acidic and neutral 
conditions, such that a H3O+ and water molecule were included in the systems for the 
two conditions respectively. The acidic and neutral activation barriers were calculated at 
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23.60 kcal/mol and 27.95 kcal/mol respectively, in agreement with experimental data 
where neutral hydrolysis is slower than the acid counterpart. They also conclude that 
oxaliplatin exhibits a different behaviour from cisplatin, where in neutral conditions 
cisplatin will reach DNA in the mono-aqua form, oxaliplatin will be fully hydrolysed. 
 
Whilst cisplatin, carboplatin, and oxaliplatin are the only platinum drugs that have 
gained global approval, there are a family of newer drugs that have seen local approval 
and as such there is less available literature based on computational studies of these 
complexes. As well as studying the hydrolysis of oxaliplatin above, Russo et al.140 used 
similar methodologies to study the hydrolysis of nedaplatin in acidic and neutral 
conditions. The acidic and neutral activation barriers were calculated at 31.7 kcal/mol 
and 28.6 kcal/mol respectively. Through comparison with carboplatin and oxaliplatin 
they found similar trends and hypothesised that in neutral conditions nedaplatin will 
reach DNA as the fully hydrolysed complex. 
 
Russo and co-workers have also carried out a comparative study between carboplatin, 
oxaliplatin, and nedaplatin based around formation of monoadducts with guanine and 
adenine nucleobases.141 All complexes in question preferentially bound to guanine over 
adenine and that binding to guanine was a hydrogen bond controlled process, imposing 
both structural and kinetic control. Carboplatin was found to have the lowest activation 
barrier in neutral and acidic conditions for platination of guanine, which was attributed 
to hydrogen bond networks formed at the transition state geometry. The authors 
concluded that whilst binding to adenine was considerably slower than guanine, it could 
be observed in standard conditions, in contrast to previous studies on hydrolysed 
cisplatin. 
 
1.3.3 Kiteplatin 
 
Kiteplatin, or [(cis-1,4-DACH)PtCl2], is a relatively new platinum anti-cancer drug with 
an isomeric form of the DACH ligand observed in oxaliplatin, as shown in figure 
1.3.3.1. Early reports of the activities of this drug have shown that it exhibits greater 
potency against platinum resistant cell lines than cisplatin.142 Further studies by Kohlar 
and co-workers have shown observed cytotoxicity in murine leukemia and human 
ovarian cancer cells.143,144 
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Figure 1.3.3.1 Structure of Kiteplatin. 
 
Margiotta et al.145 combined experimental and computational studies to examine the 
potential of kiteplatin at treating colorectal cancer. This type of cancer is one of the 
most common worldwide, with approximately one million new cases diagnosed each 
year,146 and the only other drug effective at treating colorectal cancer is oxaliplatin. 
Comparisons of kiteplatin and oxaliplatin show that the former exhibits enhanced 
aqueous solubility. However, ONIOM calculations using BHandH/AMBER on 
kiteplatin and oxaliplatin DNA adducts failed to show significant differences between 
the two drugs but did show some evidence that kiteplatin induced DNA distortion closer 
resembles that of cisplatin than oxaliplatin. The authors conclude that kiteplatin could 
be used very effectively in the treatment of patients with oxaliplatin resistant colorectal 
cancer. As a result of the relatively recent discovery of the potential application of this 
drug, there have been very few other computational studies of this complex and as such 
this forms a large part of the work presented in chapter 5. 
 
1.3.4 Ruthenium Anti-Cancer Drugs 
 
The majority of research in the field of transition metal based anti-cancer drugs is 
focused on the development of platinum complexes as shown above, but this is not to 
say that other transition metals could not be used for this application. Some of them that 
have shown potential anti-tumour activity include titanium,147 gold,148,149 rhenium,150 
iridium,151 copper,152 cobalt,153 and ruthenium.154-156 Also Robertazzi and Platts157 have 
studied all the transition metals in the d-block of elements, to examine interactions with 
guanine and guanine-cytosine base pairs. A preference for binding to the N7 site was 
observed for most metals, similar to platinum based drugs, but earlier transition metal 
drugs, such as titanium, favour the O6 site. 
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The focus here will be on the use of ruthenium transition metal complexes, such as 
those studied in chapters 3 and 4. Whilst there are several platinum drugs that have been 
approved and many more in trials there are only two notable ruthenium drugs in clinical 
trials including (trans-[tetrachlorobis(1H-indazole) ruthenate (III)]).158 The other of 
these is (trans-[tetrachloro (dimethylsulfoxide) (imidazole) ruthenate (III)]), which has 
shown to be effective as an antimetastatic agent.159 Although its mechanism of action of 
all steps is unknown, hydrolysis steps do occur with the chloride ligands similar to 
cisplatin. Several computational studies using B3LYP and implicit solvent models have 
been carried out on this complex to calculate barriers of the first hydrolysis step with 
values of 23.2 kcal/mol160 and 24.8 kcal/mol,161 with the discrepancies likely due to the 
use of different solvent models. 
 
Another prominent class of ruthenium complexes with potential anti-cancer activity are 
those discovered by Sadler,155,162-165 containing arene ligands. In these complexes the 
ruthenium is coordinated to an arene ligand, such as biphenyl or anthracene, through η6 
type coordination, with an ethylenediamine chelating ligand and a single chloride 
ligand, as shown in figure 1.3.4.1. Complexes of this type have shown to have a similar 
mode of action compared to cisplatin, through hydrolysis of the chloride ligand to give 
an activated aqua complex which can bind to nucleophilic sites on DNA via a ligand 
substitution reaction.166-168 
 
Ru
H2N
NH2
Cl
+
 
 
 
Figure 1.3.4.1 Sadler ruthenium complexes with biphenyl arene ligand (left) and 
anthracene arene ligand (right). 
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Sadler et al.169,170 carried out studies on the interactions of these ruthenium complexes 
to compare the biphenyl and cymene (p-isopropyltoluene) ligands. It was found that the 
size of the arene has great effect on the activity of the drug, extended arene systems 
result in greater distortion of DNA, as a result of possible intercalation with the 
nucleobases. The smaller complexes are unable to form these interactions so a large part 
of the distortion is resultant of steric interactions. 
 
Gkionis et al.78 used BHandH to investigate the binding of these ruthenium arene 
complexes to isolated nucleobases with a variety of aromatic ligands. A clear preference 
to guanine over any other base was found and approximately a 23.9 kcal/mol difference 
in binding energy between guanine and adenine in the gas phase. Hydrogen bonding 
and π-stacking interactions were shown to play a significant role in stabilising the bound 
complexes. Hydrogen bonding occurred independently of the arene, between the 
nucleobases and the NH of the ethylenediamine ligand, whilst stacking interactions 
occurred with the larger aromatic systems.  
 
Gossens et al.171 also studied the binding of these ruthenium arene complexes, using 
benzene and cymene, to guanine, adenine, and cytosine using the DFT functional BP86 
and MP2 methods. The calculated trend in strength of binding energies is comparative 
to that of cisplatin as, G(N7) >> C(O2) ~ C(N3) > A(N7) > G(O6). The same group 
have also examined the binding of the hydrolysed benzene ruthenium complex with 
BP86 calculations and docking studies.166  
 
Deubel and Lau172 used B3LYP with implicit solvent models to compare organometallic 
ruthenium complexes with cisplatin with regards to selectivity of biological targets. 
They conclude that both cisplatin and the ruthenium complex strongly bind to guanine 
and both drugs result in cell death, despite that the monofunctional ruthenium 
complexes are recognised and repaired in cell in a different manner to the bifunctional 
cisplatin adducts. 
 
Gossens et al.173 used classical and QM/MM molecular dynamics simulations to model 
a variety of ruthenium arene complexes binding to major grooves on DNA. The 
complexes studied with the ethylenediamine ligand, the ones of interest here, showed 
selectivity for guanine rich sequences and are driven to the binding site by electrostatic 
interactions. When close to binding distance the amino groups form hydrogen bonds 
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with the O6 atom, while ruthenium coordinates to the N7 atom, which ultimately results 
in distortion to the Watson-Crick base pair at the cymene side. The ruthenium DNA 
adduct was calculated to be approximately 11 kcal/mol more stable than the isolated 
hydrolysed ruthenium complex. 
 
Futera et al.174 used QM/MM techniques, combining B3LYP and AMBER, to study the 
ruthenium benzene complex interacting with DNA. A preference for binding to N7 of 
guanine is once again found, which is energetically stabilised by approximately 12 
kcal/mol but the process was found to be kinetically inhibited with high barriers of 
approximately 28 kcal/mol. The possibility of ruthenium acting like cisplatin and 
forming intrastrand structures was also explored, while the structures were energetically 
preferred in the QM/MM model, significant geometrical rearrangement was required. 
 
The computational studies carried out on these 'piano stool' ruthenium arene complexes 
have focused on hydrolysis reactions and interactions with nucleobases, while very few 
have examined a large range of potential extended aromatic systems. Sadler's studies 
have shown that the size of the arene can have a great effect on the activity and how 
much distortion is imbued onto the DNA, as such the work within chapter 3 and within 
reference 82 is based on a series of different ligands and how much distortion on 
relatively small base pair steps of DNA occurs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                    Chapter 1: Introduction 
25 
1.4 References 
 
1. Burley, S.K.; Petsko, G.A. Science 1985, 229, 23. 
2. Hunter, C.A.; Sanders, J.K.M. J. Am. Chem. Soc. 1990, 112, 5525. 
3. Hunter, C.A.; Singh, J.; Thornton, J.M. J. Mol. Biol. 1991, 218, 837. 
4. Gamez, P.; van Albada, G.A.; Mutikainen, I.; Turpeinen, U.; Reedijk, J. Inorg. 
Chim. Acta. 2005, 358, 1975. 
5. Aime, S.; Gianolio, E.; Uggeri, F.; Tagliapietra, S.; Barge, A.; Cravotto, G. J. 
Inorg. Biochem. 2006, 100, 931. 
6. Brammer, L.; Rivas, J.C.M.; Atencio, R.; Fang, S.Y.; Pigge, F.C. Dalton Trans. 
2000, 3855. 
7. Meyer, E.A.; Castellano, R.K.; Diederich, F. Angew. Chem-Int. Edit. 2003, 42, 
1210. 
8. Zimmerman, S.C.; Wu, W.M.; J. Am. Chem. Soc. 1989, 111, 8054. 
9. Hisamatsu, Y.; Takami, H.; Shirai, N.; Ikeda, S.I.; Odashima, K.; Tetrahedron 
Lett. 2007, 48, 617-. 
10. Hunter, C.A. Angew. Chem-Int. Edit. 2004, 43, 5310. 
11. Hill, J.G.; Platts, J.A.; Werner, H.-J.; Phys. Chem. Chem. Phys. 2006, 8, 4072. 
12. Tsuzuki, S.; Honda, K.; Uchimaru, T.; Mikami, M.; Tanabe, K. J. Am. Chem. 
Soc. 2000, 122, 3746.  
13. Watson, J.D.; Crick, F.H.C.  Cold Spring Harbor Symposia on Quantitative 
Biology 1953, 18, 123. 
14. http://www.mun.ca/biology/scarr/MGA2_02-07.html 
15. http://www.atdbio.com/content/5/Nucleic-acid-structure 
16. Dunning, T.H. J. Chem. Phys. 1989, 90, 1007. 
17. Sponer, J.; Riley, K.E.; Hobza, P. Phys .Chem. Chem. Phys. 2008, 10, 2595. 
18. Halkier, A.; Helgaker, T.; Jorgensen, P.; Klopper, W.; Koch, H.; Olsen, J.; 
Wilson, A.K. Chem. Phys. Lett. 1998, 286, 243. 
19.  Morgado, C.A.; Jurečka, P.; Svozil, D.; Hobza, P.; Šponer, J. J. Chem. Theory 
Comput. 2009, 5, 1524. 
20. Zhao, Y.; Truhlar, D.G. J. Phys. Chem. A 2005, 109, 6624. 
21. Jurečka, P.; Hobza, P. J. Am. Chem. Phys. 2003, 125, 15608. 
22. Sinnokrot, M.O.; Sherrill, C.D. J. Phys. Chem. A 2006, 110, 10656. 
23. Johnson, E.R.; Wolkow, R.A.; Dilabio, G.A. Chem. Phys. Lett. 2004, 394, 334. 
24. Hobza, P.;  Selzle, H.L.; Schlag, E.W. J. Phys. Chem. B 1996, 100, 18790. 
25. Jurečka, P.; Hobza, P. Chem. Phys. Lett. 2002, 365, 89. 
26. Riley, K.E.; Platts, J.A.; Řezáč, J.; Hobza, P.; Hill, J.G. J. Phys. Chem. A 2012, 
16, 4159-4169. 
27. Jurečka, P.; Šponer, J.; Černý, J.; Hobza, P. Phys. Chem. Chem. Phys. 2006, 8, 
1985-1993. 
28. Řezáč, J.; Riley, K.E.; Hobza, P. J. Chem. Theory Comput. 2011, 7, 2427-2438. 
29. Řezáč, J.; Riley, K.E.; Hobza, P. J. Chem. Theory Comput. 2011, 7, 3466-3470. 
30. Pulay, P. Chem. Phys. Lett. 1983, 100, 151. 
31. Saebø, S.; Pulay. P. Annu. Rev. Phys. Chem. 1993, 44, 213. 
32. Hampel, C.; Werner, H.-J. J. Chem. Phys. 1996, 104, 6286. 
33. Schütz, M.; Hetzer, G.; Werner, H.-J. J. Chem. Phys. 1999, 111, 5691. 
34. Hetzer, G.; Schütz, M.; Stoll, H.; Werner, H.-J. J. Chem. Phys. 2000, 113, 9443. 
35. Vahtras, O.; Almlöf, J.; Feyereisen, M.W. Chem. Phys. Lett. 1993, 213, 514 
36. Hättig, C.; Weigend, F. J. Chem. Phys. 2000, 113, 5154 
37. Schütz, M.; Manby, F.R. Phys. Chem. Chem. Phys. 2003, 5, 3349 
38. Werner, H.-J.; Manby, F.R.; Knowles, P.J. J. Chem. Phys. 2003, 118, 8149-8160 
                                                                                                                                    Chapter 1: Introduction 
26 
39. Polly. R.; Werner, H.-J.; Manby, F.R.; Knowles, P.J. Mol. Phys. 2004, 102, 2311. 
40. Grimme, S. Chem. Eur. J. 2004, 10, 3423. 
41. Hill, J.G.; Platts, J.A. J. Chem. Theory Comput. 2007, 3, 80. 
42. Distasio, R.A.; Head-Gordon, M. Mol. Phys. 2007, 105, 1073. 
43. Zhao, Y.; Truhlar, D.G. J. Chem. Theory Comput. 2009, 5, 324. 
44. Hobza, P.; Sponer, J.; Polasek, M. J. Am. Chem. Soc. 1995, 117, 792-798. 
45. Sponer, J.; Leszczynski, J.; Hobza, P. J. Phys. Chem. 1996, 100, 5590-5596. 
46. Hobza, P.; Šponer, J. J. Am. Chem. Soc. 2002, 124, 11802-11808. 
47. Hobza, P.; Šponer, J. J. Chem. Rev. 1999, 99, 3247-3276. 
48. Sponer, J.; Leszczynski, J.; Hobza, P. Biopolymers 2001, 61, 3-31. 
49. Sponer, J.; Leszczynski, J.; Hobza, P. J. Phys. Chem. A 1997, 101, 9489-9495. 
50. Sponer, J.; Leszczynski, J.; Hobza, P. J. Comput. Chem. 1996, 17, 841-650. 
51. Černý, J.; Hobza, P. Phys. Chem. Chem. Phys. 2005, 7, 1624-1626. 
52. Hesselmann, A.; Jansen, G. Chem. Phys. Lett. 2003, 367, 778-784. 
53. Grimme, S. J. Comput. Chem. 2004, 25, 1463-1473. 
54. Zhao, Y.; Truhlar, D.G. Theor. Chem. Account 2008, 120, 215-241. 
55. Keal, T.W.; Tozer, D.J. J. Chem. Phys. 2004, 121, 5654-5660. 
56. Zhao, Y.; Truhlar, D.G. Chem. Phys. Lett. 2011, 502, 1-13. 
57. Zhao, Y.; Truhlar, D.G. J. Chem. Phys. 2006, 125, 194101. 
58. Zhao, Y.; Schultz, N.E.; Truhlar, D.G. J. Chem. Theory Comput. 2006, 2, 364. 
59. Zhao, Y.; Schultz, N.E.; Truhlar, D.G. J. Chem. Phys. 2005, 123, 161103.  
60. Zhao, Y.; Truhlar, D.G. J. Phys. Chem. A. 2006, 110, 13126. 
61. Zhao, Y.; Truhlar, D.G. J. Chem. Theory Comput. 2008, 4, 1849. 
62. Zhao, Y.; Truhlar, D.G. Acc. Chem. Res. 2008, 41, 157. 
63. Zhao, Y.; Truhlar, D.G. J. Am. Chem. Soc. 2007, 129, 8440. 
64. Zhao, Y.; Truhlar, D.G. Phys. Chem. Chem. Phys. 2008, 10, 2813. 
65. Zhao, Y.; Truhlar, D.G. J. Phys. Chem. C 2008, 112, 4061. 
66. Zhao, Y.; Truhlar, D.G. Org. Lett. 2006, 8, 5753. 
67. Piacenza, M.; Grimme, S. J. Am. Chem. Soc. 2005, 127, 14841-14848. 
68. Piacenza, M.; Grimme, S. Chem.Phys.Chem. 2005, 6, 1554-1558. 
69. von Lilienfeld, O. A.; Tavernelli, I.; Rothlisberger, U.; Sebastiani, D. Phys. Rev. 
Lett. 2004, 93, -. 
70. Antony, J.; Grimme, S. Phys. Chem. Chem. Phys. 2006, 8, 5287-5293. 
71. Peverati, R.; Baldridge, K. K. J. Chem. Theory Comput. 2008, 4, 2030-2048. 
72. Pavone, M.; Rega, N.; Barone, V. Chem. Phys. Lett. 2008, 452, 333-339. 
73. Grimme, S.; Antony, J.; Ehrlich, S.; Krieg, H.; J.Chem.Phys. 2010, 132, 154104. 
74. Grimme, S. J. Comput. Chem. 2006, 27, 1787-1799. 
75. Becke A.D. J. Chem. Phys. 1993, 98, 1372. 
76. Waller M.P.; Robertazzi, A.; Platts, J.A.; Hibbs, D.E.; Williams, P.A. J. Comput. 
Chem. 2006, 27,491. 
77. Robertazzi, A.; Platts, J.A. Chem. A Eur. J. 2006, 12, 5747-5756. 
78. Gkionis, K.; Platts, J.A.; Hill, J.G. Inorg. Chem. 2008, 47, 3893-3902. 
79. Gkionis, K.; Hill J.G.; Oldfield, S.P.; Platts, J.A. J. Mol. Mod. 2009, 15, 1051-
1060. 
80. Gkionis, K.; Platts, J.A. J. Bio. Inorg. Chem. 2009, 14, 1165-1174. 
81. Mutter, S.T.; Platts, J.A. Chem. A Eur. J. 2010, 16, 5391-5399. 
82. Mutter, S.T.; Platts, J.A. J. Phys. Chem. A 2011, 115, 11293-11302. 
83. Gkionis, K.; Platts, J.A. Comp. Theo. Chem. 2012, 993, 60-65. 
84. Wall, R. K.; Shelton, A. H.; Bonaccorsi, L. C.; Bejune, S. A.; Dube, D.; 
McMillin, D. R. J. Am. Chem. Soc. 2001, 123, 11480-11481. 
85. Reha, D.; Kabelac, M.; Ryjacek, F.; Sponer, J.; Sponer, J. E.; Elstner, M.; Suhai, 
S.; Hobza, P. J Am Chem Soc 2002, 124, 3366-3376. 
                                                                                                                                    Chapter 1: Introduction 
27 
 
86. Cusumano, M.; Di Pietro, M. L.; Giannetto, A. Inorg. Chem. 1999, 38, 1754-
1758. 
87. Nakatani, K.; Matsuno, T.; Adachi, K.; Hagihara, S.; Saito, I. J. Am. Chem. Soc. 
2001, 123, 5695-5702. 
88. Hecht, C.; Friedrich, J.; Chang, T. C. J. Phys. Chem. B 2004, 108, 10241-10244. 
89. Wheate, N. J.; Brodie, C. R.; Collins, J. G.; Kemp, S.; Aldrich-Wright, J. R. 
Mini-Rev. Med.Chem. 2007, 7, 627-648. 
90. Strekowski, L.; Wilson, B. Mutat. Res-Fund. Mol. M. 2007, 623, 3-13. 
91. Baraldi, P. G.; Tabrizi, M. A.; Preti, D.; Fruttarolo, F.; Avitabile, B.; Bovero, A.; 
Pavani, G.; Carretero, M. D. N.; Romagnoli, R. Pure Appl. Chem. 2003, 75, 187-
194. 
92. Baraldi, P. G.; Bovero, A.; Fruttarolo, F.; Preti, D.; Tabrizi, M. A.; Pavani, M. 
G.; Romagnoli, R. Med. Res. Rev. 2004, 24, 475-528. 
93. Yamori, T.; Matsunaga, A.; Sato, S.; Yamazaki, K.; Komi, A.; Ishizu, K.; Mita, 
I.; Edatsugi, H.; Matsuba, Y.; Takezawa, K.; Nakanishi, O.; Kohno, H.; 
Nakajima, Y.; Komatsu, H.; Andoh, T.; Tsuruo, T. Cancer Res. 1999, 59, 4042-
4049. 
94. Rastogi, K.; Chang, J. Y.; Pan, W. Y.; Chen, C. H.; Chou, T. C.; Chen, L. T.; Su, 
T. L. J. Med. Chem. 2002, 45, 4485-4493. 
95. Guddneppanavar, R.; Bierbach, U. Anti-Cancer Agent Me. 2007, 7, 125-138. 
96. Baraldi, P. G.; Cacciari, B.; Guiotto, A.; Romagnoli, R.; Zaid, A. N.; Spalluto, G. 
Farmaco 1999, 54, 15-25. 
97. Baker, E. S.; Manard, M. J.; Gidden, J.; Bowers, M. T. J. Phys. Chem. B 2005, 
109, 4808-4810. 
98. Clarke, M. J.; Zhu, F. C.; Frasca, D. R. Chem. Rev. 1999, 99, 2511-2533. 
99. Calamai, P.; Guerri, A.; Messori, L.; Orioli, P.; Speroni, G. P. Inorg. Chim. Acta. 
1999, 285, 309-312. 
100. Berners-Price, S. J.; Mirabelli, C. K.; Johnson, R. K.; Mattern, M. R.; Mccabe, F. 
L.; Faucette, L. F.; Sung, C. M.; Mong, S. M.; Sadler, P. J.; Crooke, S. T. Cancer 
Res. 1986, 46, 5486-5493. 
101. Collery, P.; Keppler, B.; Madoulet, C.; Desoize, B. Crit. Rev. Oncol. Hemat. 
2002, 42, 283-296. 
102. Rixe, O.; Ortuzar, W.; Alvarez, M.; Parker, R.; Reed, E.; Paull, K.; Fojo, T. 
Biochem. Pharmacol. 1996, 52, 1855-1865. 
103. Bakhtiar, R.; Ochiai, E. I. Gen. Pharmacol. 1999, 32, 525-540. 
104. Murray, J. H.; Harding, M. M. J. Med. Chem. 1994, 37, 1936-1941. 
105. Sun, R. W. Y.; Ma, D. L.; Wong, E. L. M.; Che, C. M. Dalton. T. 2007, 4884-
4892. 
106. Milacic, V.; Fregona, D.; Dou, Q. P. Histol Histopathol 2008, 23, 101-108. 
107. Milacic, V.; Chen, D.; Giovagnini, L.; Diez, A.; Fregona, D.; Dou, Q. P. Toxicol. 
Appl. Pharm. 2008, 231, 24-33. 
108. Sherman, S. E.; Lippard, S. J. Chem. Rev. 1987, 87, 1153-1181. 
109. Gonzalez, V. M.; Fuertes, M. A.; Alonso, C.; Perez, J. M. Mol. Pharmacol. 2001, 
59, 657-663. 
110. Natile, G.; Marzilli, L. G. Coordin. Chem. Rev. 2006, 250, 1315-1331. 
111. Peyrone,  M. Ann. Chemie Pharm. 1845, 51, 129. 
112. Rosenberg, B.; Van Camp, L.V.; Krigas, T. Nature (London), 1965, 205, 698. 
113. Rosenberg, B.; Van Camp, L.V.; Trosko, J.E.; Mansour, V.H. Nature (London), 
1969, 222, 385. 
114. Wong, E.; Giandomenico, C.M. Chemical Rev, 1999, 99, 2451. 
115. Reedijk, J. Chem. Commun. 1996, 801. 
                                                                                                                                    Chapter 1: Introduction 
28 
116. Galanski, M.; Jakupec, M.A.; Keppler, B.K. Curr. Med. Chem. 2005, 12, 2075. 
117. Jakupec, M. A.; Galanski, M.; Keppler, B. K. Rev. Physiol. Biochem. 
Pharmacol., 2003, 146, 1. 
118. Woynarowski, J.M.; Faivre, S.; Herzig, M.C. Mol. Pharmacol. 2000, 58, 920–7. 
119. Basch, H.; Krauss, M.; Stevens, W. J.; Cohen, D. Inorg. Chem. 1985, 24, 3313. 
120. Carloni, P.; Andreoni, W.; Hutter, J.; Curioni, A.; Giannozzi, P.; Parrinello, M. 
Chem. Phys. Lett. 1995, 234, 50. 
121. Pavankumar, P.N.V.;  Seetharamulu, P.; Yao, S.;  Saxe, J.D.;  Reddy, D.G.;  
Hausheer, F.H. J. Comput. Chem. 1999, 20, 365. 
122. Kozelka, J.; Berges, J.; Attias, R.; Fraitag, J. Ang. Chem. Int. Ed. 2000, 39, 198. 
123. Lopes, J.F.; Rocha, W.R.; Dos Santos, H.F.;  De Almeida, W.B. J. Chem. Phys. 
2008, 128. 
124. Robertazzi, A.; Platts, J.A. J. Comput. Chem. 2004, 25, 1060. 
125. Zhang, Y.; Guo, Z.; You, X.-Z. J. Am. Chem. Soc. 2001, 123, 9378-9387. 
126. Lau, J.K.-C.; Deubel, D.V. J. Chem. Theory Comput. 2006, 2, 103-106. 
127. Raber, J.; Zhu, C.; Eriksson, L. A. Mol. Phys. 2004, 102, 2537-2544. 
128. Burda, J. V.; Zeizinger, M.; Leszczynski, J. Comput. Chem. 2005, 26, 907-914. 
129. Basch, H.; Krauss, M.; Stevens, W.J. ;Cohen, D. Inorg. Chem. 1986, 25, 684-
688. 
130. Baik, M-H.; Friesner, R.A.; Lippard, S.J. J. Am. Chem. Soc. 2003, 125, 14082-
14092. 
131. Tornaghi, E.; Andreoni, W.; Carloni, P.; Hutter, J.; Parinello, M. Chem. Phys. 
Lett. 1995, 246, 469-474. 
132. Giese, B.; Deacon, G.B; Kuduk-Jaworska, J.; McNaughton D. Biopolymers 2002, 
67, 294-297. 
133. Wysokiński, R.; Michalska, D. J. Comput. Chem. 2001, 22, 901-912. 
134. Wysokiński, R.; Kuduk-Jaworska, J.; Michalska, D J. Mol. Struct. Theochem 
2006, 758, 169-179 
135. Pavelka, M.; Lucas, M.F.A.; Russo, N. Chem. Eur. J. 2007, 13, 10108-10116. 
136. Sarmah, P.; Deka, R.C. Int. J. Quant. Chem. 2008, 108, 1400-1409. 
137. Gao, H. Spectrochimica Acta Part A 2011, 79, 687-693. 
138. Tyagi, P.; Gahlot, P.; Kakkar, R. Polyhedron 2008, 27, 3567-3574. 
139. Lucas, M.F.A.; Pavelka, M.; Alberto, M.E.; Russo, N. J. Phys. Chem. B 2009, 
113, 831-838. 
140. Alberto, M.E.; Lucas, M.F.A.; Pavelka, M.; Russo, N. J. Phys. Chem. B 2009, 
113, 14473-14479. 
141. Alberto, M.E.; Butera, V.; Russo, N. Inorg. Chem. 2011, 50, 6965-6971. 
142. Hoeschele, J.D.; Hollis Showalter, H.D.; Kraker, A.J.; Elliott, W.L.; Roberts, 
B.J.; Kampf, J.W. J. Med. Chem. 1994, 37, 2630-2636. 
143. Shamsuddin, S.; Takahashi, I.; Siddik, Z.H.; Khokhar, A.R. J. Inorg. Biochem. 
1996, 61, 291−301. 
144. Shamsuddin, S.; Santillan, C.C.; Stark, J. L.; Whitmire, K.H.; Siddik, Z. H.; 
Khokhar, A. R. J. Inorg. Biochem. 1998, 71, 29−35. 
145. Margiotta, N.; Marzano, C.; Gandin, V.; Osella, D.; Ravera, M.; Gabano, E.; 
Platts, J.A.; Petruzzella, E.; Hoeschele, J.D.; Natile, G. J. Med. Chem. 2012, 55, 
7182-7192. 
146. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; 
Canon, J.-L.; Van Laethem, J.-L.; Maurel, J.; Richardson, G.; Wolf, M.; Amado, 
R.G. J. Clin. Oncol. 2007, 25, 1658-1664. 
147. Ghosh, P.; D'Cruz, O.J.; Narla, R.K.; Uckun, F.M. Clin. Cancer Res. 2000, 6, 
1536-1545. 
 
                                                                                                                                    Chapter 1: Introduction 
29 
148. Hoke, G.D.; Macia, R.A.; Meunier, P.C.; Bugelski, P.J.; Mirabelli, C.K.; Rush, 
G.F.; Matthews, W.D. Toxicol. Appl. Pharmacol. 1989, 100, 293-306. 
149. Calamai, P.; Carotti, S.; Guerri, A.; Mazzei, T.; Messori, L.; Mini, E.; Orioli, P.; 
Speroni, G.P. Anticancer Drug Des. 1998, 13, 67-80. 
150. Katsaros, N.; Anagnostopoulou, A. Crit. Rev. Oncol. Hematol. 2002, 42, 297-
308.  
151. Sava, G.; Giraldi, T.; Mestroni, G.; Zassinovich, G. Chem. Biol. Interact 1983, 
45, 1. 
152. Yang, P.; Wang, H.F.; Gao, F.; Yang, B.S. J. Inorg. Biochem. 1996, 62, 137-145 
153. Jung, M.; Kerr, D.E.; Senter, P.D. Arch. Pharm. 1997, 330, 173-176. 
154. Sava, G.; Zorzet, S.; Giraldi, T.; Mestroni, G.; Zassinovich, G. Eur. J. Cancer 
Clin. Oncol. 1984, 20, 841-847. 
155. Morris, R.E.; Aird, R.E.; Murdoch, P.D.; Chen, H.M.; Cummings, J.; Hughes, 
N.D.; Parsons, S.; Parkin, A.; Boyd, G.; Jodrell, D.I.; Sadler, P.J. J. Med. Chem. 
2001, 44, 3616-3621. 
156. McNae, I.W.; Fishburne, K.; Habtemariam, A.; Hunter, T.M.; Melchart, M.; 
Wang, F.Y.; Walkinshaw, M.D.; Sadler, P.J. Chem. Commun. 2004, 1786-1787. 
157. Robertazzi, A.; Platts, J.A. J. Biol. Inorg. Chem. 2005, 10, 854-866. 
158. Hannon, M.A. Pure Appl. Chem. 2007, 79, 2243-2261. 
159. Levina, A.; Mitra, A.; Lay, P.A. Metallomics 2009, 1, 458-470. 
160. Chen, J.C.; Chen, L.M.; Liao, S.Y.; Zheng, K.C.; Ji, L.N. J. Phys. Chem. B 2007, 
111, 7862. 
161. Besker, N.; Coletti, C.; Marrone, A.; Re, N. J. Phys. Chem. B 2008, 112, 3871. 
162. Chen, H. M.; Parkinson, J. A.; Parsons, S.; Coxall, R. A.; Gould, R. O.; Sadler, P. 
J. J. Am. Chem. Soc. 2002, 124, 3064-3082. 
163. Chen, H. M.; Parkinson, J. A.; Morris, R. E.; Sadler, P. J. J. Am. Chem. Soc. 
2003, 125, 173-186. 
164. Habtemariam, A.; Melchart, M.; Fernandez, R.; Parsons, S.; Oswald, I. D. H.; 
Parkin, A.; Fabbiani, F. P. A.; Davidson, J. E.; Dawson, A.; Aird, R. E.; Jodrell, 
D. I.; Sadler, P. J. J. Med. Chem. 2006, 49, 6858-6868. 
165. Peacock, A.F.A.; Sadler, P. J. Chem-Asian J. 2008, 3, 1890-1899. 
166. Rothlisberger, U.; Gossens, C.; Tavernelli, I. J. Phys. Chem. A 2009, 113, 11888-
11897. 
167. Chval, Z.; Futera, Z.; Burda, J. V.  J. Chem. Phys. 2011, 134, 024520. 
168. Futera, Z.; Klenko, J.; Sponer, J. E.; Sponer, J.; Burda, J. V.  J. Comput. Chem. 
2009, 30, 1758-1770. 
169. Novakova, O.; Kasparkova, J.; Bursova, V.; Hofr, C.; Vojtiskova, M.; Chen, H. 
M.; Sadler, P. J.; Brabec, V. Chem. Biol. 2005, 12, 121-129. 
170. Liu, H. K.; Wang, F. Y.; Parkinson, J. A.; Bella, J.; Sadler, P. J. Chem-Eur. J. 
2006, 12, 6151-6165. 
171. Rothlisberger, U.; Gossens, C.; Tavernelli, I. J. Chem. Theory Comput. 2007, 3, 
1212-1222. 
172. Deubel, D. V.; Lau, J. K. C. Chem. Commun. 2006, 2451-2453. 
173. Rothlisberger, U.; Gossens, C.; Tavernelli, I. J. Am. Chem. Soc. 2008, 130, 
10921-10928. 
174. Futera, Z.; Platts, J.A.; Burda, J.V. J. Comput. Chem. 2012, 33, 2092-2101. 
 
                                                                                                                                            Chapter 2: Theory 
30 
Chapter 2: Theory 
 
2.1 Introduction 
 
To understand and analyse the results of calculations and to know how reliable a result 
is an understanding of the theoretical background is needed. This chapter provides the 
necessary background on the methods that underpin the computational approaches that 
have been carried out within this work. The basis of this comes from a selection of the 
standard computational chemistry textbooks.1-6 
 
2.2 Hartree-Fock Theory 
 
2.2.1 Schrödinger Equation 
 
In modern quantum theory there is a fundamental postulate, that for any chemical 
system a wavefunction, Ψ, exists. This wavefunction contains all information about the 
system and through manipulation with operators it is possible to obtain the observable 
properties, with the one that is usually of greatest interest being the total energy of the 
system. In mathematical notation this equates to the shorthand form of the non-
relativistic, time-independent Schrödinger equation. 
 HΨ=EΨ (eq. 2.1) 
 
Expansion of equation 2.1,  results in a second order partial differential equation, where 
H is the Hamiltonian operator and E is a scalar value, which represents the system 
energy. The operator is expressed in terms of the positions of nuclei, R, and electrons, r, 
and for a system of N electrons and M nuclei the Hamiltonian can be constructed in the 
form of equation 2.2. 
 
ܪ = − 12෍ߘ஺ଶே
௜ୀଵ
−෍
12ܯ஺ ߘ஺ଶெ
஺ୀଵ
−෍෍
ܼ஺
ݎ௜஺
+ ෍෍ 1
ݎ௜௝
+ ෍෍ ஺ܼܼ஻
ܴ஺஻
ெ
஻வ஺
ெ
஺ୀଵ
ே
௝வ௜
ே
௜ୀଵ
ெ
஺ୀଵ
ே
௜ୀଵ
 
 
 
(eq. 2.2) 
Where i and j are electrons, A and B are nuclei, Z is the nuclear atomic number, MA is 
the ratio of the mass of nucleus A to an electron, and ∇2 is the Laplacian operator, 
equation 2.3. 
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ߘଶ = ߲ଶ
߲ݔଶ
+ ߲ଶ
߲ݕଶ
+ ߲ଶ
߲ݖଶ
 (eq. 2.3) 
 
Equation 2.2 can be further split, where the first and second terms are the kinetic energy 
operators for the electrons and nuclei respectively and the third, fourth, and fifth terms 
are the Coulombic interactions representing electron-nucleus attraction, electron-
electron repulsion, and nucleus-nucleus repulsion respectively. 
 
2.2.2 Born-Oppenheimer Approximation 
 
For any system containing three or more particles it is impossible to solve the 
Schrödinger equation exactly, this arises from the correlated motion of particles, and is 
a fundamental issue known as the three or many-body problem. Therefore to be able to 
carry out calculations on systems containing more than two particles, several 
approximations need to be made. One of the fundamental approximations used is the 
Born-Oppenheimer approximation and it allows the motion of particles to be decoupled 
by neglecting nuclear kinetic energy and treating the nuclear-nuclear repulsion as a 
constant. This is possible as there is a large ratio between the masses of the nuclei and 
the electrons and therefore change in position of electrons can be considered 
instantaneous in relation to the nuclei. As a result of this the full Hamiltonian can be 
split into the sum of the nuclear and electronic Hamiltonians. 
 
ܪ௧௢௧௔௟	 = ܪ௘௟௘௖௧௥௢௡௜௖ + ܪ௡௨௖௟௘௔௥	 (eq. 2.4) 
 
ܪ௘௟௘௖௧௥௢௡௜௖ = − 12෍ߘ஺ଶே
௜ୀଵ
−෍෍
ܼ஺
ݎ௜஺
+ ෍෍ 1
ݎ௜௝
ே
௝வ௜
ே
௜ୀଵ
ெ
஺ୀଵ
ே
௜ୀଵ
 (eq. 2.5) 
 
The total wavefunction of the system is also split into the product of the electronic and 
nuclear wavefunctions, which results in the simplified Schrödinger equation (eq. 2.7), 
where electrons move in a fixed field of nuclei. 
 
Ψ௧௢௧௔௟ = Ψ௘௟௘௖௧௥௢௡௜௖Ψ୬୳ୡ୪ୣୟ୰ (eq. 2.6) 
 H௘௟௘௖௧௥௢௡௜௖Ψ௘௟௘௖௧௥௢௡௜௖ = ܧ௘௟௘௖௧௥௢௡௜௖Ψ௘௟௘௖௧௥௢௡௜௖  (eq. 2.7) 
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The total energy of the system can then be calculated from the electronic energy and the 
nuclear-nuclear repulsion, which is constant for a given geometry. 
 
2.2.3 Born Interpretation 
 
It is important to be able to interpret the wavefunctions that are present in the above 
equations as alone they have no clear physical meaning. Born proposed an interpretation 
using the product of the wavefunction and its complex conjugate, Ψ*. 
 |Ψ|ଶ = Ψ∗ߖ (eq. 2.8) 
 
The value |Ψ|2, when multiplied by a volume element, dτ, gives the probability of 
finding an electron within that volume of space. Integration of this probability density 
over all space should yield the total number of electrons in the system, N. 
 
නΨ∗ߖ݀߬ = ܰ (eq. 2.9) 
 
If the wavefunction is an eigenfunction of an operator, Â, it is possible to calculate an 
observable property, A, of that operator, (eq. 2.10). If the wavefunction is normalised 
the denominator of equation 2.10 equals 1. 
 
ܣ = ∫Ψ∗ÂΨ݀߬
∫Ψ∗ߖ݀߬
 (eq. 2.10) 
 
2.2.4 Molecular Orbital Approximation 
 
The molecular orbital approximation is a further approximation that can be used in 
many electron systems, which cannot be solved exactly by the Schrödinger equation, in 
which the total wavefunction is split into the product of one electron wavefunctions, 
which are the molecular orbitals. As the electrons are in question here, it is important to 
not only take into account their spatial coordinates but also their spin orientation, which 
can be up or down. Electron spin can be described by either the functions α(ω) or β(ω), 
where ω is the spin variable. Products of the spatial and spin functions for a single 
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electron give spin orbitals, χ, and many electron systems can be represented as a product 
of spin orbitals, which are called Hartree products, ΨHP. 
 
Ψு௉(1,2, . . .ܰ) = 	 ߯ଵ(1)߯ଶ(3). . . ߯ே(ܰ) (eq. 2.11) 
 
To obey the antisymmetry principle the interchange of the coordinates of any two 
electrons must also yield a change on the sign of the wavefunction and Hartree products 
do not satisfy this. However a linear combination of Hartree products does and 
wavefunctions expressed in this way can be expressed in the form of a Slater 
determinant. 
 
Ψ = 1
√ܰ! ተ߯ଵ(1) ߯ଶ(1) ⋯ ߯ே(1)߯ଵ(2) ߯ଶ(2) ⋯ ߯ே(2)⋮ ⋮ ⋱ ⋮
߯ଵ(ܰ) ߯ଶ(ܰ) ⋯ ߯ே(ܰ)ተ (eq. 2.12) 
 
This form does obey the antisymmetry principle, as interchanging the coordinates of 
two electrons corresponds to interchanging two rows of the Slater determinant, which 
results in a change in the sign of the determinant. As a result of this the Pauli exclusion 
principle is satisfied, such that two electrons cannot have the same set of quantum 
numbers, since this would correspond to two rows of the determinant being equal, 
equivalent to Ψ=0. 
 
The Hartree-Fock method (HF) introduces this to the Schrödinger equation, by use of 
the one-electron Fock operator, f, which allows the electron-electron repulsion to be 
expressed in terms of an average potential, VHF, that the ith electron experiences from 
the remainder of the electrons in the system. 
 
݂ = − 12ߘ௜ଶ −෍ ܼ஺ݎ௜஺ + ܸுிெ
஺ୀଵ
 (eq. 2.13) 
 
ܸுி = 	෍ ܬ௝ − ܭ௝
௝
 (eq. 2.14) 
 
The first two terms of the Fock operator are the one-electron Hamiltonian of an electron 
moving in space in relation to the nuclei. The potential, VHF, contains Coulombic 
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interactions, J, which represent the electrostatic repulsion between the negatively 
charged electrons, and exchange interactions, K, which describe the spin correlation. 
Incorporation of the Fock operator gives the Hartree-Fock equation. 
 
݂߯(1) = ߝ߯(1) (eq. 2.15) 
 
Due to the form of the Fock operator, which depends on the coordinates of all electrons, 
a solution for one electron will directly affect the other electron, arising from the VHF 
term, therefore the Hartree-Fock method must be solved iteratively in a procedure called 
the self-consistent field method. 
 
2.2.5 Roothaan-Hall Equations 
 
Solving the Hartree-Fock equations directly for molecules is not practical, so an 
alternate route is taken where each spin orbital is written as a linear combination of 
atomic orbitals. 
 
߯௜ = ෍ܥ௩௜߶௩௄
௩
 (eq. 2.16) 
 
Using equation 2.16, the Hartree-Fock equations take the form of equation of 2.17. This 
can then be manipulated with a specific basis and through integration to give the 
Roothaan-Hall equations in matrix form, eq. 2.18. 
 
݂෍ܥ௩௜߶௩
௄
௩
= ߝ௜෍ܥ௩௜߶௩௄
௩
 (eq. 2.17) 
 
ܨܥ = ܵܥߝ (eq. 2.18) 
 
Where F is the Fock matrix, S is the overlap matrix, C is the matrix of coefficients, and 
ε is a diagonal matrix containing the orbital energies. These orbital energies represent 
the energy of an electron in a spin orbital and it is therefore possible to relate the total 
energy of the system to these values through equation 2.19. 
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ܧ = ෍ߝ௜ே
௜ୀଵ
−෍෍(2ܬ௜௝ −ܭ௜௝)ே ଶൗ
௝ୀଵ
ே
ଶൗ
௜ୀଵ
 (eq. 2.19) 
 
2.3 Basis Sets 
 
The linear combination of atomic orbitals has already been expressed above, by 
equation 2.16, and is a widely used method for calculating molecular orbital energies 
and coefficients. The molecular orbitals are expressed as one-electron functions that are 
centred on the nuclei, also known as basis functions. A set of these functions results in a 
basis set, which are commonly constructed from one of two functions, Slater-type 
orbitals (STO), equation 2.20, or Gaussian type orbitals (GTO), equation 2.21. 
 
߯఍,௡,௟,௠(ݎ,ߠ,߶) = ܰ ௟ܻ,௠(ߠ,߶)ݎ௡ିଵ݁ି఍௥ (eq. 2.20) 
 
߯఍,௡,௟,௠(ݎ,ߠ,߶) = ܰ ௟ܻ,௠(ߠ,߶)ݎଶ௡ିଵି௟݁ି఍௥మ (eq. 2.21) 
 
For instances where the electron and nucleus are at long distances or the distance 
between the two is zero the STOs provide a better description. STOs have a finite 
gradient at zero distance that correctly describes the cusp at the nucleus and have a more 
correct exponential decay, than the GTOs, at long range. With STOs, however, one 
cannot analytically calculate three or four centre two electron integrals that arise while 
solving the HF equations, which limits their use to high accuracy calculations on atomic 
systems or methods where the integrals are parameterized, such as semi-empirical 
methods. 
 
The GTOs have clear shortcomings at small and large distances, as they show a more 
rapid decay than STOs and lack a description of the cusp when approaching the nucleus. 
As a result of this between the two functions the STOs are more accurate, but Gaussian 
functions can be used to express atomic orbitals as linear combinations of the primitive 
Gaussians to give an approximate STO, this is known as contraction of Gaussian 
functions. Even though there is an increase in number of basis functions using this 
approach, where the GTOs need approximately three times as many as the STOs, the 
integrals are easier to calculate which outweighs the increase in the number of 
functions. 
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Figure 2.3.1 STO and GTO functions. 
 
2.3.1 Minimal Basis Sets 
 
The minimal basis set is the smallest that describes all electrons within the atoms 
making up the system in the ground state configuration, where each occupied orbital is 
described by one basis function. The STO-3G basis set7 is an example of this where 
each orbital is represented by three primitive Gaussians. Problems arise with use of 
minimal basis sets as they are often not accurate enough to correctly describe the system 
so improvements need to be made. There are several approaches, which include 
doubling the number of basis functions, resulting in a basis set said to be double-ζ, as 
opposed to minimal basis sets which are single-ζ. In this case the number of primitive 
Gaussians does not necessarily change but the number of molecular orbital coefficients 
increases. The use of split-valence basis can also be applied, where only the valence 
orbitals have the number of basis functions increased and the core orbitals, which 
usually do not change during chemical transformations, are treated less accurately. An 
example of split valence basis sets are those of the Pople series, where one of the 
common ones is 6-31G, for this the core orbitals are represented by six primitive 
Gaussians and the valence orbitals are represented by two functions, made up separately 
of three and one primitive Gaussians.8 
 
It is possible to further improve basis sets by including functions that describe higher 
angular momentum also called polarisation functions. Polarisation functions can include 
p-functions on hydrogen and d-functions on first row elements, although it is not always 
f(r)
r
STO
GTO
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necessary to include higher angular momentum functions on hydrogen, unless it is 
playing an active role in chemical transformations. Diffuse functions can also be 
included in a standard basis set that allow for expanded areas of electron density 
through smaller exponents, this can be useful in treatment of negatively charged species 
or lone pairs of electrons. Polarisation functions are usually denoted by a *, where the 
use of two includes both p and d polarisation functions whilst one just includes d 
polarisation functions. Diffuse functions are denoted by a +, where one applies just to 
heavy atoms and two include diffuse functions on all atoms. For example the Pople 
basis set, 6-31+G**, includes diffuse functions on heavy atoms, p polarisation functions 
for hydrogen, and d polarisation functions for heavy atoms. 
 
2.3.2 Effective Core Potential 
 
Calculations on systems that contain metals or the heavier main group elements, 
particularly the late transition metals, can cause issues to arise due to the increased 
amount of electrons. Not only is there an issue relating to large numbers of basis 
functions to accurately model the system but also relativistic effects can begin to play a 
part. As the core electrons interact with increasing nuclear charge, their velocities 
increase to fractions of the speed of light that can no longer be considered negligible. 
Effective core potentials (ECP), or pseudopotentials can be used in these situations, that 
describe the core electrons in terms of a potential that accounts for electrostatic effects 
and often accounts for relativistic corrections as well. These pseudopotentials are 
constructed by describing the valence electrons with a set of nodeless pseudo orbitals 
and the core electrons are described by a potential, which is a functional of the distance 
between the nuclei and electrons. 
 
2.3.3 Counterpoise Method 
 
When basis sets of finite size are used, results of calculations are susceptible to basis set 
superposition error (BSSE), which can result in the artificial lowering of energies. If the 
basis set used is not infinite the electronic density near a nucleus can be described by 
functions that are located on other nuclei and this is the source of the error. As infinite 
or complete basis sets are not practical for systems, the route taken to correct BSSE is 
that of the counterpoise method.9 The counterpoise corrected interaction energy of a 
complex, AB, can be calculated by equation 2.22. 
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Δܧ = ܧ௔௕(ܣܤ)஺஻ − ܧ௔௕(ܣ)஺஻ − ܧ௔௕(ܤ)஺஻ (eq. 2.22) 
 
The superscript values denote the basis set, whilst the subscript denotes the geometry of 
the fragment. This method calculates the interaction energy of AB, by calculating the 
energies of the monomers, A and B, while they retain their geometry from the complex 
and including the basis functions of the other monomer in the form of ghost functions, 
without the nuclei being present. 
 
2.4 Post Hartree-Fock Methods 
 
2.4.1 Correlation Energy 
 
In section 2.2.4, the HF method was described, in that by using the Fock operator it is 
possible to average electron-electron interactions by use of a potential. This energy 
calculated by use of the HF method results in a value that is not exact as it does not take 
into account the energy arising from correlation (EC). The exact energy can therefore be 
calculated by summation of the HF energy and the EC energy. 
 
ܧ௘௫௔௖௧ = ܧா஼ + ܧுி  (eq. 2.23) 
 
The correlation energy is usually of great importance within chemical systems and is 
vital in the accurate treatment of systems that contain dispersion based interactions, 
which form as a result of the correlated motion of electrons. The HF method has been 
advanced to yield more computationally accurate and more expensive methods, which 
can be collectively called the post-HF methods. 
 
2.4.2 Configuration Interaction 
 
Configuration interaction (CI) allows calculation of energies that account for electron 
correlation by constructing the total wavefunction as a linear combination of the ground 
state determinant and excited state determinants, equation 2.24. The HF single 
determinant wavefunction is represented by ΦHF and the excited determinants are 
represented by Φi, where S, D, and T are the singly, doubly, and triply excited 
determinants respectively. 
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Ψ = ܿ଴Φୌ୊ + ෍ܿௌΦୗ
ୗ
+ ෍ܿ஽Φୈ
ୈ
+ ෍்ܿΦ୘
୘
+. . . = ෍ܿ௜Φ୧ஶ
୧ୀ଴
 (eq. 2.24) 
 
Inclusion of all excited states leads to the method termed full configuration interaction, 
which is the most accurate quantum chemical method. As would be expected from a 
technique that yields such a high level of accuracy, the large number of integrals, as 
each term in equation 2.24 is a product of basis functions, means that this method is 
only applicable to the smallest of systems. This approach also has the disadvantage of 
being size-inconsistent when the series is truncated, such that the energy of a system 
with monomers at large separation does not equal the sum of the isolated monomer 
energies. 
 
2.4.3 Coupled Cluster 
 
The coupled cluster (CC) method calculates the excited states by use of an excitation 
operator, T (eq. 2.25), that is applied to a reference HF wavefunction. T1 is the operator 
of single excitations; T2 is the operator of double excitations and so forth. This allows 
the coupled cluster wavefunction to take the form of equation 2.26. 
 
ܶ = ଵܶ + ଶܶ +. . . ேܶ (eq. 2.25) 
 
Ψ = ்݁Φ଴ (eq. 2.26) 
 
்݁ = 1 + ܶ + 12ܶଶ + 16ܶଷ+. . . = ෍ 1݇!ஶ
௞ୀ଴
ܶ௞ (eq. 2.27) 
 
If all possible excitations are taken into account by the cluster operator it is possible to 
calculate a wavefunction equivalent to that of the full CI method, in practice this is 
computationally expensive and the excitation operator is truncated to give more 
practical methods such as CCSD and CCSDT, where T=T1+T2 and T= T1+T2+T3 
respectively. 
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2.4.4 Many-Body Perturbation Theory 
 
An alternate route to account for correlation energy, is that of many-body perturbation 
theory, as proposed by Møller and Plesset. This method is based on Rayleigh-
Schrödinger perturbation theory, where the true Hamiltonian is expressed in the form of 
the zeroth order Hamiltonian, H0, and a perturbation term, V, which includes a 
parameter, λ, which takes a value that varies between zero and one. 
 
ܪ = ܪ଴ + ߣܸ (eq. 2.28) 
 
The eigenfunction, Ψi
(0), and eigenvalue, Ei(0), represent the zeroth order Hamiltonian 
and therefore in a system where λ equals zero these represent the true Hamiltonian. In 
instances where λ does not equal zero, the eigenfunctions and eigenvalues of the 
Hamiltonian can be expressed as Taylor expansions of λ, where n denotes the order to 
which corrections to energy and wavefunction apply. 
 
Ψ௜ = Ψ௜(଴) + ߣΨ௜(ଵ) + ߣଶΨ௜(ଶ)+. . . = ෍ߣ௡Ψ௜(௡)
௡ୀ଴
 (eq. 2.29) 
 E௜ = E௜(଴) + ߣܧ௜(ଵ) + ߣଶE௜(ଶ)+. . . = ෍ߣ௡E௜(௡)
௡ୀ଴
 (eq. 2.30) 
 
The first order correction to the energy is Ei(1), the second order correction to the energy 
is Ei(2), and so forth. These energies can be calculated from the eigenfunctions, as shown 
by equations 2.31-2.34 below, showing the zeroth order correction to the third order 
correction. 
 
ܧ௜
(଴) = නΨ௜(଴) ܪ଴Ψ௜(଴)݀߬ (eq. 2.31) 
 
ܧ௜
(ଵ) = නΨ௜(଴) ܸΨ௜(଴)݀߬ (eq. 2.32) 
 
ܧ௜
(ଶ) = නΨ௜(଴) ܸΨ௜(ଵ)݀߬ (eq. 2.33) 
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ܧ௜
(ଷ) = නΨ௜(଴) ܸΨ௜(ଶ)݀߬ (eq. 2.34) 
 
In Møller-Plesset perturbation theory the zeroth order Hamiltonian is the sum of the one 
electron Fock operators, so to show an improvement over the HF method, equation 2.33 
shows that at least a second order correction to the energy needs to be applied, this 
method is referred to as MP2. 
 
Compared to the truncated CI methods, Møller-Plesset perturbation methods have 
shown to be size consistent for all orders, however these methods do not obey the 
variational theorem, i.e. the energy calculated from the approximation of the true 
wavefunction might not necessarily be greater than the true energy, whilst the HF 
method does obey this principle. Another issue in using this method is, that along with 
CI and CC methods, the calculations can be expensive. Perturbation methods are not as 
impractical as CI and CC, however their use is still limited to relatively small system 
sizes. However further variations have been applied to these methods in order to make 
them more applicable for larger scale systems. One of these is the use of localized 
orbitals, where excitations are restricted to sets of virtual orbitals, termed domains, that 
are spatially close to the occupied orbitals. Application of this local correlation method 
to MP2 is termed LMP2 and due to use of localized orbitals BSSE can be effectively 
eliminated when a large enough basis set is used.10 Another route to decrease 
computational cost is to replace the expensive calculation of the 4-index-2-electron 
integrals with a cheaper combination of 2- and 3-electron integrals. This is termed 
density fitting, DF, and in instances has shown to reduce computational cost of MP2 by 
an order of magnitude.11,12 Combination of density fitting and local correlation methods 
has been used throughout this work and when used with MP2 is termed DF-LMP2.13 
 
2.5 Density Functional Theory 
 
Density functional theory (DFT) has become a widespread method that is more 
computationally inexpensive than the post-HF methods mentioned above, but can 
improve on results from the HF method, by giving good geometries and it can account 
for electron correlation. Instead of calculating the wavefunction, DFT calculates the 
total electronic density distribution as a means to calculate the electronic energy. 
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2.5.1 Hohenberg-Kohn Theorems 
 
The origins of DFT are found in the Thomas-Fermi model from the late 1920s, where 
the electronic energy was attempted to be calculated from the electron density, but flaws 
in this approach, such as the inability to describe molecular bonding, rendered this 
method impractical for any real system. However the first real advancement in the use 
of DFT for molecules came from the two Hohenberg-Kohn theorems, developed in 
1964. Their first theorem demonstrates that the ground state energy and other system 
properties can be uniquely defined by the electron density, which can be expressed in a 
way that the energy is a unique functional of the density, ρ(r). 
 
ܧ[ߩ(ݎ)] = න ௘ܸ௫௧(ݎ)ߩ(ݎ)݀ݎ + ܨ[ߩ(ݎ)] (eq. 2.35) 
 
The first term of equation 2.35 represents the interaction of electrons with an external 
potential, Vext(r), which is usually due to Coulombic interactions with nuclei. The 
second term, F[ρ(r)], is the sum of the electron's kinetic energy and interelectronic 
interactions. The second theorem demonstrates that the density obeys the variational 
principle, such that any trial density will result in an energy that is greater than or equal 
to the exact energy. 
 
2.5.2 Kohn-Sham Equations 
 
The second significant advancement in DFT came in 1965, where Kohn and Sham 
proposed a practical way to solve the Hohenberg-Kohn theorems for interacting 
electrons. The issue with the expression for the first theorem in equation 2.35 is that the 
term F[ρ(r)] is not known, Kohn and Sham approached this as a sum of terms to 
represent contributions to the total function. 
 
ܨ[ߩ(ݎ)] = ܧ௄ா[ߩ(ݎ)] + ܧு[ߩ(ݎ)] + ܧ௑஼[ߩ(ݎ)] (eq. 2.36) 
 
EKE[ρ(r)] is the kinetic energy, EH[ρ(r)] is the electron-electron Coulombic repulsion 
energy, and EXC[ρ(r)] contains contributions from both exchange and correlation. The 
kinetic energy term is defined as the kinetic energy of a system of non-interacting 
electrons that has the same density as the real system and the electron-electron repulsion 
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term is the Hartree electrostatic energy, using these terms the full expression for the 
energy for the Kohn-Sham method can be expressed as equation 2.37. 
 
ܧ[ߩ(ݎ)] = ෍න߰௜(ݎ) (−∇ଶ2ே
௜ୀ଴
)߰௜(ݎ)݀ݎ + 12නනߩ(ݎଵ)ߩ(ݎଶ)|ݎଵ − ݎଶ| ݀ݎଵ݀ݎଶ
+ ܧ௑஼[ߩ(ݎ)] −෍න ܼ஺|ݎ − ܴ஺|ߩ(ݎ)݀ݎெ
஺ୀଵ
 
(eq. 2.37) 
 
2.5.3 Local Density Approximation 
 
The difference between most DFT methods lies in the exchange-correlation functional, 
EXC[ρ(r)], if this term was exact it would be possible to find a perfect solution for any 
system, but as this is not known approximations are made and one of the advantages of 
DFT is that even relatively simple approximations give favourable results. The simplest 
of these is local density approximation, LDA, which is based on the uniform electron 
gas model, in which the electron density is constant throughout space, therefore 
integration over all space will give the total exchange-correlation energy, where the 
term εXC[ρ(r)], is the exchange-correlation energy of a uniform electron gas. 
 
ܧ௑஼[ߩ(ݎ)] = නߩ(ݎ)ߝ௑஼[ߩ(ݎ)]݀ݎ (eq. 2.38) 
 
LDA assumes that spin is zero at all points, so in instances where α and β densities are 
not equal the more general method local spin density approximation, LSDA, is used. 
 
2.5.6 Generalised Gradient Approximation 
 
The use of an ideal model, such as the uniform electron gas model, has inherent errors. 
To overcome errors the exchange-correlation energies should not only depend on the 
density but the derivatives of the density should also be considered. These methods are 
known as gradient corrected or as generalised gradient approximation, GGA. These 
methods are considered as corrections to LDA and LSDA, such as the popular 
functional proposed by Becke14, B88. 
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ܧ௫஻଼଼ = ܧ௫௅஽஺ − ߛ෍න ߩ௦(ݎ)ସଷݔ௦ଶ1 + 6ߛݔ௦ݏ݅݊ℎିଵݔ௦ ݀ݎ
௦
 (eq. 2.39) 
 
ݔ௦ = |∇ߩ௦(ݎ)|
ߩ௦(ݎ)ସଷ  (eq. 2.40) 
 
2.5.7 Hybrid DFT Methods 
 
Hybrid DFT methods are those that use a combination of the exact HF exchange energy 
with LSDA exchange energy, these can also include gradient correction terms. One of 
the most widely used DFT methods is that of Becke's three-parameter functional, 
B3LYP.15 This method uses a combination of exact, LSDA, and B88 exchange with a 
combination of LSDA and Lee-Yang-Parr, LYP,16 correlation energy, where the terms 
are weighted using three parameters by fitting to experimental data. Another hybrid 
method, that has been used extensively throughout this work, is that of Becke's Half and 
Half functional, BHandH.17 This functional uses half exact and half LDA exchange 
coupled with the LYP correlation term, as shown by equation 2.41. 
 
ܧ௑஼
஻ு௔௡ௗு = 12ܧ௑ுி + 12ܧ௑௅஽஺ + ܧ஼௅௒௉ (eq. 2.41) 
 
2.5.8 Dispersion Corrected DFT 
 
The use of DFT shows that electron correlation is accounted for and as these methods 
are much more computationally efficient than the post-HF methods above, it is a useful 
technique to get favourable geometries and energies on systems beyond the capability of 
the more accurate correlated methods. But whilst electron correlation is accounted for, 
the inexact treatment of the correlation term means that systems containing van der 
Waals forces, such as dispersion based interactions, do not give proper descriptions of 
the r-6 relationship at longer distances. However this is not the case for all functionals, 
for example BHandH has been shown to be effective for dispersion based systems, 
through what is assumed as a cancellation of errors.18 
 
There are other approaches to account for dispersion in DFT methods, functionals can 
be highly parameterised to account for these interactions, such as Truhlar's Minnesota 
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family of functionals.19,20 Another route which has been used throughout this work is 
that of an empirical correction, in the form of an atom pairwise sum over r-6 potentials, 
to the Kohn-Sham energy to account for dispersion, this technique is termed DFT-D and 
in the form below was formulated by Grimme.21 
 
ܧ஽ி்ି஽ = ܧ௄ௌି஽ி் + ܧௗ௜௦௣  (eq. 2.42) 
 
ܧௗ௜௦௣ = −ݏ଺ ෍ ෍ ܥ଺௜௝ܴ௜௝଺ ௗ݂௠௣ேೌ೟௝ୀ௜ାଵ
ேೌ೟ିଵ
௜ୀଵ
(ܴ௜௝) (eq. 2.43) 
 
ௗ݂௠௣(ܴ௜௝) = 11 + ݁ିௗ(ோ೔ೕ/ோೝିଵ) (eq. 2.44) 
 
Where Nat is the number of atoms in the system, Rij is the distance between two atoms i 
and j, C6ij is the dispersion coefficient for the two atoms, s is a global scaling factor 
which is dependent on the functional used, and fdmp is a damping function as shown by 
equation 2.44. The dispersion correction in equation 2.42 is termed D2 and has been 
refined for a broader range of applicability and higher accuracy. This newer approach is 
termed D3 and also takes into account r-8 terms as well as r-6 terms, as shown by 
equation 2.45.22 
 
ܧௗ௜௦௣
஽ଷ = −12෍(ݏ଺ ܥ଺௜௝ܴ௜௝଺ + [ ௗ݂௠௣(ܴ௜௝)]଺ +௝ஷ௜ ݏ଼ ܥ଼௜௝ܴ௜௝଼ + [ ௗ݂௠௣(ܴ௜௝)]଼) (eq. 2.45) 
 
2.6 Quantum Mechanics/Molecular Mechanics 
 
The methods above can be used to great effect when carrying out calculations on small 
to medium size systems, but issues can arise when the desired system is too large, this is 
particularly prevalent in biological systems, such as DNA, or systems that require the 
presence of explicit solvent molecules. In these cases a combination of quantum 
mechanics and molecular mechanics (QM/MM) can be used, where the part of the 
system that is of greatest interest is treated at the QM level and the remainder is treated 
with a force field method, which was first introduced by Warshel and Levitt in 1976.23  
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The total energy of the system can be written as the sum of the QM energy, EQM, the 
MM energy, EMM, and the energy of the interaction between the two parts of the system, 
EQM/MM. 
 
ܧ௧௢௧௔௟ = ܧொெ + ܧெெ + ܧொெ/ெெ (eq. 2.46) 
 
2.6.1 Molecular Mechanics 
 
Molecular Mechanics (MM), sometimes known as force field methods, differ from 
quantum mechanical methods in a way that electronic motion is neglected and energy is 
calculated as a function of nuclear positions. As a result of this MM can be used for 
systems that contain a large amount of atoms and can yield results of reasonable 
accuracy when compared to ab initio methods, at a fraction of the computational cost. A 
typical force field calculates energy through the summation of five potential terms as 
shown in equation 2.47. 
 
ܧ = 12 ෍ ݇௜(݈௜
௕௢௡ௗ௦
− ݈௜,଴)ଶ + 12 ෍ ݇௜(ߠ
௔௡௚௟௘௦
− ߠ௜,଴)ଶ 
																										+ 12 ෍ ௡ܸ(1
௧௢௥௦௜௢௡௦
+ ܿ݋ݏ(݊߱ − ߛ))
+ ෍ ෍ (4ߝ௜௝[(ߪ௜௝ ݎ௜௝ൗ )ଵଶ − (ߪ௜௝ ݎ௜௝ൗ )଺]ே
௝ୀ௜ାଵ
ே
௜ୀଵ
+ ݍ௜ݍ௝4ߨߝ଴ݎ௜௝) 
(eq. 2.47) 
 
The first term represents a summation of the interaction between pairs of bonded atoms, 
modelled as a harmonic potential that shows an increase in energy as bond length 
deviates from the reference. The second term models all intermolecular bond angles and 
is also represented by a harmonic potential. The third term is periodic potential to model 
energy change of bond rotation. The fourth term combines the non-bonding interactions, 
through use of the Lennard-Jones potentials, and the electrostatic interactions through 
Coulombic potentials, respectively. 
 
The AMBER force field has been used within this work and stands for Assisted Model 
Building and Energy Refinement24. It has been calibrated for use in biological 
simulations of nucleic acids and proteins, against diffraction studies and quantum 
mechanical studies. This model has some differences from the standard form, to be 
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effective in its treatment of biological systems, such as a potential term in the form r-12-
r-10, being included to explicitly model hydrogen bonds and inclusion of explicit lone 
pairs in sulphur hydrogen bonding. 
 
2.6.2 ONIOM 
 
ONIOM is a QM/MM scheme that stands for Our own N-layered Integrated Orbital 
Molecular mechanics, that was developed by Morokuma and co-workers25-28. This 
method allows use of multiple layers but will be restricted to two layers, high and low 
for QM and MM respectively, within this work. The extrapolated ONIOM energy is 
written in the form of equation 2.48, where the term real relates to the entire system and 
the term model relates to the part of the system that is of interest. 
 
ܧ௛௜௚௛ ,௥௘௔௟ைேூைெ = ܧ௛௜௚௛ ,௠௢ௗ௘௟ + ܧ௟௢௪ ,௥௘௔௟ − ܧ௟௢௪,௠௢ௗ௘௟ (eq. 2.48) 
 
2.7 Semi-Empirical Methods 
 
Semi-empirical methods are approximate molecular orbital theories which attempt to 
reduce the computational cost of the traditional Hartree-Fock method. The source of the 
greatest proportion of time spent carrying out a HF calculation is the calculation and 
manipulation of integrals so in order to decrease computational effort the aim is to 
approximate or neglect some of these integrals. This can be achieved in part by only 
considering the valence electrons explicitly, whilst the core electrons are accounted for 
in the nuclear charge or with functions that model repulsion from the combined nuclei 
and electrons. 
 
Many semi-empirical methods are based on the zero differential overlap approximation, 
which sets the overlap between pairs of different orbitals to zero for all volume 
elements. This results in a simplification of the Roothaan-Hall equations, as the overlap 
matrix is reduced to a unit matrix, and all three and four centre integrals being set to 
zero. These approximations are compensated by including parameterisation of the 
remaining integrals, which can be based on experiments or more accurate calculations. 
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2.8 Quantum Theory Atoms In Molecules 
 
2.8.1 Electron Density 
 
Quantum Theory Atoms In Molecules (QTAIM) is a method to partition the electron 
density between the atoms in a molecule as a population analysis scheme and was 
developed by Bader.29 This approach is based on the electron density, which can be 
defined in terms of the wavefunction, as shown in equation 2.49. 
 
ߩ(ݎ) = න߰∗(ݎ)߰(ݎ)݀ݎ (eq. 2.49) 
 
Analysis of the topology of the electron density can be used to define key points in the 
system specifically through the gradient of the density. This gradient vector forms a 
curve around the molecule that at all points is perpendicular to the contours of electron 
density and must have a beginning, which is usually infinity, and an end where it 
disappears, which are referred to as a critical points, as represented for ethene in figure 
2.8.1.1. 
 
 
Figure 2.8.1.1 Gradient vector paths associated with an ethene molecule.6 
 
The electron density can also be used to observe molecules in other ways such as 3D 
maps of the density in relation to planes of molecules, the contours of the density can be 
shown in 2D plots, and an isosurface can be mapped to show molecular shape and the 
surface of the molecule, as shown by representations of ethene in figure 2.8.1.2. 
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a) b) c) 
Figure 2.8.1.2 Electron density of ethene represented as a) 3D relief, b) 2D contour 
map, and c) isodensity surface.6 
 
2.8.2 Critical Points 
 
Critical points occur when the gradient vector equals zero and they can be maxima, 
minima, or saddle points in relation to the curvature of the electron density. This can be 
found by diagonalising the 3x3 Hessian matrix, the second derivatives, of the electron 
density and the eigenvalues from this show the curvature in each direction. Each critical 
point can be classified by rank, which equals the number of non zero eigenvalues and in 
the case where all three eigenvalues are non zero there are four possible types. 
 
1. (3,-3): This type has all three eigenvalues negative and shows a local maximum 
in the density, this is indicative of nuclear positions. 
2. (3,-1): This type has two of the eigenvalues negative with the density maximum 
in the plane that corresponds to the axes of the negative eigenvalues, this is 
indicative of a chemical bond and is termed a bond critical point (BCP). 
3. (3,+1): This type has two of the eigenvalues positive with the density minimum 
in the plane that corresponds to the axes of the positive eigenvalues, this is 
found within rings and is termed a ring critical point (RCP). 
4. (3,+3): This type has all three eigenvalues positive and shows a local minimum 
in the density, this if found within cages and is termed a cage critical point 
(CCP). 
 
The BCP is usually of most interest as it defines a bond path between the critical point 
and the nuclei along which the electron density is a maximum. This bond path is 
indicative of an interaction between two atoms but this does not necessarily indicate a 
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covalent interaction. At these points along with the density, the Laplacian of the 
electron density should also be considered, ∇2ρ. 
 
∇ଶߩ(ݎ) = ߲ଶߩ(ݎ)
߲ݔଶ
+ ߲ଶߩ(ݎ)
߲ݕଶ
+ ߲ଶߩ(ݎ)
߲ݖଶ
 (eq. 2.50) 
 
∇2ρ shows a measure of the local concentration of the charge density, i.e. when ∇2ρ > 0 
there is a local depletion of electron density and when ∇2ρ < 0 there is locally 
concentrated charge. Using this it is possible to characterise the nature of interactions at 
the BCPs. An example being hydrogen bonds, which have an electron density at critical 
points an order of magnitude smaller than covalent bonds as well as a positive 
Laplacian of the electron density.30 
 
2.9 Practical Considerations 
 
2.9.1 Geometry Optimisation 
 
The Potential Energy Surface, PES, of a system is a hypersurface of the potential energy 
which is a function of the nuclear positions. Where there are N nuclei in a system there 
are 3N-6 coordinate dimensions to describe the nuclear arrangement, as a result of this 
to visualise the PES in polyatomic systems cannot be done without taking into account 
derivatives of the energy. Stationary points can be found at places on the surface where 
the first derivative of the energy is equal to zero, these are usually the points of greatest 
interest in chemical systems as they equate to minima, maxima, and saddle points. 
 
As there can be several of these stationary points on the surface the goal of geometry 
optimisation is to find the lowest minimum, which is also referred to as the global 
minimum. The global minimum corresponds to the most stable conformation and the 
lowest energy, whilst other local minima correspond to lower energy areas in relation to 
adjacent areas on the surface but are not the most stable configurations of  the system. It 
is possible for systems to move between minima with the addition of energy to the 
system, this is achieved by passing over the surrounding barriers through another type 
of stationary point, the saddle point, which in chemical systems is also known as the 
transition state. To distinguish between minima and saddle points, where the first 
derivative is zero for both, the second derivative is taken, by calculation of the Hessian 
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matrix, where negative eigenvalues are transition states and zero eigenvalues are 
minima. 
 
 
Figure 2.9.1.1 An example of a potential energy surface, taken from reference 31. 
 
Optimisation of chemical systems aims to find these minima and in some cases the 
transition states, this is achieved through optimisation algorithms and one of the most 
common and simplest methods to include second derivatives is the Newton-Raphson 
method. This approach writes a function, f(x), as a Taylor expansion around the point 
x0, where the first derivative can be written in the form of equation 2.51. 
 
݂′(ݔ) = ݔ݂′(ݔ଴) + (ݔ − ݔ଴)݂′′(ݔ଴) (eq. 2.51) 
 
If the function, f(x), is purely quadratic the second derivative is equal everywhere and 
so the second derivative of x is equal to the second derivative of x0. So at the minimum 
where the first derivative of f(x) equals zero, x can be calculated by equation 2.52. 
 
ݔ = ݔ଴ − ݂′(ݔ଴)݂′′(ݔ଴) (eq. 2.52) 
 
If x0 is a hypothetical solution to f´(x)=0, then x in equation 2.52 is a new solution, this 
shows the equation is used to provide an iterative solution. However this operation can 
be time-consuming as for each step the Hessian matrix must be calculated and inverted. 
Variants on this methods have been used which aim to reduce computational effort by 
only requiring first derivatives and gradually constructing the inverted Hessian matrix in 
successive iterations, these methods a termed quasi-Newton methods. 
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Combination of the Newton-Rhapson method with Pulay's direct inversion of iterative 
subspace, DIIS, which is used to aid convergence within self consistent field reactions 
has yielded a method termed geometry DIIS, GDIIS, which has shown to be more 
efficient in the optimisation of large molecules.32 A further improvement to this method 
has also been presented by Li and Frisch33 which uses an energy-represented DIIS, this 
is termed GEDIIS and has shown improvements over the other methods here. 
 
2.9.2 Solvent Models 
 
To carry out accurate simulations on molecules or chemical systems the effect of the 
solvent present should be accounted for. This can be done in two ways, the solvent can 
be accounted for explicitly, but in these cases the addition of the necessary amount of 
extra molecules can render a calculation impractical. The other approach is to account 
for the effect of the solvent implicitly by describing it as a uniform polarisable medium 
with a dielectric constant, ε, with a cavity in which the solute or molecule of interest is 
placed, this method is termed the self consistent reaction field, SCRF. Interaction with 
the solvent results in a perturbation of the molecule, which in turn perturbs the reaction 
field, this can be accounted for in the Hamiltonian. 
 
ܪ௧௢௧௔௟ = ܪ଴ − ߤ் 2(ߝ − 1)(2ߝ + 1)ߙଷ < Ψ|ߤ|Ψ > (eq. 2.53) 
 
In equation 2.53 H0 is the unperturbed Hamiltonian, μ is the dipole moment, and α is the 
radius of the cavity. In this approach there is an energy penalty that needs to be 
accounted for which arises from formation of the cavity, ΔGcavity, however along with 
this there is some stabilisation resulting from electrostatic and van der Waals 
interactions between the solute and solvent, ΔGelec and ΔGdisp respectively. In this way 
the free energy change of solvation can be written as equation 2.54. 
 
∆ܩ௦௢௟௩௔௧௜௢௡ = ∆ܩ௖௔௩௜௧௬ + ∆ܩ௘௟௘௖ + ∆ܩௗ௜௦௣ (eq. 2.54) 
 
Two solvent models have been used throughout this work, the polarisable continuum 
model, PCM,34 which uses a van der Waals surface to model the cavity, and the 
conductor like screening model, COSMO.35 COSMO differs from the dielectric medium 
methods in that the cavity is embedded in a conductor with infinite dielectric constant. 
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The advantage of this is that screening effects for a conductor are easier to handle and 
small corrections to results of the conductor can give appropriate values for solvents 
with high dielectric constants, such as water. Another advantage is that the potential on 
the surface of the conductor from the solvent and solute charges is set to zero which 
results in convenient boundary conditions for determining surface charges. 
 
2.9.3 Structural Analysis of DNA 
 
To analyse the structures of DNA helices that have been studied throughout this work, 
base pair parameters have been utilised. These show a combination of rotational and 
translational parameters that can be used to distinguish geometry around a base pair step 
and allow effective comparison between different structures. Figure 2.9.3.1 exhibits the 
six parameters considered, alongside a reference coordinate frame. The shift, rise, and 
slide parameters are translational and the roll, tilt, and twist are rotational. This form of 
analysis was carried out using the x3DNA software.36 
 
  
Figure 2.9.3.1 Base pair parameters considered in this work.37 
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2.9.4 Programs and Methods 
 
All DFT calculations have been performed using Gaussian 03,38 or Gaussian 09.39 
Unless specified the basis set 6-31+G** has been used and where required the Stuttgart-
Dresden ECP, SDD,40 has been used for transition metals. All ONIOM calculations 
have been carried out using Gaussian 09, with the AMBER force field. Where needed 
the PCM solvent model has been used. 
 
All DFT-D calculations have been carried out using turbomole v5.10,41 exclusively 
using the B97-D42 functional with the def2-TZVP43 basis set and the def2-ECP 
pseudopotential40 where required. Unless specified B97-D was carried out using the D2 
correction. Density fitting in the form of resolution of identity, (ri) has been utilised. D3 
dispersion corrections were calculated using the DFT-D3 program.22 Where needed the 
COSMO solvent model has been used. 
 
All local MP2 and local CCSD calculations have been carried out using the Molpro 
suite of programs44 using aug-cc-pVTZ basis sets for heavy atoms and cc-pVTZ for 
hydrogen.45 The density fitting approximation has been employed for all calculations, 
where the aug-cc-pVTZ fitting basis set has been used for HF and MP2 where 
available.46,47 
 
Semi-empirical calculations using the PM648 and PM6-DH249 models were carried out 
using the MOPAC software.50 Where needed the COSMO solvent model has been used. 
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Chapter 3: Non-Covalent Interactions of Transition Metal Complexes 
 
3.1 Introduction 
 
The work in this chapter aims at testing the suitability of two DFT functionals, BHandH 
and B97-D, for calculating non-covalent interactions of transition metal complexes 
containing coordinated aromatic systems. Both methods show potential as BHandH has 
been used to calculate stacking interactions of benzenes, pyridines, and nucleobases1 
and B97-D has been constructed with an empirical dispersion correction to account for 
non-covalent interactions.2 Model systems have been studied to validate methods which 
have then been used on ruthenium arene 'piano-stool' anti-cancer complexes, to study 
interactions in 'real' biological systems. The content in sections 3.2.1 and 3.2.2 comes 
from work within our group, published in references 3 and 4 respectively. All the work 
presented here from these publications was carried out by myself, with the exception of 
the CBS(T) calculations in section 3.2.1, which were carried out by my supervisor Dr 
Jamie Platts. 
 
3.2 Interactions within Intermolecular Complexes 
 
3.2.1 Non-Covalent Interactions of Ferrocene and 6(C6H6)Cr(CO)3 
 
Transition metal complexes that contain coordinated aromatic rings have the potential to 
form non-covalent interactions in the same way benzene or analogous molecules do. 
Directly coordinated arenes can form CH...π interactions with methane and π...π 
stacking interactions with benzene. These interactions have been probed with two test 
systems, ferrocene, which contains iron with two cyclopentadienyl ligands coordinated 
in the η5 fashion and (C6H6)Cr(CO)3 which contains chromium with benzene 
coordinated in the η6 fashion and three carbonyl ligands. These were chosen as a mix of 
sandwich and half-sandwich neutral complexes containing two types of coordinated 
aromatic ring. Four interaction types have been examined with these two complexes: 
methane, with a CH pointing toward the aromatic ring; and three benzene formations, 
parallel displaced (PD), T-shaped (T), and inverted-T as shown in figure 3.2.1.1. 
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Figure 3.2.1.1 Schematic representation of intermolecular complexes of methane and 
benzene with ferrocene and 6(C6H6)Cr(CO)3 . 
 
Ferrocene and 6(C6H6)Cr(CO)3 were constructed and initially optimised using BP86/ 
6-31+G**, which has shown to be a suitable functional for optimisation of systems 
containing transition metals.5 Both structures confirm the validity of this, as 
comparisons against experimental crystal structure6 and gas phase electron diffraction 
data7 are in excellent agreement, as shown in table 3.2.1.1. 
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Table 3.2.1.1 Comparison of experimental and BP86 optimised geometries for 
6(C6H6)Cr(CO)3 and ferrocene (Å and ). 
 Expt a DFT 
6(C6H6)Cr(CO)3   
Cr-CO 1.834 (4) 1.839 
C-O 1.173 (9) 1.174 
Cr-CH 2.233 (9) 2.229 
C-C 1.414 (9) 1.426 
Ferrocene   
Fe-C 2.054 (3) 2.047 
C-C 1.435 (2) 1.441 
C-H 1.080 (7) 1.091 
mean-C-Hb 3.7 (9) 1.35 
aEstimated standard deviations given in parenthesis. 
bAngle between C-H and mean plane C. 
 
The intermolecular systems shown in figure 3.2.1.1, were constructed from the 
optimised transition metal complexes and methane, with a CH bond of methane 
pointing to the centre of the coordinated ring and benzene in three formations, PD, T, 
and inverted-T. Starting distances and angles of the benzene molecules are based on the 
high level optimised equilibrium values of the benzene dimer as reported in reference 8. 
Similarly the methane system is based on values for the methane...benzene system 
reported in reference 9. The functional of interest to be used here is that of BHandH, 
which has been shown to be effective in calculating interaction energies of the 
uncoordinated analogues of the systems shown in figure 3.2.1.1.1 To check its 
suitability rigid scans were carried out on the constructed intermolecular systems, by 
scanning along the distance between the centroid of the ring and the proton pointing 
towards it, in intervals of 0.1 Å, in the cases of methane, T, and inverted-T. For PD the 
vertical distance between the two rings was the coordinate that was scanned. Along with 
the BHandH scans an ab initio method, DF-LMP2, was also used to act as a benchmark. 
As a result of these scans equilibrium distances and interaction energies at these 
distances are reported in table 3.2.1.2 and the scan for the ferrocene methane system is 
shown in figure 3.2.1.2. 
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Table 3.2.1.2 Equilibrium distances and interaction energies of 6(C6H6)Cr(CO)3 and 
ferrocene systems at equilibrium distances (Å and kcal/mol). 
 BHandH DF-LMP2 
 req E req E 
6(C6H6)Cr(CO)3     
Methane 2.60 -1.60 2.80 -1.38 
T 2.50 -2.06 2.50 -2.53 
PD 3.40 -3.00 3.30 -5.80 
Inverted-T 4.80 -6.27 4.80 -6.55 
Ferrocene     
Methane 2.50 -1.97 2.80 -1.44 
T 2.40 -3.02 2.50 -2.97 
PD 3.40 -1.67 3.30 -4.14 
Inverted-T 4.70 -3.23 4.70 -4.70 
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Figure 3.2.1.2 Scan profile of the Methane ferrocene system using BHandH and DF-
LMP2. 
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The data in table 3.2.1.2 shows that the minima of the scans for BHandH and DF-LMP2 
have similar equilibrium distances, with the exception of the methane complexes the 
distances differ by no more than 0.1 Å. The scan in figure 3.2.1.2 shows that even for 
the methane ferrocene system, which from the equilibrium distances has the greatest 
difference between BHandH and DF-LMP2, the profiles follow a similar shape, with 
BHandH slightly underestimating the minima and overestimating the interaction energy 
when compared to the DF-LMP2 values. This indicates that, in general, BHandH is as 
successful at locating minimum energy geometry as MP2, which means that it should be 
suitable at carrying out full optimisation of these intermolecular complexes. 
 
These systems were then fully optimised without symmetry restrictions using 
BHandH/6-31+G** and binding energies of the metal complex methane/benzene 
interactions were calculated at this level, with basis set superposition (BSSE) accounted 
for with the counterpoise method. To supplement these values, binding energies were 
also calculated with another DFT functional, B97-D, which contains an empirical 
dispersion correction to account for electron correlation and has been used extensively 
throughout this work, as well as two ab initio techniques as benchmarks, DF-LMP2 and 
CBS(T). CBS(T) is considered the current state of the art method for calculating non-
covalent interactions, this entails extrapolating to the basis set limit with a method such 
as MP2 and then correcting with a coupled cluster method, CCSD(T), with a smaller 
basis set, in this case cc-pVDZ.3,10-12 Rigid scans to check the accuracy of B97-D for 
optimisation were not carried out as this functional was tested against BHandH and 
experimental data in section 5.2.1 and tested against BHandH for these complexes 
below. All binding energy calculations were carried out at the geometry of the BHandH 
optimised structures and results are reported in table 3.2.1.3. 
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Table 3.2.1.3 Binding energies of 6(C6H6)Cr(CO)3 and ferrocene complex…systems 
calculated using DFT, MP2, and CBS(T) (kcal/mol). 
 BHandH  B97-D  DF-LMP2 CBS(T)3 
6(C6H6)Cr(CO)3     
Methane -1.29 -1.25 -1.35 -1.27 
T -2.06 -2.45 -2.53 -2.38 
PD -2.92 -2.68 -5.62 -4.22 
Inverted-T -6.12 -5.40 -6.49 -5.85 
Ferrocene     
Methane -1.69 -1.42 -1.44 -1.47 
T -2.95 -2.70 -2.97 -2.86 
PD -1.60 -2.77 -3.99 -3.00 
Inverted-T -3.17 -4.03 -3.94 -3.57 
 
For the chromium complexes all four methods give the same ranking, where inv-T > PD 
> T > methane. Values for the methane complex are in good agreement with no 
difference greater than 0.1 kcal/mol. BHandH energies for the T complex are slightly 
underestimated when compared to the CBS(T) values, which is to be considered the 
more accurate of the benchmark methods, whilst the B97-D value is slightly 
overestimated. The inv-T complex gives the opposite result where BHandH gives a 
stronger binding energy than B97-D, when compared to CBS(T) energies, this system 
also has significantly higher values than the corresponding T system, this is most likely 
due to additional interactions formed between the oxygen of carbonyl ligands and the 
protons on the free benzene. The most striking differences between DFT and ab initio 
are for the PD complexes, where the DFT methods give energies approximately 1.5 
kcal/mol weaker than the CBS(T) values, DF-LMP2 significantly overestimates here, 
but this is not unexpected for this method.13,14 However overall both DFT functionals 
give reasonable binding energies compared to benchmarks for this metal complex. 
 
The ferrocene complexes aren't as conclusive in their energy ordering between methods, 
conversely though the energy differences between the different conformations are 
smaller, as shown by the small differences between the T and PD systems for CBS(T) 
and B97-D. Between the two functionals, B97-D generally gives values more 
comparable to the benchmarks, with the exception of the T complex, where BHandH 
performs better. The BHandH energy for the PD complex is the most anomalous result 
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and is significantly underestimated when compared to CBS(T), with the exception of 
this result and the slight differences in order both functionals still give reasonable 
binding energies. 
 
As all the binding energies were calculated at the BHandH/6-31+G** optimised 
structures, the same systems have also been optimised using the B97-D functional to 
check the validity of the geometries yielded by the former method. Figure 3.2.1.3 shows 
the optimised structures at the BHandH level for both complexes, at a visual 
comparison between the two functionals significant differences cannot be discerned, 
hence only one set of structures are reported. To further compare the structures selected 
geometrical parameters have been measured and are reported in table 3.2.1.4.  
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6(C6H6)Cr(CO)3 Ferrocene 
 
Figure 3.2.1.3 Optimised structures of 6(C6H6)Cr(CO)3 and ferrocene using 
BHandH/6-31+G**. 
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Table 3.2.1.4 Selected geometrical parameters of optimised 6(C6H6)Cr(CO)3 and 
ferrocene complexes calculated using BHandH and B97-D (Å and °). 
Complex Method Distance a 
Angle between 
planes 
Centroid...H—C 
6(C6H6)Cr(CO)3       
CH4  BHandH 2.50  179.86 
         B97-D 2.64  179.15 
PD  BHandH 3.59 0.14  
        B97-D 3.80 0.77  
T      BHandH 2.49 89.35 150.10 
        B97-D 2.42 79.91 157.78 
inv-T  BHandH 2.29 73.90 166.40 
           B97-D 2.34 74.27 163.42 
Ferrocene     
CH4  BHandH 2.53  179.20 
         B97-D 2.61  177.88 
PD  BHandH 3.80 9.24  
        B97-D 3.87 8.74  
T      BHandH 2.37 89.84 179.15 
        B97-D 2.45 89.80 179.24 
inv-T  BHandH 2.41 84.06 173.08 
           B97-D 2.44 83.22 172.17 
aDefined as distance from donor hydrogen to acceptor centroid, or centroid...centroid 
distance in PD, i.e. the distance between the centroid of the two parallel rings. 
 
For the chromium complexes there are very small differences between the donor 
hydrogen/centroid to centroid distances, no larger than 0.21 Å. For the methane, PD, 
and inv-T systems there are insignificant differences in the reported angles. The only 
system that shows any real discernible difference is the T complex, where BHandH 
gives a structure that the two rings are perpendicular, whilst in the B97-D structure the 
benzene tilts slightly off the ideal by approximately 10 °, although even with this 
difference both methods are in good agreement. The ferrocene complexes are generally 
in closer agreement than the chromium complexes, with differences in the distance 
parameter no greater than 0.08 Å and insignificant differences in the angle 
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measurements. Overall, for both complexes, BHandH and B97-D give structures that 
are comparable so the binding energy comparison above is suitable. 
 
3.2.2 Non-Covalent Interactions of [6(C6H6)Ru(en)Cl]+ 
 
The transition metal complex [6(C6H6)Ru(en)Cl]+, is based around Sadler's ruthenium 
arene anti-cancer drugs, containing benzene coordinated in the 6 fashion. It is possible 
for it to form non-covalent interactions within intermolecular complexes including 
methane and benzene, specifically CH… interactions and … stacking, around the 
coordinated benzene ring. These interactions have been probed with a comparison of the 
two DFT methods used above, BHandH and B97-D, and one ab initio approach, 
MP2/6-31G(0.25)d, to ascertain the effectiveness of calculating binding energies and 
finding optimised structures. This MP2(0.25) approach uses a basis set containing more 
diffuse d functions, with an exponent of 0.25 instead of 0.8, which has shown to give 
good results for systems containing dispersion based reactions.15 The CBS(T) method 
has not been attempted here as the data above shows reasonably good agreement with 
the DFT methods, therefore it was deemed unnecessary to carry out these calculations 
on another set of systems. Complexes were constructed with one methane C-H bond 
pointing towards the coordinated aromatic system, and benzene in three formations, 
parallel displaced (PD), T-shaped (T), and “inverted” T-shaped, as shown in figure 
3.2.2.1. These model systems were optimised using BHandH/6-31+G**/SDD and B97-
D/def2-TZVP, with binding energies (tables 3.2.2.1 and 3.2.2.2) and geometrical 
parameters (table 3.2.2.3) reported below. 
 
   
 
Methane PD T Inverted-T 
 
Figure 3.2.2.1 Intermolecular complexes of methane and benzene with 
[6(C6H6)Ru(en)Cl]+. 
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Due to the low symmetry of the ruthenium complex, there are several possible starting 
orientations for geometry optimisations: for instance, six possible inverted-T structures 
could be envisaged. All were explored, and systems with the lowest energy used for 
further analysis. During optimisation, a tendency for higher energy structures to flip to 
lower energy ones was noted, indicating that small barriers separate the different forms. 
To attain full optimisation in such cases, coordinates were extracted at the point before 
the flip and used as the starting point of a new optimisation wherein the system 
optimised to the desired local minimum. 
 
Table 3.2.2.1 Binding energies of ruthenium complex…systems calculated using DFT 
and MP2 (kcal/mol). 
 BHandH  B97-D  MP2(0.25) 
Methane -1.65 -1.53 -0.77 
T -2.43 -2.81 -2.27 
PD -7.04 -7.72 -8.02 
Inverted-T -11.78 -13.02 -11.72 
 
The calculated binding energies of the ruthenium systems are reported in table 3.2.2.1. 
The energies calculated using all three techniques are in good general agreement, 
having the same ranking of: inverted-T > PD > T > methane, and values are within ca. 1 
kcal/mol of one another. Values for the methane complex differ little from that for 
methane…benzene in the same orientation (literature value of -1.45 kcal/mol calculated 
using CCSD(T) at the basis set limit9). The T-shaped complex has binding energies 
slightly larger than, although probably within the expected errors of the methods used, a 
reference value for the benzene dimer in the same orientation (-2.24 kcal/mol using 
CCSD(T) with a triple ζ basis set8). 
 
In contrast, binding energies for the parallel displaced and inverted-T forms are much 
larger than the analogous values in the benzene dimer. (PD reference = -2.51 kcal/mol, 
calculated using CCSD(T) with a triple ζ basis set8). The calculations in section 3.2.1 
show that metal complexation increases stabilization of these forms, with CBS(T) 
values of -4.22 and -5.85 kcal/mol for PD and inverted-T forms of Cr(C6H6)(CO)3 
respectively. The values in table 3.2.2.1 are significantly more negative than those 
reported in table 3.2.1.3, a difference that may be due to the positive charge on the Ru 
complex rather than the neutral complexes studied above. Much of the increased 
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stabilization seems to stem from more favourable electrostatic interactions, especially 
cation..., in the PD and inverted-T forms. Further to this, the inverted-T system is seen 
to form additional NH… interactions with the ethylenediamine ligand, the other 
systems are unable to form analogous interactions, which could in part explain the 
increase in binding energy. 
 
To try to better quantify the origins of the extra stability in these Ru-complexes, 
Hartree-Fock (HF) binding energies as well as the –D dispersion contribution to B97-D 
binding energy are reported in table 3.2.2.2. The inability of HF to calculate dispersion 
yields values that give a better insight into electrostatic interactions. In the isolated 
benzene dimer, HF binding energies are +0.80 and +3.52 kcal/mol for T-shaped and PD 
forms, respectively. Table 3.2.2.2 demonstrates that the T-shaped form, in which the Ru 
complex acts as a proton acceptor, is less stabilised by electrostatic interactions than the 
free benzene dimer. In contrast, the inverted-T form, in which the Ru complex is a 
proton donor, is actually stable at the HF level. This may be due to the proximity of the 
acceptor benzene to the metal centre or to formation of N—H... interactions, 
possibilities that are explored in more detail below. The parallel displaced form is not 
bound at the HF level, but the repulsion is 2 kcal/mol smaller than in the free benzene 
dimer, indicating that this is indeed one source of the extra stability observed in table 
3.2.2.1. 
 
Table 3.2.2.2 Hartree-Fock binding energies and dispersion contributions (kcal/mol). 
 HF/6-31+G(d,p) a -D b 
Methane 1.63 -3.35 
T 3.07 -4.63 
PD 1.38 -9.52 
Inverted-T -1.19 -11.13 
aCounterpoise corrected.  
bDispersion contribution to B97-D binding energy. 
 
Alongside contributions from electrostatics, the large dispersion contributions to 
binding energy reported in table 3.2.2.2 go some way to explaining the strong binding 
energy within this system. Values for the methane and T-shaped complexes are close to 
those for isolated benzene as a proton acceptor (-2.73 and -4.56 kcal/mol, respectively). 
However, in the parallel-displaced form the dispersion correction is larger than in the 
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free benzene dimer (-7.15 kcal/mol), such that the very large binding energy of this 
form is due to enhanced dispersion interactions as well as electrostatics. 
 
Table 3.2.2.3 Selected geometrical parameters of optimised complexes (Å and °). 
 
Complex 
 
Method 
Distance a 
Angle between 
planes 
Centroid...H—C  
CH4  BHandH 2.54  176.59 
         B97-D 2.53  176.33 
PD  BHandH 3.67 15.65  
        B97-D 3.53 8.39  
T      BHandH 2.49 88.61 148.95 
        B97-D 2.53 88.68 176.86 
Inverted-T  BHandH 3.73 82.17 149.06 
           B97-D 3.66 84.24 126.08 
aDefined as distance from donor hydrogen to acceptor centroid, or centroid...centroid 
distance in PD. 
 
Selected geometrical parameters for all complexes are shown table 3.2.2.3. For the 
methane complex, both functionals give very similar structures with almost identical 
H…centroid distance, and root mean square deviation over all atoms of just 0.051 Å. 
Within this RMSD value, the difference between DFT optimized geometry of Ru 
complexes accounts for 0.050 Å, showing both functionals give very similar positions 
for the methane molecule. The centroid...H—C angles show that C—H coordinates 
directly above the centre of the arene. An ideal parallel-displaced complex would have 
parallel angle planes of benzene rings, but in both cases significant tilt is observed at the 
local minimum, indicating some movement towards the inverted-T structure. A rather 
larger tilt and slightly greater centroid...centroid distance is observed with BHandH than 
with B97-D, but overall agreement is good. Nevertheless, a rather large RMSD of 0.89 
Å is observed, since the difference in tilt angle gives rise to differences in position of all 
atoms.  
 
For the two T-shaped systems a similar pattern of broad similarity between methods is 
observed. Both functionals give centroid…H distances and angles between planes 
values that are in close agreement, however the centroid-C-H angle differs, with B97-D 
giving a near 180 ˚ angle, and BHandH tilting the benzene off centre, as seen previously 
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for the free benzene dimer.16,17 Deviation from the ideal perpendicular orientation is 
again observed, an effect that is rather greater with BHandH than for B97-D. Both 
methods show relatively close N—H… contacts in the optimized inverted-T 
complexes, again resulting in changes from the idealised form of perpendicular benzene 
rings. B97-D results in rather closer N-H… contacts, such that the free benzene ring 
moves further from the coordinated ring compared to BHandH, this accounting for the 
rather large RMSD between methods of 0.59 Å.  
 
The largest difference in the DFT binding energies and structures is found in the 
inverted-T system. To further probe this difference, QTAIM analysis was carried out on 
these complexes, with the results shown in figure 3.2.2.2. Using both methods, 
interactions with the ethylenediamine ligands as well with the coordinated arene are 
present in the minimum energy geometry: in the BHandH case, one arene...benzene and 
two ethylenediamine...benzene C—H... are located, whereas in the B97-D case one 
N—H… as well as two arene...benzene and two ethylenediamine...benzene C—H... 
are present. Thus, the increased binding energy and less ideal geometry found with B97-
D appears to be due to formation of more ethylenediamine...benzene contacts rather 
than any fundamental difference in description of interactions between functionals. 
 
 
  
 
Figure 3.2.2.2 Molecular graphs of inverted-T complex calculating using BHandH 
(left) and B97-D (right). Red dots indicate (3, -1) or bond critical points: a cluster of 
such points is found around Ru due to use of ECP, but intermolecular contacts are 
unaffected. 
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3.3 Interactions within Intramolecular Complexes 
 
The anticancer properties of these "piano stool" ruthenium arene complexes have been 
well documented and several different extended aromatic and partially saturated arene 
ligands have been employed in place of benzene.18-22 The interactions of a series, shown 
in figure 3.3.1, consisting of benzene (bz), cymene (cym), biphenyl (biph), anthracene 
(anth), dihydroanthracene (dha), and tetrahydroanthracene (tha) have been extensively 
studied with DNA in chapter 4, using the B97-D functional, with a D2 type correction. 
To confirm the validity of this functional compared to a wide range of other methods, as 
well the same functional employing a newer empirical dispersion correction, tests have 
been carried out on the different ruthenium arene systems coordinated to guanine and 
adenine, through the loss of the chloride ligand. An example of these two systems for 
the benz arene is shown in figure 3.3.2. 
 
 
Figure 3.3.1 Structures of the arenes coordinated to ruthenium. 
 
  
i) ii) 
Figure 3.3.2 Structure of ruthenium benz complex coordinated to i) guanine and ii) 
adenine. 
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To attempt to increase the accuracy of this dispersion correction a more recent type, 
termed D3, has been formalised by Grimme.23 This D3 correction includes r-8 terms for 
close contact interactions as well as the r-6 terms for longer range contacts. Ryde et al., 
have used both DFT-D2 and DFT-D3 to calculate binding energies of a methyl group 
within a cobalt corrin ring, with the intent of finding whether DFT-D type functionals 
treat ligand binding to transition metal complexes correctly.24 Within their system of 
interest the small ligand results in short range interactions that have large dispersion 
based contribution to the energy, when using the functional BP86 with the D3 
correction; they show that the r-8 term becomes dominant. From comparison of binding 
energies to higher level DF-LMP2, which has also been shown by Hill and Platts25 to 
give metal-ligand binding energies with typical errors of less than 1 kcal/mol, and DF-
LCCSD they conclude that DFT-D3 provides reasonably accurate estimates. In light of 
these results, calculations have been carried out for binding energies of the ruthenium 
arenes to nucleobase systems using B97-D3, to ascertain whether D3 correction shows 
significant improvement over D2, even though this system does not contain relatively 
short metal ligand interactions. A wide variety of functionals available in the default 
library of Gaussian 09 have also been explored in this section, to observe whether there 
are any other functionals not explored so far that show good results for this application 
when compared to benchmark ab initio values. 
 
3.3.1 Ruthenium Arene Guanine Complexes 
 
Using the B97-D2 optimised structures from the calculations carried out on the 
ruthenium arene GG/CC complexes in chapter 4, systems that contain just the 
ruthenium complex and a single guanine, bound to ruthenium through N7 atom, were 
constructed by removing the additional nucleobases and sugar phosphate backbone. The 
additional hydrogen needed in the N9 position was added by hand, based on the 
geometry of an optimised B97-D2 guanine molecule. These structures were used to 
carry out binding energy calculations between the ruthenium and N7 nitrogen without 
further optimisation, using a combination of hybrid and pure DFT functionals, double 
hybrid methods, and post Hartree-Fock methods. 
 
Binding energies for the ruthenium arene complexes bound to guanine have been 
calculated, i.e. the energy of the bond between the ruthenium and N7 atom of guanine, 
using B97-D2 and BHandH and are reported in table 3.3.1.1 and shown graphically in 
                                                          Chapter 3: Non-Covalent Interactions of Transition Metal Complexes 
73 
figure 3.3.1.1. In addition to these values, the recent revision to the D2 correction, D3, 
has been applied to the B97 functional for these systems, to give B97-D3 binding 
energies. The damping function for these dispersion corrections would be expected to 
have significance on the corrections, but Grimme et al. have reported, in a paper 
examining the effect of damping in DFT-D calculations, that the Becke Johnson (BJ) 
damping gives negligible difference for the B97-D function on test sets containing non-
covalent interactions, compared to the standard damping function, therefore the standard 
damping function has been used throughout.26 A method of greater accuracy was 
required to benchmark these results, DF-LMP2 with the basis set aug-cc-pVTZ, was 
used for this and binding energies calculated are reported alongside the DFT methods in 
table 3.3.1.1. 
 
Table 3.3.1.1 Binding energies of ruthenium arene complexes to guanine calculated 
using B97-D2, B97-D3, BHandH, and DF-LMP2, values in parenthesis are the 
empirical dispersion corrections (kcal/mol). 
 B97-D2 B97-D3 BHandH DF-LMP2 
Benz -93.37 (-17.07) -90.32 (-14.02) -98.13 -95.38 
Cym -89.02 (-20.23) -82.51 (-16.72) -92.22 -89.84 
Bip -85.17 (-26.73) -81.05 (-22.61) -91.88 -94.80 
Anth -79.30 (-27.69) -75.35 (-23.75) -84.46 -87.59 
Dha -91.44 (-31.20) -86.93 (-26.69) -96.96 -97.79 
Tha -91.05 (-30.98) -86.52 (-26.45) -97.71 -97.02 
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Figure 3.3.1.1 Graph illustrating the difference in binding energies (kcal/mol) for the 
Ru complexes with guanine calculated using DF-LMP2, BHandH, B97-D2, and B97-
D3. 
 
In an attempt to carry out more accurate benchmark calculations, DF-LCCSD 
calculations were carried out, with the same basis set as the DF-LMP2 calculations, due 
to the system size and expense of these calculations only two of the complexes were 
successful. The benzene and dha systems yielded binding energies of –94.40 and –97.19 
kcal/mol respectively, which is within 1 kcal/mol of the DF-LMP2 values of –95.38 
kcal/mol for benzene and –97.79 kcal/mol for dha. This small error between the chosen 
benchmark method and the more accurate calculations confirms its suitability for use 
here. 
 
For the benzene complex B97-D2 and BHandH are within reasonable agreement of the 
DF-LMP2 values, with differences of no greater than +/- 3 kcal/mol. The high binding 
energy for this ligand has been noted before and explained due to the electronic nature 
of the benzene ligand. The cymene complex also has binding energies calculated using 
these two methods that are within good agreement with the more accurate method. B97-
D2 performs very well for this complex with a difference of less than 1 kcal/mol, while 
BHandH overestimates by approximately 2.5 kcal/mol. For the remaining four ligands 
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B97-D2 consistently underestimates the binding energies when compared to the DF-
LMP2 values, with values between 8 and 10 kcal/mol greater. BHandH however 
performs much better for these four, with a difference no greater than 3 kcal/mol for 
anth and bip, and a difference of no greater than 1 kcal/mol for the dha and tha 
complexes.  
 
The binding energies calculated using B97-D3 are more positive and therefore show a 
weaker interaction compared to B97-D2. This difference is fairly uniform across all six 
complexes with a difference of approximately 4 kcal/mol. From the values of the 
dispersion corrections, shown in parenthesis in table 3.3.1.1, it can be confirmed that D2 
corrections give a greater estimation of non-covalent interaction energies. When 
comparing these values to DF-LMP2 values, B97-D2 slightly underestimates the 
binding energies, with a further decrease in the binding energy from using the D3 
correction, this shows that for these systems being studied the D2 correction is 
somewhat surprisingly more suitable. 
 
Traditionally many DFT methods fail or under perform at calculating non covalent 
interactions, B3LYP being an example of this,1 but instead of applying an empirical 
correction to account for dispersion, new functionals can be parameterised to account 
for dispersion. The Minnesota functionals are a family of such methods developed by 
Trulhar, including M06 and M06-2X.27 A hybrid version of the B97 functional with 
dispersion correction has also been formalised, named wB97XD.28 Binding energies for 
the ruthenium guanine complexes were calculated using these three methods to compare 
against the benchmark and the DFT-D values, values are reported in table 3.3.1.2. 
 
Table 3.3.1.2 Binding energies of ruthenium arene complexes to guanine calculated 
using dispersion corrected DFT functionals, M06, M06-2X, and wB97XD (kcal/mol). 
 M06 M06-2X wB97XD 
Benz -85.56 -84.34 -89.62 
Cym -79.23 -78.78 -83.96 
Bip -78.76 -79.59 -85.13 
Anth -73.69 -76.72 -80.54 
Dha -83.62 -84.54 -89.92 
Tha -84.56 -84.92 -90.51 
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Both M06 and M06-2X perform to a similar standard with a difference between their 
calculated binding energies of approximately 1 kcal/mol, with the exception of anth, 
which has a difference of approximately 3 kcal/mol. They both underestimate binding 
energies when compared to the benchmark DF-LMP2 values by 10-16 kcal/mol, which 
is a greater difference compared to the B97-D values. The wB97XD functional 
performs slightly better than the Minnesota functionals used here, although it does 
underestimate when compared to the DF-LMP2 values. It calculates similar values to 
both the B97-D2 and B97-D3 results, as one would expect, but has energies that lie 
between the two different pure DFT-D methods. Data for the DF-LMP2, Minnesota, 
and hybrid B97 functionals is shown graphically in figure 3.3.1.2. 
 
 
Figure 3.3.1.2 Graph illustrating the difference in binding energies (kcal/mol) for the 
ruthenium complexes with guanine calculated using DF-LMP2, M06, M06-2X, and 
wB97XD. 
 
The graphical representations in figures 3.3.1.1 and 3.3.1.2 further show that, for this 
system, when compared to the DF-LMP2 values the DFT-D functionals performs better 
than M06 and M06-2X, and within that B97-D2 performs better than B97-D3 and 
wB97XD. To further examine this system an additional selection of pure and hybrid 
DFT functionals were used to calculate the ruthenium guanine binding energies and 
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compared to the benchmark DF-LMP2 values, the pure functionals are reported in table 
3.3.1.3 and a graphical representation shown in figure 3.3.1.3. The hybrid functionals 
are reported in table 3.3.1.4 and graphical representation shown in figure 3.3.1.4. 
 
Table 3.3.1.3 Binding energies of ruthenium arene complexes to guanine calculated 
using a selection of GGA DFT functionals (kcal/mol). 
 PBE BLYP TPPS 
Benz -84.49 -75.55 -85.37 
Cym -75.01 -65.40 -74.27 
Bip -69.62 -57.70 -68.27 
Anth -62.78 -51.64 -61.12 
Dha -73.14 -60.17 -71.59 
Tha -72.63 -59.78 -71.45 
 
 
Figure 3.3.1.3 Graph illustrating the difference in binding energies (kcal/mol) for the 
ruthenium complexes with guanine calculated using DF-LMP2, PBE, BLYP, and TPPS. 
 
The dispersion corrections calculated using D2 and D3, reported in table 3.3.1.1, show 
that non covalent interactions play a large role in these systems, more so for the bip, 
anth, dha, and tha ligands. This is expected as the extended aromatic regions or the C-H 
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groups in the partially saturated systems can form additional stabilising interactions 
with the guanine. As the three pure DFT functionals do not treat dispersion correctly it 
is not surprising that they give poor binding energy values when compared to DF-
LMP2. The two systems where the pure functionals perform better, benz and cym, have 
smaller dispersion contributions as the ligands are smaller and have no aromatic regions 
over the guanine. From the data in table 3.3.1.3 and the graph in figure 3.3.1.3 it is clear 
that none of these functionals are suitable for the system being studied here. BLYP 
shows the weakest binding energies compared to DF-LMP2, PBE performs marginally 
better than TPSS but at its best it is still a difference of greater than 10 kcal/mol from 
the benchmark values. 
 
Table 3.3.1.4 Binding energies of ruthenium arene complexes to guanine calculated 
using a selection of hybrid DFT functionals (kcal/mol). 
 PBE0 B3LYP TPSSh mPW1PW91 
Benz -84.11 -77.83 -83.19 -82.09 
Cym -76.00 -69.03 -74.60 -73.74 
Bip -72.16 -63.30 -69.34 -69.29 
Anth -65.12 -57.04 -62.15 -62.09 
Dha -75.31 -65.90 -72.55 -72.02 
Tha -76.11 -66.87 -73.15 -72.79 
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Figure 3.3.1.4 Graph illustrating the difference in binding energies (kcal/mol) for the 
ruthenium complexes with guanine calculated using DF-LMP2, mPW1PW91, PBE0, 
TPSSh, and B3LYP. 
 
As mentioned above BHandH performs remarkably well for calculating non-covalent 
interactions and data from table 3.3.1.1 also confirms this as BHandH binding energies 
are within a small error of the benchmark DF-LMP2 values. However the other 
selection of hybrid DFT functionals shown in table 3.3.1.4 do not reproduce the more 
accurate results to an acceptable level. These functionals traditionally do not treat 
dispersion correctly so it is not surprising that they underestimate the energies. It is clear 
from both the data and graph that B3LYP performs worst here, it was also mentioned 
above that tests on B3LYP have shown it calculates purely dispersion based interactions 
as unfavourable. TPSSh and mPW1PW91 perform at a similar level, with a difference 
no greater than 1 kcal/mol, PBE0 performs marginally better but still significantly 
underestimates the binding energies in the systems where dispersion is more prominent. 
From observation of figure 3.3.1.4 it is clear that none of the hybrid functionals 
reproduce the DF-LMP2 binding energies to an acceptable level, producing values too 
low by a minimum of 10 kcal/mol. 
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With the acceptable performance of the two most suitable DFT functionals, BHandH 
and B97-D2, for this system it was then decided to test double hybrid and post Hartree-
Fock methods, that could be implemented for a system of the size in question here. MP2 
using the same basis set as for the DFT calculations was tested, along with MP2(0.25). 
A double hybrid method with empirical dispersion correction of the type D2, B2PLYP-
D with the same basis set used for the MP2 and DFT calculations, was also tested; 
binding energies are reported in table 3.3.1.5 and represented graphically in figure 
3.3.1.5. 
 
Table 3.3.1.5 Binding energies of ruthenium arene complexes to guanine calculated 
using MP2, MP2(0.25), and B2PLYP-D (kcal/mol). 
 MP2 MP2(0.25) B2PLYP-D 
Benz -87.61 -92.00 -89.68 
Cym -81.82 -85.82 -83.30 
Bip -83.82 -88.47 -83.02 
Anth -78.46 -83.40 -77.65 
Dha -87.75 -92.61 -88.64 
Tha -87.56 -91.97 -89.19 
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Figure 3.3.1.5 Graph illustrating the difference in binding energies (kcal/mol) for the 
ruthenium complexes with guanine calculated using DF-LMP2, MP2, MP2(0.25), and 
B2PLYP-D. 
 
MP2 calculations do take into account dispersion interactions, but in cases have been 
shown to have errors up to 100%.13 The binding energies calculated using MP2 with the 
6-31+G(d,p) and SDD basis sets, are underestimated when compared to the DF-LMP2 
energies but still have an acceptable error, however using MP2(0.25) with the smaller 
basis set with the more diffuse d functions gives much more favourable binding 
energies. B2PLYP-D binding energies are of a similar accuracy to the MP2 values, 
which can be seen in figure 3.3.1.5. Observation of figure 3.3.1.5 also confirms that 
MP2(0.25) is the best method of these for calculations involving the binding of 
ruthenium guanine complexes. 
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Table 3.3.1.6 The mean unsigned error (MUE) in kcal/mol, Spearman correlation rank, 
and Pearson correlation of all methods used for the ruthenium arene guanine systems 
against the benchmark DF-LMP2 method. 
 MUE R2 Spearman Rank R2 Pearson Correlation 
MP2 9.23 0.99 0.91 
MP2(0.25) 4.69 0.94 0.94 
B2PLYPD 8.49 0.71 0.78 
BHandH 2.12 0.71 0.77 
B97-D2 6.01 0.77 0.72 
B97-D3 9.96 0.77 0.63 
wB97XD 7.12 0.94 0.87 
M06 12.83 0.71 0.73 
M06-2X 12.25 0.94 0.83 
PBE0 18.94 0.49 0.34 
TPSSh 21.24 0.31 0.26 
B3LYP 27.07 0.31 0.20 
mPW1PW91 21.73 0.31 0.28 
PBE 20.79 0.37 0.23 
TPSS 22.06 0.37 0.21 
BLYP 32.03 0.37 0.10 
 
Table 3.3.1.6 shows error values of all the methods used above compared to the 
benchmark DF-LMP2 values. These include the R2 Pearson correlation, which is a 
measure of the linear dependence of two variables; the R2 Spearman rank correlation, 
which is a non-parametric version of the Pearson correlation; and the mean unsigned 
error (MUE), which is the average of the magnitude of the difference of the method 
with the benchmark. From analysis of the MUE values the best method is BHandH, 
with a MUE of 2.12 kcal/mol, then MP2(0.25), with a MUE of 4.69 kcal/mol. The B97-
D functionals also give favourable MUE values, with B97-D2, wB97XD, and B97-D3 
giving errors of 6.01, 7.12, and 9.96 kcal/mol respectively. The double hybrid method, 
B2PLYPD, and the two post Hartree-Fock methods also give reasonable errors with 
MUE values less than 10 kcal/mol. The R2 values for the MP2 and MP2(0.25) are both 
very close to a value of one, which is indicative of perfect correlation, this would be 
expected as they are both very similar calculations to those carried out for the 
benchmark DF-LMP2 method. The other methods that have favourable MUEs, have R2 
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values that range 0.63 to 0.94, indicating that the energy ranking of several of the 
methods is different for two complexes, as can be seen in the figures above. 
 
The two Minnesota functionals perform moderately well, with relatively low MUEs and 
good R2 values, but under perform compared to the aforementioned DFT functionals 
and the post Hartree-Fock methods. The other hybrid DFT functionals perform 
significantly poorer, with MUE values ranging from 18.94 kcal/mol for PBE0 to 27.07 
kcal/mol for B3LYP, they also have poor R2 values, with the highest at 0.49. The pure 
DFT functionals also give poor binding energies when compared to the benchmarks, 
with relatively high MUE values and very poor R2 values. However the poor 
performance of these methods is not unexpected as it is known that they don’t treat 
dispersion correctly, which is why the more accurate methods and the dispersion 
corrected methods give much more favourable values compared to the benchmark used 
here, which is the best available. 
 
3.3.2 Ruthenium Arene Adenine Complexes 
 
In order to be sure that the methods, that show promise, are not specific to the systems 
in question, another system was constructed where the nucleobase being studied was 
adenine instead of guanine. The ruthenium arene guanine systems above were modified 
by hand to transform the guanine into adenine, these were then fully optimised using 
B97-D2. For these optimised systems binding energies were calculated with all the 
same methods as shown above. Benchmark DF-LMP2 values are reported in table 
3.3.2.1, along with the better performing methods shown above, B97-D2, B97-D3, 
BHandH, and MP2(0.25), these are displayed graphically in figure 3.3.2.1. 
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Table 3.3.2.1 Binding energies of ruthenium arene complexes to adenine calculated 
using DF-LMP2, MP2(0.25), BHandH, B97-D2, and B97-D3 (kcal/mol). 
 B97-D2 B97-D3 BHandH MP2(0.25) DF-LMP2 
Benz -69.16 -65.56 -71.83 -67.68 -72.43 
Cym -62.85 -58.68 -66.40 -62.33 -67.55 
Bip -62.68 -58.17 -67.50 -64.47 -71.07 
Anth -60.54 -56.37 -65.90 -61.92 -68.27 
Dha -70.93 -66.98 -74.75 -69.89 -76.72 
Tha -70.04 -66.02 -74.64 -69.08 -75.97 
 
 
Figure 3.3.2.1 Graph illustrating the difference in binding energies for the ruthenium 
complexes with adenine calculated using DF-LMP2, B97-D2, B97-D3, MP2(0.25), and 
BHandH. 
 
Analysis of the calculated binding energies using several methods for the guanine 
ruthenium arene systems has shown that the methods that best reproduce the benchmark 
values were BHandH, followed by MP2(0.25), and B97-D2. For the adenine systems 
once again BHandH gives the best results, with a difference from DF-LMP2 values of 
no greater than 2.5 kcal/mol, with the exception of the biphenyl complex at a difference 
of approximately 4.6 kcal/mol. Unlike the guanine system, where BHandH 
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overestimates the binding energies, in this case the energies are underestimated. B97-D2 
also performs relatively well, with an average difference from the benchmark of 6.0 
kcal/mol, once again the biphenyl system has the greatest error. For the guanine system 
MP2(0.25) performed marginally better than B97-D2, but in this case they both 
calculate similar values. Out of the methods shown in table 3.3.2.1 and figure 3.3.2.1, 
B97-D3 performs the worst, compared to the B97-D2 values it underestimates the 
binding energies by approximately 4.0 kcal/mol, as can also be seen for the guanine 
complexes. 
 
DF-LCCSD calculations were also carried out to confirm the use of DF-LMP2 as 
benchmark, but as above, due to expense and time only the benzene and dha systems 
were studied. Using the same basis set as DF-LMP2, the DF-LCCSD binding energies 
were calculated as –69.18 kcal/mol for benzene and -73.56 kcal/mol for dha. These 
values, while not in as close agreement as the guanine DF-LCCSD values, are still in 
reasonable agreement with the DF-LMP2 values of –72.43 kcal/mol and -76.72 
kcal/mol for benzene and dha respectively. The binding energies were also calculated 
for all the DFT and post Hartree-Fock methods used above, MUE values and R2 values 
are reported in table 3.3.2.2. 
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Table 3.3.2.2 The mean unsigned error (MUE) in kcal/mol, Spearman correlation rank, 
and Pearson correlation of all methods used for the ruthenium arene adenine systems 
against the benchmark DF-LMP2 method. 
 MUE R2 Spearman Rank R2 Pearson Correlation 
MP2 10.65 0.94 0.96 
MP2(0.25) 6.11 0.94 0.95 
B2PLYPD 9.12 0.94 0.89 
BHandH 1.83 0.94 0.93 
B97-D2 5.97 0.83 0.83 
B97-D3 10.04 0.83 0.80 
wB97XD 8.08 0.89 0.96 
M06 13.88 0.89 0.86 
M06-2X 13.38 1.00 0.95 
PBE0 18.25 0.66 0.64 
TPSSh 20.09 0.66 0.52 
B3LYP 25.90 0.66 0.46 
mPW1PW91 20.76 0.66 0.58 
PBE 19.49 0.66 0.48 
TPSS 20.62 0.66 0.45 
BLYP 30.03 0.66 0.30 
 
Analysis of the data in table 3.3.2.2 shows that the methods used in table 3.3.2.1 and 
figure 3.3.2.1, are the ones that reproduce the benchmark data best. The wB97XD 
functional also performs well and has a lower MUE than B97-D3. All these methods 
give reasonable MUE values and good R2 values, with once again BHandH performing 
best, followed by B97-D2 and MP2(0.25). The Minnesota functionals once again have 
very good correlation with the DF-LMP2 values, but have slightly worse MUEs than 
the DFT-D methods. The remaining hybrid functionals and the non-dispersion corrected 
pure DFT functionals perform poorly, to a similar standard as in the guanine system, 
giving large errors in energy and low R2 values. 
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3.3.3 Comparison of Nucleobases 
 
The binding energies calculated for the guanine and adenine systems above are not 
directly comparable, as the adenine was fully optimised, while the guanine was a 
fragment of a larger DNA structure that retained its geometry from that form. To allow 
direct comparisons the guanine system used has been fully optimised at the B97-D2 
level, with the def2-TZVP basis set, as used for optimisation of the adenine complexes. 
For these newly optimised guanine complexes binding energies have been calculated, 
using the methods highlighted above as being able to best reproduce the benchmarks, as 
well as the benchmark methods. The differences between the energies of the 
reoptimised guanine and adenine complexes are reported in table 3.3.3.1 below, the 
optimised guanine binding energies are reported in the appendix. 
 
Table 3.3.3.1 Guanine-Adenine binding energy difference (kcal/mol). 
 B97-D2 BHandH MP2(0.25) DF-LMP2 
Benz -23.87 -25.67 -23.16 -22.05 
Cym -23.07 -25.22 -22.96 -22.03 
Bip -23.15 -25.63 -23.34 -22.12 
Anth -19.91 -21.18 -20.43 -18.75 
Dha -20.57 -20.68 -21.46 -20.04 
Tha -20.60 -22.16 -21.70 -20.27 
 
The newly optimised guanine complexes have binding energies that have relatively 
small errors from the guanine structures above, that were taken from the conformation 
within a larger DNA fragment. From visual observation of the start and end points of 
the optimisations the structures had little rearrangement, leading to these minor 
differences in binding energies.  
 
The preference of binding of ruthenium arene complexes to nucleobases, has been 
widely reported in publications,29-35 with a clear preference for the N7 position of 
guanine being accepted. This effect has also been seen for several other anti-cancer 
metal complexes, particularly platinum (II) based drugs such as cisplatin.36 Analysis of 
data in table 3.3.3.1 shows a greater binding energy of approximately 20 kcal/mol for 
guanine over adenine, both at the N7 position, across all six arene systems being 
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studied. This is in good agreement with results by Gkionis et al.,32 and Futera et al.,37 
using BHandH/M05 and MP2 respectively. 
 
3.4 Conclusions 
 
The aim of these calculations was to confirm whether using the GGA functional B97 
with an empirical dispersion correction of the type D2, was suitable to calculate binding 
energies within transition metal complexes, in light of recent publications using the 
newer D3 correction. Benchmark binding energies were calculated using DF-LMP2 and 
warranted by carrying out selected DF-LCCSD calculations. As well as the two B97-D 
functionals, several pure DFT, hybrid DFT, and post Hartree-Fock methods were tested 
and results have shown that the best methods are BHandH, B97-D2, and MP2(0.25). 
With wB97XD, B2PLYPD, and B97-D3 also performing adequately, but not to the 
desired level of accuracy. Analysis of the B97-D2 binding energies and through 
comparison to other more reported methods such as DF-LMP2 and BHandH, it is clear 
that this method can suitably reproduce values of significantly more expensive 
calculations. It has also been shown that it can reproduce sensible values of binding 
energies for systems that contain ruthenium arene based complexes binding to purine 
type nucleobases. 
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Chapter 4: Ruthenium (II) Arene Complexes and their Interactions with DNA 
 
4.1 Introduction 
 
The ruthenium (II) complexes being studied in this chapter are based on those 
synthesized by the Sadler group1-5 and studied through coordination to nucleobases and 
non-covalent interactions in sections 3.3 and 3.2.2 respectively. The ruthenium has a 
chelating bi-coordinate ethylenediamine (en) ligand and a variety of arene systems 
coordinating in an η6 fashion. These arenes being studied are benzene (benz), cymene 
(cym), biphenyl (bip), anthracene (anth), dihydroanthracene (dha), and 
tetrahydroanthracene (tha), as shown in figure 4.1.1. 
 
 
Figure 4.1.1 Structures of the arenes coordinated to ruthenium. 
 
Due to these ruthenium complexes showing potential as anti-cancer drugs, their 
interactions with DNA are of interest, especially as the systems containing extended 
aromatic region have the capability to act as intercalators and can therefore form 
additional π-interactions with the aromatic regions of nucelobases. To attempt to probe 
these interactions DFT techniques have been utilised to obtain optimised structures and 
binding energies of this selection of complexes with the DNA duplex GpC·CpG, which 
has been extensively studied in analogous systems containing platinum anti cancer 
agents. The relatively low computational cost of DFT, compared to techniques that 
more accurately model non-covalent interactions, is key here, with two routes being 
explored, that of DFT with an empirical dispersion correction and a QM/MM method 
combining BHandH with the AMBER forcefield. 
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4.2 Optimisation of Base Pair Steps 
 
Study of metal-DNA interactions is a challenge, even with the relatively low 
computational cost of DFT. For the complexes here, all but the benzene model are in 
excess of 150 atoms when including the metal complex, two base pairs and sugar-
phosphate backbone. Previous work to make such calculations viable has been carried 
out by utilising hybrid quantum mechanics/molecular mechanics method (QM/MM) 
methods,6 in which only a small portion of the overall structure is modelled at the full 
DFT level and the remainder with a molecular mechanics (MM) approach. Although 
this approach has been used with some success, the suitability of standard MM methods 
for transition metal systems is far from guaranteed. Transition metals generally exhibit 
strong d-orbital effects that can be hard to capture in molecular mechanics form.7  
 
In order to circumvent the need for empirical MM parameters for Ru, the aim of this 
chapter is to use full DFT to examine the binding of ruthenium(II) complexes of the 
form [6(arene)Ru(II)(en)]n+ to DNA, by obtaining optimised geometries and binding 
energies at this level. This data should not only give new insight into the interactions 
between metal complex and DNA and within the DNA fragment, but will also form a 
valuable benchmark for testing faster but more approximate methods, such as QM/MM, 
that could be used to examine larger fragments of DNA. Calculations and results within 
this chapter are based on those published by our group within reference 8. 
 
4.2.1 Optimisations using B97-D 
 
Interactions of ruthenium complexes shown above with DNA were studied in three 
different forms: 1) with an “open” DNA structure and the arene ligand acting as an 
intercalator between base pairs; 2) with the same open DNA structure, but with the 
arene pointing away from DNA; 3) with DNA in its canonical B- form and the arene 
group pointing away from DNA (figure 4.2.1.1). The “open” DNA structure was 
constructed by modifying the crystal structure of a DNA-intercalator complex with the 
nucleic acid database ID DRBB19.9 This is a dinucleoside monophosphate structure 
with UpA·ApU sequence; this was modified to give a suitable representation of a 
GpC·CpG fragment with an open structure allowing space for intercalator. The 
canonical B-DNA was constructed using the w3DNA web interface.10 The guanine 
coordinated to ruthenium, through the N7 site, will be referred to as G1, forming a base 
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pair with cytosine, referred to as C1. The non-coordinated base pair step will be referred 
to as C2 and G2 for cytosine and guanine, respectively as shown in figure 4.2.1.1. The 
efficiency of the pure DFT B97-D method, when implemented with resolution of 
identity (RI) approximation, allows study of the entire system of the ruthenium arene 
complex with two base pairs and associated sugar phosphate backbone and Na+ 
counterions at the full DFT level. 
 
C1 G2
G1 C2
5' 3'
3' 5'
[(en)Ru(6-arene)]n+
 
open/in 
  
C1 G2
G1 C2
[(6-arene)Ru(en)]n+
 
open/out 
  
C1 G2
G1 C2[(6-arene)Ru(en)]n+
 
canonical/out 
 
Figure 4.2.1.1 Numbering sequence for base pairs in model DNA systems and 
schematic form of the three DNA systems. 
 
Following optimisation of all systems using B97-D/def2-TZVP (with an ECP on 
ruthenium), the binding energy of the ruthenium fragment to DNA was calculated, as 
were selected geometrical parameters. For some of the systems several possible 
orientations of arene were identified, relating to orientation with respect to ruthenium, 
twist of biphenyl along the phenyl-phenyl bond, and tilt of the tha and dha about the 
saturated carbons. Optimisations were run for several different orientations for twenty 
cycles, after which the lowest energy systems were taken through to full optimisation 
and reported below.  
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Table 4.2.1.1 Binding energies of the ruthenium arene complex to GC DNA fragment 
in the three forms (kcal/mol).  
DNA / arene open / in a canonical / out open / out 
Benz -174.28 
-52.48 
-168.92 / 
Cym 
 
-172.41 
-61.28 
-169.89 -161.19 
Bip -169.70 
-67.63 
-157.86 -172.97 
Anth -167.27 
-72.45 
-154.84 -169.06 
Dha -177.91 
-77.91 
-154.84 -169.98 
Tha -179.55 
-79.07 
-154.92 -169.34 
aFirst line gas phase, second line aqueous PCM solvent. 
 
Table 4.2.1.1 reports binding energies of the ruthenium fragments to three different 
forms of DNA, and figure 4.2.1.2 shows the most important data graphically. Values are 
not corrected for basis set superposition error (BSSE), since counterpoise correction 
was carried out on the benz, anth and tha open / in systems, finding that correction was 
less than 0.1 kcal/mol in all cases, i.e. essentially negligible relative to other errors in 
functional, basis set etc. Grimme et al11 have also shown when a suitably large basis set 
is employed in DFT-D methods results become essentially free of BSSE. Table 4.2.1.1 
shows the large stabilization that stems from formation of covalent Ru—N7 bonds, 
along with various non-covalent interactions, in the gas-phase. The partially saturated 
dha and tha complexes are particularly strongly bound when the arene acts as an 
intercalator systems (denoted “open / in”), whereas the fully aromatic anthracene 
complex is the most weakly bound complex to this form of DNA. In this context, we 
note that Sadler and co-workers have not considered anthracene in experimental studies: 
it is included here to examine the effects of rigidity and aromaticity relative to the 
saturated analogues. From this data, it appears that the increased rigidity of the 
anthracene ligand does not lend itself to efficient intercalation between base pairs. The 
biphenyl complex is slightly more strongly bound than anthracene, apparently due to the 
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flexibility of rotation around the central C—C bond which allows formation of closer 
and therefore stronger stacking and C—H… interactions.  
 
-200
-150
-100
-50
0
Bz Cym Bipy Anth Dha Tha
Gas Phase
Aqueous
 
Figure 4.2.1.2 Gas- and aqueous-phase binding energies for open/in complexes 
(kcal/mol). 
 
The large binding energy of the benzene complex has been noted before,12 and was 
assigned to differences in the electronic structure of this ligand relative to others in the 
series, giving rise to stronger Ru—N covalent bonding. This is also observed in the 
cymene system, which has a large binding energy. The importance of the electronic 
structure of the benzene and cymene complexes is evident in their binding energies to 
DNA in its canonical B- form, for which the arene ligand points away from DNA. Here, 
both complexes are found to be ca. 10 kcal/mol more strongly bound than the remaining 
complexes. The remaining systems have very similar binding energies, consistent with 
the lack of significant non-covalent interactions between arene and DNA in this 
orientation. Binding energies are rather larger, but still similar for the orientation of 
arene away from DNA in its open form. The cymene system for the open/out form 
however has a significantly lower binding energy than the other ligands. In this 
orientation the bulky isopropyl substituent points into the gap in DNA, increasing 
unfavourable steric interactions and lowering binding energy. For the latter, no value is 
reported for benzene as optimization leads to the same geometry as for the arene 
pointing into DNA. 
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Table 4.2.1.1 and figure 4.2.1.2 also report binding energies corrected for the relative 
solvation of complexes and fragments, using a PCM model of aqueous solvent. 
Solvation corrections are relatively uniform for the larger arenes, at between 95 and 100 
kcal/mol, but the corrections for benzene and cymene are much larger at 122 kcal/mol 
and 111 kcal/mol respectively, reducing the magnitude of the binding energies 
substantially. Following this correction, the benzene complex is by some distance the 
most weakly bound of the complexes considered, followed by the cymene complex. 
Inclusion of PCM correction also inverts the order of stability of biphenyl and 
anthracene complexes, and confirms that the greatest stability stems from the large but 
flexible dha and tha arene ligands. 
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i) 
 
 
 
 
ii) 
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iii) 
 
 
iv) 
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v) 
 
vi) 
 
Figure 4.2.1.3 Optimised structures of ruthenium arene ( i) bz, ii) cym, iii) bip, iv) anth, 
v) dha, and vi) tha) complexes with “open-in” DNA systems. Ruthenium-arene 
fragment is shown in bold, with DNA as wireframe; hydrogens on sugar-phosphate 
backbone omitted for clarity. 
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In addition, the enhanced π-stacking interaction expected for arenes bound to positively 
charged metal centres, as discussed in section 3.2.2, apparently also plays a role here. 
This is evident in the optimized geometry, shown in figure 4.2.1.3, in which a relatively 
close stacking interaction between the coordinated benzene and G2 is observed. Without 
the arene in the open region of the DNA the coordinated benzene can form a closer 
interaction to the G2 guanine, as shown in table 4.2.1.2. The benzene complex and all 
the open/out systems have much closer interactions with G2, while the presence of an 
arene within the DNA gap results in closer C2 interactions. The greater freedom of the 
smaller benzene complex compared to the larger arene systems allows for formation of 
relatively close interactions with both G2 and C2 contributing to its large binding 
energy. 
 
Table 4.2.1.2 Distance between centroid of coordinated arenes to centroid of C2 
cytosine and G2 guanine for open/in and open/out systems (Å) a. 
 Open/in  Open/out  
 C2 G2 C2 G2 
Benz 4.25 3.35 - - 
Cym 4.18 4.13 4.73 3.31 
Bip 3.93 4.24 4.77 3.33 
Anth 4.21 4.22 5.12 3.20 
Dha 4.04 4.26 5.05 3.20 
Tha 3.99 4.31 4.83 3.22 
aDefined as the distance between the centroid of the coordinated aromatic ring and the 
centroid of the 6-membered ring of the relevant base. 
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Table 4.2.1.3 Geometrical parameters of hydrogen bonds (Å and ˚). 
DNA / arene open / in canonical / out Open / out 
Benz 
  r(N—H...O6) 
  (N—H...O6)  
  r(N—H...OP) 
  (N—H...OP) 
 
1.70 
168.5 
1.83 
163.9 
 
1.63 
165.8 
- 
- 
N/A 
Cym 
  r(N—H...O6) 
  (N—H...O6)  
  r(N—H...OP) 
  (N—H...OP) 
 
1.69 
171.5 
1.944 
159.0 
 
1.65 
164.0 
- 
- 
 
1.72 
167.5 
1.864 
162.9 
Bip 
  r(N—H...O6) 
  (N—H...O6)  
  r(N—H...OP) 
  (N—H...OP) 
 
1.75 
152.4 
1.87 
167.4 
 
1.66 
166.4 
- 
- 
 
1.69 
174.6 
1.89 
162.3 
Anth 
  r(N—H...O6) 
  (N—H...O6)  
  r(N—H...OP) 
  (N—H...OP) 
 
1.80 
157.4 
1.90 
169.9 
 
1.64 
165.6 
- 
- 
 
1.69 
171.8 
1.89 
164.0 
Dha 
  r(N—H...O6) 
  (N—H...O6)  
  r(N—H...OP) 
  (N—H...OP) 
 
1.75 
162.4 
1.86 
168.4 
 
1.65 
163.4 
- 
- 
 
1.69 
172.9 
1.89 
164.1 
Tha 
  r(N—H...O6) 
  (N—H...O6)  
  r(N—H...OP) 
(N—H...OP) 
 
1.74 
164.5 
1.87 
168.2 
 
1.64 
165.8 
- 
- 
 
1.69 
171.8 
1.89 
164.4 
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In all systems studied, a hydrogen bond is formed between one of the N—H of the 
ethylenediamine ligands and the O6 of G1, as detailed in table 4.2.1.3. In the open/in 
and open/out systems, another H-bond is formed between the second N—H of the 
ligand and the formally O- of a phosphate group on the sugar phosphate backbone; 
however, the canonical form does not possess this hydrogen bond. By forming the 
intercalator gap, the backbone deforms from its canonical orientation moving the 
phosphate group into a suitable orientation to form H-bonds with the coordinated 
complex. The benzene complex forms the shortest hydrogen bond to OP in the open/in 
system and cymene forms the shortest H-bond to O6, the presence of the smaller arenes 
apparently results in more freedom of movement during optimisation allowing the 
ruthenium complex to form these closer interactions. The larger arenes form slightly 
longer H-bonds, perhaps due to unfavourable steric interactions formed by the larger 
ligands, or due to competition between stacking and H-bonding. However this may have 
little effect as the change in distance overall is small, changing by ca. 0.1 Å across the 
series. In the other forms considered, variation in H-bond length is much less, 
presumably due to the lesser role of non-covalent interactions of arenes, which point 
away from DNA.  
 
To form ideal stacking interactions, the planar constituents should be exactly parallel. 
The angles between the planes of the extended arene regions and of the 6-membered 
rings of the nucleobases for the open/in system are reported in table 4.2.1.4. The 
benzene complex forms a stacking interaction with G2, with an angle between the two 
planes of 11.88 ˚. The angle between the planes of benzene and C1 is similar, but the 
intramolecular distance is too large to form an interaction. The cymene complex forms a 
stacking interaction between the coordinated ring and C2 with angle between planes of 
11.6 ˚, and like for the benzene there is a near parallel interaction with C1, albeit with a 
large distance. For the biphenyl complex, freedom of rotation about the central C—C 
bond allows the non-coordinated ring to form an almost parallel (4.64 ˚) interaction with 
G2. The anthracene system has the lowest binding energy, attributed to the rigidity of 
the ligand not allowing efficient intercalation. The angles formed between the planes of 
anthracene and C1, G2, and C2 support this view, having relatively large values, 
although the anthracene ligand is almost parallel to G1. A similar pattern is found for 
dihydroanthracene and tetrahydroanthracene complexes, but these have less reliance on 
π…π stacking interactions, as CH…π interactions prevail in the intercalative region. 
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Table 4.2.1.4 Angle between the planes of the nucleobases and the average plane of the 
arene ligand (˚). 
DNA / arene G1-arene C1-arene  G2-arene  C2-arene  
Benz 23.9 11.6 11.9 30.7 
Cym 28.3 4.5 22.4 11.6 
Bip 18.1 27.5 4.6 36.9 
Anth 2.6 16.4 19.6 20.0 
Dha 3.0 27.7 14.7 31.7 
Tha 6.0 29.0 13.4 31.5 
 
Further analysis was carried out on the intercalated complexes by comparing the DNA 
structure to a standardised canonical structure to obtain the shift, slide, rise, tilt, roll, and 
twist values, as reported in table 4.2.1.5, using the x3DNA program. The most striking 
difference lies in the value of rise, i.e. the vertical separation of base pairs, which ranges 
from 7.5 to 8.5 Å and is therefore more than twice the equivalent value in B-DNA. Slide 
values are also much larger than in the canonical form, and are uniformly negative in 
the optimized Ru-complexes. Variations in shift from the canonical value are also large, 
but for this parameter both positive and negative values are found. Roll angles are all 
significantly more positive than the standard value, indicating substantial opening of the 
base pairs induced by ruthenium complexation, while twist values are uniformly smaller 
than the standard value. 
 
Table 4.2.1.5 Base-pair parameters for optimized intercalated complexes, along with 
standard B-DNA values for GC (Å and °). 
 Shift Slide Rise Tilt Roll Twist 
Benz -2.11 -4.38 8.53 -12.1 12.0 20.3 
Cym -2.16 -4.08 8.00 -5.5 12.2 10.3 
Bip 0.84 -3.87 7.75 3.2 8.9 20.9 
Anth -1.17 -3.29 7.50 -3.0 8.6 18.9 
Dha -1.07 -3.49 7.98 -4.5 10.3 22.8 
Tha 1.06 -3.42 8.06 4.0 8.3 22.0 
B-DNA 0.00 0.54 3.38 0.0 1.7 38.0 
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As well as calculating binding energies, quantum theory atoms in molecules (QTAIM) 
analysis was carried out on the open/in system to quantify interactions within the 
intercalator region, using the AIM2000 package. We are particularly interested in the 
(3,-1) bond critical points (BCP), minima in the bond direction and maxima in 
perpendicular directions, which are informative about any interactions present (cf. 
section 2.8.2). 
 
Table 4.2.1.6 Number and types of interactions for optimized intercalated complexes 
(open/in), calculated using AIM. 
 coordinated ring free ring(s) 
 π…π CH…π π…π CH…π 
Benz 6 0 - - 
Cym 2 7 - - 
Bip 3 1 7 0 
Anth 3 1 7 0 
Dha 4 0 4 4 
Tha 4 0 5 8 
 
The numbers of non-covalent interactions calculated for the open/in system, as reported 
in table 4.2.1.6, are in broad alignment with binding energy data. Bip and anth both 
have eleven interactions, less than dha, with twelve, and tha, with seventeen. This 
agrees with the ordering of binding energies, but is not indicative of the overall strength 
of the interactions, as shown by the benz and cym systems which have fewer 
interactions than bip and anth, but more π…π stacking from the directly coordinated 
ring, where the additional cation…π interactions may have an effect. As expected, 
increased saturation of the arene increases the number of CH…π interactions, shown by 
the increase through anth to tha. 
 
4.2.2 Optimisations using ONIOM 
 
For the greatest level of accuracy when simulating interactions between transition metal 
complexes and DNA the highest level of theory available is ideal. However, as 
mentioned above, these ruthenium arene GC adducts are approaching the limit of what 
is possible with full DFT, at the current level of computing. Whilst the simulations 
carried out using B97-D give relatively good indications of the interactions occurring at 
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the area within DNA, where these complexes bind, there is also an interest in larger 
molecules, where full DFT is impractical and would be too computationally expensive 
to carry out. In these cases, where there is still a focus on accurate calculation of 
interactions and electronics in a local area of the system, a hybrid approach combining 
quantum mechanics and molecular mechanics (QM/MM) is undertaken. 
 
In QM/MM calculations a small area of the entire molecule that is of greatest interest, in 
this case the ruthenium, arene, en ligand, and G1 nucleobase, is treated with quantum 
mechanics, dubbed the high layer, whilst the remainder is treated with molecular 
mechanics, the low layer. This is explained in greater detail in chapter 2. This approach 
enables accurate treatment of the binding site of these ruthenium arene complexes and 
the potential to increase the size of the DNA fragment to which it is bound, to that 
beyond the capabilities of full DFT. 
 
Whilst it would be possible here to increase the size of these ruthenium DNA adducts, 
this approach will use QM/MM to optimise and calculate binding energies of the same 
systems examined in section 4.2.1, with an aim to test if using this more approximate 
method can yield similar results to those obtained with B97-D, for systems of the size 
associated with drug dimer adducts. The QM/MM method chosen for these calculations 
is ONIOM, where the high layer includes the entire ruthenium drug and the single 
guanine to which it is bound, the low layer includes the remaining nucleobases, sugar 
phosphate backbone, and the sodium counter ions, the link atom is replaced with a 
hydrogen on the N9 of guanine for calculations on the high layer. The chosen method is 
that used by Gkionis et al., in studies of platinum-DNA complexes, where the high layer 
is treated with the DFT functional BHandH and the low layer with AMBER molecular 
mechanics.13 The interest is still focusing on non-covalent interactions occurring 
between the drug and DNA so the use of a functional that can model these is key here, 
hence the choice of BHandH, which has shown to be effective in section 3.2. 
 
Calculations were only carried out on the open/in systems, as this was the configuration 
of greatest interest so deemed best suited for comparison. The starting points for 
optimisation were taken as the optimised B97-D structures. The optimisations were 
carried out initially using the 'geometry optimisation using direct inversion in the 
iterative subspace' (GDIIS) algorithm and with the parameters defined in reference 13, 
used for analogous systems containing platinum complexes. The structures failed to 
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fully optimise from this step, so from these outputs the lowest energy structure was 
taken and further optimised in Cartesian coordinates until the forces and gradient of the 
energy was deemed low enough that the structure was optimised. Within systems that 
have 'floppy' structures and a large degree of freedom, like the ones in question here, the 
potential energy surface can be quite flat, so it can be difficult to find the global minima, 
hence why these requirements were used to confirm optimisation. Binding energies of 
these optimised structures were calculated and are reported in table 4.2.2.1. 
 
Table 4.2.2.1 Gas Phase Binding energies of the ruthenium arene complex to GC DNA 
(kcal/mol). 
DNA / arene Binding Energy 
Benz -189.43 
Cym -182.44 
Bip -185.19 
Anth -186.03 
Dha -191.66 
Tha -195.89 
 
The binding energies reported in table 4.2.2.1 have been calculated using BHandH on 
the entire molecule, with BSSE accounted for using the counterpoise method. This 
approach however would not be suitable for larger molecules but in this case was 
carried out to enable a better comparison with the results obtained using B97-D. The tha 
complex yields the greatest binding energy, as expected due to it being able to form the 
greatest amount of stabilising non covalent interactions with the adjacent nucelobases. 
Dha gives the second greatest binding energy, approximately 4 kcal/mol less than tha, 
as explained above likely due to increased rigidity of the aromatic region acting as 
intercalator, this can also be attributed to the lower binding energy of the anth ligand. 
The unusually high binding energy of the benz system has been noted above, as well as 
the bip system having a lower than expected value, due to the smaller amount of 
interactions it can form even though it has more flexibility through rotation of the C-C 
bond between the phenyl rings. In the case of cymene it has comparatively lower 
binding energy than what would be expected from the values in table 4.2.1.1, to explain 
this observation of the structures is required, with the optimised systems that show 
significant difference shown in figure 4.2.2.1 and the associated base pair parameters 
reported in table 4.2.2.2. 
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i) 
 
ii) 
 
Figure 4.2.2.1 Optimised structures of ruthenium arene i) bz, ii) cym complexes with 
“open-in” DNA systems. Ruthenium-arene fragment is shown in bold, with DNA as 
wireframe.  
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Table 4.2.2.2 Base-pair parameters for optimized intercalated complexes, along with 
standard B-DNA values for GC (Å and °). 
 Shift Slide Rise Tilt Roll Twist 
Benz -0.61 -1.74 3.49 7.01 -6.15 24.31 
Bip -1.34 -2.48 6.27 13.56 26.42 25.94 
Anth 0.77 -2.68 6.85 -1.64 -5.04 19.14 
Dha -0.56 -2.46 6.96 4.89 2.84 23.20 
Tha -1.16 -3.29 7.72 0.61 4.81 18.16 
B-DNA 0.00 0.54 3.38 0.00 1.70 38.00 
 
 As mentioned above, the binding energy for cymene is lower than would be expected 
as for the ONIOM structures it has the lowest value, whilst for B97-D it is almost 
comparative with benzene in the gas phase. Observation of the cymene structure in 
figure 4.2.2.1 ii) shows that the base pair has undergone severe distortion from the 
expected structure, with the hydrogen bonds between bases broken. The movement of 
the nucleobases away from the isopropyl group would result in fewer stabilising 
interactions as unlike the B97-D case, the benzene ring coordinated to ruthenium does 
not form stacking interactions with above cytosine, this is likely the reason for the lower 
binding energy. 
 
The distortion of the nucleobase configuration within cymene resulted in the x3DNA 
program not recognising a base pair step, hence base pair parameters were not obtained 
for this system, explaining its absence in table 4.2.2.2. For the remainder of the systems 
there is a small change in shift when compared to B-DNA, with all, apart from anth, 
being a negative change. For the slide parameter there is uniformly negative change, 
being greatest for tha and smallest for benz, whilst comparable for the remaining 
systems. The rise shows the greatest difference, as would be expected due to the arenes 
acting as intercalators, with the exception of benzene, which is comparable to B-DNA. 
The optimised benzene structure in figure 4.2.2.1 i) shows that unlike the B97-D case 
where the cytosine moved above the coordinated benzene to form a stacking interaction, 
the gap within the DNA closes. 
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4.2.3 Comparison between B97-D and ONIOM 
 
It has been noted above that the benzene and cymene complexes have different 
structures for the optimisations with B97-D and ONIOM. Benzene forms a stacking 
interaction with the C2 cytosine when optimised with B97-D and the intercalating 
region partially closes when optimised with ONIOM and the cymene structure, when 
optimised with ONIOM, results in a base pair step too distorted to obtain parameters. 
From visual observation of the remaining structures, the adducts with the larger arene 
ligands (anth, dha, and tha) have comparable structures. This is further reinforced by the 
base pair parameters with no difference between them greater than 2.06 Å for shift, 
slide, and rise. However there are more significant differences within the tilt and roll 
parameters, notably for the roll value for anth and tilt for dha, but overall the two 
optimisation methods are in reasonable agreement for the structures of these systems. 
 
When comparing the base pair parameters for the biphenyl system, optimised using the 
two methods, there are some stark differences between the tilt and roll parameters. This 
is not particularly evident from a comparison between the structures, but is most likely 
attributed to the C2 cytosine, which has a smaller angle with the plane of the G1 
guanine, at 8.09 °, within in the ONIOM optimised structure, compared to 30.29 ° in the 
B97-D optimised structure. This large difference is not necessarily indicative of a 
significant difference between the structures and whilst not in as good agreement as the 
anth, dha, and tha, the bip is somewhat comparable between the two optimisation 
techniques. 
 
From the graphical comparison between the gas phase binding energies of the B97-D 
and ONIOM optimised structures, in figure 4.2.3.1, the ordering for anth, dha, and tha is 
in good agreement, although there is some minimal difference between the magnitude 
of the change between dha and tha. The change in strength of binding energy ordering 
of the cym and benz systems can be attributed to the difference in the structures. The 
smaller geometrical change between the bip systems is also likely to account for 
BHandH resulting in a weaker binding energy than anth for the ONIOM optimised, 
whilst bip is stronger than anth in the B97-D optimised structure. 
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Figure 4.2.3.1 B97-D and BHandH gas phase binding energies for open/in complexes 
(kcal/mol) 
 
As it is possible to carry out calculations on the systems, within this chapter, at the full 
DFT level, that is clearly the most desirable approach, so more credence should be 
given to the results obtained this way. Although with this method being realistically 
limited to a single base pair step, probing the effectiveness of the methods able to carry 
out calculations on the larger systems at this system size is a good test. The ruthenium 
drugs containing the smaller arene ligands, or in the case of cymene with fewer 
opportunities to create additional non-covalent interactions, show the greatest difference 
in optimised structure between the two methods. However the larger ligands are in 
relatively good agreement between B97-D and BHandH/AMBER optimised structures, 
likely due to less flexibility as they form the most non-covalent interactions. From these 
conclusions, and as increasing the size of the DNA increases the rigidity of the structure 
and so would likely yield results closer to those of the more comparable larger arene 
systems, the use of QM/MM methods for larger analogous DNA drug systems can be 
deemed to give reasonable structures. 
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Chapter 5: Platinum (II) Anti-Cancer Drugs and their Interactions with DNA 
 
5.1 Introduction 
 
Platinum anticancer drugs, such as cisplatin and oxaliplatin, have been relatively well 
explored within the literature, both experimentally and computationally (c.f. section 
1.3). The work in this chapter focuses on a relatively new drug kiteplatin or (cis-1,4-
DACH)PtCl2,1 which has an isomeric form of oxaliplatin ligand, where the 1,2 
diaminocyclohexane is replaced with one in a cis-1,4 conformation, as shown in figure 
5.1.1, and its interactions with differing sizes of DNA adducts. The biological interest in 
this drug lies in its greater potency against platinum resistant cancer cell lines and 
besides oxaliplatin, is the only drug in advanced clinical development that is active 
against one of the most common cancers worldwide, colorectal cancer.2,3 
 
Pt
ClNH2
ClNH2
 
 
Figure 5.1.1 Structure of kiteplatin. 
 
This work has been done in collaboration with Dr Nico Margiotta at Università degli 
Studi di Bari and Dr Paride Papadia at Università del Salento, who have been carrying 
out experimental studies on kiteplatin, particularly in regards to NMR experiments 
where the drug has been coordinated to several DNA fragments, single and double 
strand, of differing sizes. These platinum DNA adducts have been studied here, using a 
variety of DFT, QM/MM, and semi-empirical techniques, to elucidate structural and 
NMR data with the aim to complement data from  the ongoing experiments. 
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5.2 Single Strand DNA Platinum Adducts 
 
5.2.1 GpG 
 
The kiteplatin DNA adduct (cis-1,4-DACH)Pt(d(GpG)) was constructed from the PDB 
entry 1PGC,4 through truncation to the two coordinated guanines, with the sugar 
phosphate backbone. The oxaliplatin of the original PDB entry was then converted into 
cis-1,4-diaminocyclohexane by hand, the position of the platinum and the coordinating 
nitrogens was retained and the cyclohexane was adapted into a boat like conformation. 
This conformation was optimised within the MOPAC program, using the PM6 semi-
empirical method in the gas phase, to give the head to head conformation (HH), where 
the two guanines point in approximately the same way. A relaxed scan was carried out 
at the PM6 level, with this structure as the starting point, around the dihedral angle 1-2-
3-4, as shown in figure 5.2.1.1, at -5˚ intervals for 72 steps, using COSMO to model the 
effect of water as a solvent, with the aim to identify any other possible conformers that 
could be present. The profile of the first thirty steps of the scan is shown in figure 
5.2.1.2, beyond this point steric hindrance between the two six-membered rings of the 
guanines caused the structure to reoptimise to the original HH starting conformation.  
 
 
 
Figure 5.2.1.1 Head to head conformation of (cis-1,4-DACH)Pt(d(GpG)) showing the 
dihedral angle 1-2-3-4. 
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Figure 5.2.1.2 Profile of the first 30 points of the scan of (cis-1,4-DACH)Pt(d(GpG)) 
around the dihedral angle 1-2-3-4, energy is relative to the starting structure of the scan. 
 
From observation of the scan profile in figure 5.2.1.2, there is a shallow minimum at the 
dihedral angle 37.33 °, and from visual observation of the calculation output this point 
was confirmed to be the head to tail conformation (HT), where the guanines are 
pointing in opposite directions. The dihedral angle that is scanned is a convenient 
variable to change, to be able to interconvert the structures, but is not directly the 
reaction coordinate, which likely leads to the sharp drop in energy as seen in figure 
5.2.1.2. As a result of this the structure at the maxima is unlikely to be the transition 
state and the estimation of the rotation barrier, of 21.00 kcal/mol, is likely to be a 
significant overestimation. To further probe this, the same scan was carried out, but 
starting at the HT conformer and scanning toward the HH conformer as shown by the 
scan profile in 5.2.1.3. 
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Figure 5.2.1.3 Profile of the first thirty points of the scan of (cis-1,4-DACH)Pt(d(GpG)) 
around the dihedral angle 1-2-3-4, starting from HT, energy is relative to the starting 
structure. 
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Observation of the minima at 72.67 ° shows this structure to be the HH conformer, 
albeit with a significantly larger dihedral angle than that of the PM6 optimised structure, 
used as the starting point for the initial scan, at 47.67 °. Whilst it retains the general 
form of the guanines in the head to head conformation, there is rearrangement in the 
sugar phosphate backbone compared to the preceding minima, suggesting the strain 
induced by the backbone likely causes the increase in dihedral angle. This minimum 
also has a greater energy difference from the HT conformer, at 2.74 kcal/mol, compared 
to 0.11 kcal/mol in figure 5.2.1.2. However after a PM6 optimisation, of HH, the 
dihedral angle becomes 47.25 °, which is more comparable to the original HH structure. 
An estimation of the barrier of rotation here is also likely an overestimation at 28.87 
kcal/mol. A better estimation of the energy of the barrier for transition from HH to HT 
would be the point at which the two scans overlap, which occurs at the approximate 
dihedral angle of 8 ° with an approximation of the barrier at 8 kcal/mol. A transition 
state search was attempted in order to obtain an accurate value for the energy barrier but 
this was not possible as the calculation failed to complete. 
 
The HH conformation, used as the initial scan starting point, and the HT conformation 
found were further optimised using the PM6-DH2 method, this improves on PM6 by 
adding an empirical correction for dispersion based and hydrogen bond interactions. 
Optimisations were carried out in the gas phase and single point COSMO corrections 
for water taken at the optimised gas phase geometry. Relative energies, within the 
chosen phase, are reported in table 5.2.1.1. 
 
Table 5.2.1.1 Relative energies between conformations of HH and HT (cis-1,4-
DACH)Pt(d(GpG)) calculated using PM6-DH2 with and without COSMO corrections 
for water (kcal/mol). 
 Gas phasePM6-DH2 relative E COMSO PM6-DH2 relative E 
HH 0.00 0.00 
HT 5.05 0.11 
 
The relative energies in table 5.2.1.1 above show that in both gas phase and with the 
implicit solvent model the head to head conformation is the more stable, albeit for the 
gas phase the difference is significantly greater, at 5.05 kcal/mol, than with the COSMO 
correction at 0.11 kcal/mol. The addition of the solvent model stabilises the HT 
conformation greatly, to give a near comparable energy to that of the HH conformation. 
                                               Chapter 5: Platinum (II) Anti-Cancer Drugs and their Interactions with DNA 
116 
These numbers offer a slight difference to the values shown in the scan profile in figure 
5.2.1.2, which shows the minimum after the barrier to be more stable than the starting 
conformation; however the scan was carried out with PM6 without the dispersion 
correction, so some difference can be expected, and the two methods using the COSMO 
model show that HH and HT are very close in energy. 
 
The two PM6-DH2 optimised structures were then further optimised in the gas phase, 
using the dispersion corrected DFT functional B97-D, employing the def2-TZVP basis 
set, with ECP on the platinum atom, and enabling resolution of identity (RI) within 
Turbomole v5.10. The optimised structures, at this level of theory, of HH and HT are 
shown in figure 5.2.1.4, from two perspectives. Selected geometrical parameters for 
both the semi-empirical and DFT structures are reported in table 5.2.1.2, along with the 
structural parameters for a cisplatin GpG adduct in a close to head to head 
conformation, from the Cambridge structure database,5 which is included for 
comparison, to ensure that the methods used give suitable structures when compared to 
crystal structures of analogous complexes. 
 
  
  
HH HT 
Figure 5.2.1.4 B97-D optimised structures of HH and HT conformations, from two 
perspectives. Sugar phosphate backbone, in both, and (cis-1,4-DACH)Pt, in the lower 
diagrams, shown as wireframe for clarity. 
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Table 5.2.1.2 Geometrical parameters for optimised HH and HT structures using B97-D 
and PM6-DH2, and for the experimental crystal structure (Å or ˚). 
Parameter B97-D HH B97-D HT PM6-DH2 
HH 
PM6-DH2 
HT 
Cisplatin 
HH Expt. 
Angle between 
guaninesa 
85.5 61.79 85.04 59.83 81.20 
1-2-3-4 dihedral 
angle 
41.12 -48.36 47.68 -37.33 69.21 
N(DACH)-Pt-
N(DACH) angle 
97.00 96.32 90.39 90.81 91.70 
N(d(GpG))-Pt-
N(d(GpG)) angle 
92.02 89.95 89.19 87.46 88.30 
Pt-N(DACH) bond 
lengthb 
2.08 2.07 2.05 2.04 2.05 
Pt-N(d(GpG)) bond 
lengthb 
2.08 2.08 1.98 1.99 2.00 
aAngle between the planes of the six-membered rings of the two guanines. 
bBond lengths reported are average of the two present. 
 
The geometrical parameters reported in table 5.2.1.2 show that there is little difference 
between the optimised structures using both methods. The platinum-nitrogen bond 
lengths are shorter for the PM6-DH2 optimised structures, but not by a significant 
amount, and the angle between the planes of the guanines are in good agreement. The 
dihedral angle 1-2-3-4 and the N-Pt-N angles differ a little more, but overall the 
structures by both methods are in reasonable agreement. For comparisons with the 
geometrical parameters of the crystal structure and the B97-D HH conformation, the 
bond lengths are in reasonably good agreement, as well as the angles between the two 
guanines. The N-Pt-N angles differ slightly more as well as the dihedral angle, but as 
the crystal structure has different ligands on the platinum this is not unexpected. Overall 
though, B97-D and PM6-DH2 give reasonable structures when compared to each other, 
so using the semi-empirical method as a starting point for calculations can be justified, 
and B97-D performs suitably well for the HH conformer when compared to crystal 
structure data of analogous complexes. 
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To compare the effect of solvent models on the energies of the two conformations, 
calculated with B97-D, single point solvent corrections were carried out on the 
optimised gas phase structures using the COSMO model with water as the solvent. The 
continuous cavity option, within Turbomole, was tested and for the level of accuracy 
reported was found to have no difference on the results and therefore it was not used. 
The relative energies in the gas phase and with solvent corrections are reported in table 
5.2.1.3. 
 
Table 5.2.1.3 Relative energies between conformations of HH and HT (cis-1,4-
DACH)Pt(d(GpG)) calculated using B97-D and with COSMO solvent correction 
(kcal/mol). 
 B97-D relative energy B97-D with COSMO 
HH 3.63 8.65 
HT 0.00 0.00 
 
The B97-D relative energies in table 5.2.1.3 differ greatly to the analogous PM6-DH2 
values. For both the gas phase and solvent, B97-D reports that HT is the more stable 
conformer. However addition of the solvent model in this case also stabilises HT by 
approximately 5 kcal/mol. This implies that instead of making the two conformers 
closer in energy, as thought for the PM6-DH2 case above, it actually stabilises the HT 
conformer by a greater amount than HH. 
 
To further examine the stabilising effect of the implicit solvent model analogous 
calculations were carried out using cisplatin and oxaliplatin in place of kiteplatin. 
Starting points were constructed from the truncated PDB entry 1PGC used to construct 
the 1,4-DACH adduct. For oxaliplatin no modification, other than the truncation of the 
DNA, was needed, whilst for cisplatin the cyclohexane of oxaliplatin was removed by 
hand, and protons were added to the nitrogens to reach valency, whilst retaining the 
positions of the nitrogen and platinum atoms. 
 
Relaxed scans were carried out on the cisplatin and oxaliplatin adducts in the same 
manner as above, using the PM6 optimised structures of the modified PDB file as a start 
point, and rotating around the same dihedral angle. The HH and HT conformers were 
then optimised using PM6-DH2 and B97-D, with single point COSMO corrections. The 
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relative energies for cisplatin are reported in table 5.2.1.4 and the oxaliplatin values are 
reported in table 5.2.1.5. 
 
Table 5.2.1.4 Relative energies between conformations of HH and HT for a cisplatin 
GpG adduct calculated using PM6-DH2 and B97-D, with COSMO solvent corrections 
for both (kcal/mol). 
 PM6-DH2 PM6-DH2 with 
COSMO 
B97-D B97-D with 
COSMO 
HH 5.87 7.90 0.00 7.59 
HT 0.00 0.00 0.07 0.00 
 
Table 5.2.1.5 Relative energies between conformations of HH and HT for a oxaliplatin 
GpG adduct calculated using PM6-DH2 and B97-D, with COSMO solvent corrections 
for both (kcal/mol). 
 PM6-DH2 PM6-DH2 with 
COSMO 
B97-D B97-D with 
COSMO 
HH 6.78 11.64 3.15 9.07 
HT 0.00 0.00 0.00 0.00 
 
From the data for cisplatin and oxaliplatin in the tables above it is clear they both follow 
a similar trend to the kiteplatin adducts. Upon inclusion of a solvation model the HT 
conformer is stabilised more than HH, in all cases. This was further validated by the 
differences in energy between the gas phase and solvated structures as shown in table 
5.2.1.6, which shows that the HT conformer is more stabilised by between 2 and 8 
kcal/mol when solvated compared to the HH conformer. Compared to the kiteplatin 
data, PM6-DH2 gives a larger difference between the relative energies of the two 
conformers for cisplatin and oxaliplatin. Overall the B97-D values with COSMO 
corrections are in reasonable agreement, regarding relative energies, for all three 
platinum complexes. 
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Table 5.2.1.6 Difference in energy between gas phase and solvated HT conformers 
minus the difference in energy between gas phase and solvated HH conformers for the 
three platinum drugs at the PM6-DH2 and B97-D levels (kcal/mol) 
 PM6-DH2 B97-D 
Cisplatin -2.03 -7.66 
Oxaliplatin -5.06 -5.92 
Kiteplatin -4.94 -5.02 
 
For the chosen kiteplatin adduct (cis-1,4-DACH)Pt(d(GpG)) there are two more 
conformations than the ones mentioned above, as it is possible to have two different 
head to head and head to tail orientations, through further rotation about the dihedral 
angle 1-2-3-4, as shown in figure 5.2.1.5. 
 
 
 
Figure 5.2.1.5 The four conformations of the (cis-1,4-DACH)Pt(d(GpG)), arrows 
represent the guanine bases, while the curved line linking the arrows represents the 
backbone.6 
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The HH1 conformer in figure 5.2.1.5, is the one that is most representative of B-DNA 
and this structure is equivalent to HH used in all calculations above and from here on 
will be designated HH1. The head to tail conformations adapt lambda/delta type 
isomerisation, with the Λ isomer the one used in calculations above and represented by 
HT1 in figure 5.2.1.5. 
 
To obtain the second head to head conformation, HH2, another relaxed scan was carried 
out using PM6, this one using the HT1 B97-D optimised structure as the starting point, 
and once again rotating around the dihedral angle 1-2-3-4, shown in fig 5.2.1.1. From 
visual observation of the structures at the minima on the scan, the HH2 conformer was 
able to be indentified. Several other minima present on the scan, were identified as 
structures where the guanines adopted a conformation between the head to head and 
head to tail, where they were close to perpendicular. To obtain a structure for the ΔHT 
isomer, HT2, the same scan was carried out as for finding HT1, but the dihedral angle 
was increased by increments of 5 ˚ instead of decreased. From visual observation of the 
structures represented in the scan, the desired conformer, HT2, was able to be discerned. 
 
The two structures obtained from the scans were then further optimised using PM6-
DH2, and single point COSMO corrections were carried out at the optimised geometry. 
These optimised coordinates were then used as starting points for B97-D optimisations, 
which also used COSMO corrections at the optimised geometries. Relative energies of 
each method, for the four conformers, are reported in table 5.2.1.7 below. 
 
Table 5.2.1.7 Relative energies between conformations of HH1, HT1, HH2, and HT2 
(cis-1,4-DACH)Pt(d(GpG)) calculated using PM6-DH2 and B97-D, with COSMO 
solvent corrections for both (kcal/mol). 
 PM6-DH2 PM6-DH2 with 
COSMO 
B97-D B97-D with 
COSMO 
HH1 0.00 0.00 3.63 8.65 
HT1 5.05 0.11 0.00 0.00 
HH2 18.09 6.51 5.34 9.08 
HT2 18.89 12.48 8.52 13.38 
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From the PM6-DH2 optimisations of HH2 and HT2, it is shown that they are 
significantly less stable than the HH1 conformer. Addition of the solvent model results 
in the same pattern as the gas phase, with the order of stability for the PM6-DH2 
method HH1 > HT1 > HH2 > HT2. The energies calculated at the B97-D level in the 
gas phase show less disparity between the previous structures, HH1/HT1, and the new 
structures HH2/HT2. Although solvent corrections to PM6-DH2 lower the relative 
energies closer to the most stable conformer, HH1, for B97-D the three structures get a 
smaller change in energy compared to the relative value of the most stable HT1. At the 
B97-D level, the more accurate of the two methods, the order of stability is HT1 > HH1 
> HH2 > HT2. 
 
Table 5.2.1.8 B97-D binding energies of kiteplatin to four GpG conformations 
corrected for BSSE using counterpoise (kcal/mol). 
 Gas Phase Binding Energy COSMO Binding Energy 
HH1 -238.41 -125.28 
HT1 -230.29 -124.61 
HH2 -228.61 -121.36 
HT2 -235.22 -121.20 
 
Binding energies for kiteplatin to GpG were calculated for all four conformations. This 
was carried out using B97-D, basis set superposition error (BSSE) was corrected for 
using the counterpoise method, values are reported for the gas phase and with the 
inclusion of the COSMO model in table 5.2.1.8. Counterpoise correction was not used 
for similar calculations on ruthenium complexes carried out on the larger base pair steps 
in chapter 3 as the computational expense meant some calculations were unable to be 
completed and for the ones that did the correction was deemed negligible. However, for 
these smaller adducts the computational time is significantly less so it was possible to 
obtain values for all systems here. The binding energies show that there is no great 
difference between the four structures, with an overall difference of less than 10 
kcal/mol between them. The two head to head conformations have the largest and 
smallest values, this indicates that the geometry of the guanines and sugar phosphate 
backbone around 1,4-DACH does not have a significant effect on the binding energies. 
With the solvent model the difference between the conformers is reduced with a 
difference between greatest and smallest of 5.08 kcal/mol. The platinum complex 
remains most strongly bound to HH1, but the overall trend changes with HT2 becoming 
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the most weakly bound complex. The binding energies with COSMO corrections show 
HH1 and HT1 are clearly the more favoured conformers in accordance with relative 
energies shown in table 5.2.1.7. 
 
5.2.2 Single Strand TGGT  
 
GpG is a very small fragment of DNA, to get a better insight into how kiteplatin binds 
to DNA, larger adducts are needed. Another single strand for which experimental data 
has been collected by our collaborators, is the TGGT adduct, where the single strand is 
expanded upon by including a terminal thymine on both ends of the DNA. From the 
B97-D optimised (cis-1,4-DACH)Pt(d(GpG)) in the HH1 conformation, thymines were 
added by hand. To give a reasonable starting point for further optimisations, the system 
was optimised using PM6-DH2, but with the platinum, DACH, and the two coordinated 
guanines frozen to allow the thymines and sugar phosphate backbone to relax. From this 
structure full optimisation was carried out using PM6-DH2, the resulting structure was 
then further optimised using B97-D, selected geometrical parameters are reported in 
table 5.2.2.1, and optimised structures are shown in figure 5.2.2.1. 
 
Table 5.2.2.1 Geometrical parameters for optimised TGGT kiteplatin adducts in the 
HH1 conformation using B97-D and PM6-DH2 (Å or ˚). 
Parameter B97-D PM6-DH2 
Angle between guaninesa 87.42 82.16 
1-2-3-4 dihedral angle 49.82 41.44 
N(DACH)-Pt-N(DACH) angle 97.43 96.07 
N(d(TGGT))-Pt-N(d(TGGT)) angle 90.27 92.04 
Pt-N(DACH) bond lengthb 2.07 2.07 
Pt-N(d(TGGT)) bond lengthb 2.06 2.07 
aAngle between the planes of the six membered rings of the two guanines. 
bBond lengths reported are average of the two present. 
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B97-D PM6-DH2 
 
Figure 5.2.2.1 B97-D and PM6-DH2 optimised structures of HH1 conformation of 
TGGT kiteplatin adducts. Sugar phosphate backbone shown as wireframe for clarity. 
 
The geometrical parameters in table 5.2.2.1, and visual observation of the structures in 
figure 5.2.2.1, further confirm the conclusions above that PM6-DH2 gives suitable 
structures compared to the B97-D method. A relaxed PM6 scan was attempted in the 
same fashion as used above for the GpG adduct, in order to get a structure for the head 
to tail conformation. Due to the increased rigidity of the structure, by the presence of an 
additional two nucleobases, it was not possible to find a second conformation, at the 
point where changing the dihedral brought the guanine too close to the adjacent thymine 
the structure returned to the starting head to head conformation. 
 
Optimised cisplatin and oxaliplatin TGGT structures were also obtained using the PM6-
DH2 and B97-D methods. Using the coordinates of the kiteplatin complex where the 
thymines and sugar phosphate backbone were allowed to relax while everything else 
was frozen, the 1,4-DACH Pt part was converted into the corresponding cisplatin and 
oxaliplatin parts by hand. These structures were then optimised fully using PM6-DH2 
and B97-D. Binding energies were calculated, in the gas phase and with the COSMO 
model representing water, for all three platinum complexes to the TGGT DNA fragment 
using the counterpoise method at the B97-D level, values are reported in table 5.2.2.2. 
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Table 5.2.2.2 B97-D binding energies of cisplatin, oxaliplatin, and kiteplatin to TGGT, 
corrected for BSSE using counterpoise (kcal/mol). 
Platinum Complex Gas Phase Binding Energy COSMO Binding Energy 
Cisplatin -307.22 -135.51 
Oxaliplatin -280.82 -135.81 
Kiteplatin -278.95 -134.18 
 
Cisplatin has the largest gas phase binding energy to the TGGT DNA fragment, 
approximately 27 kcal/mol more than both oxaliplatin and kiteplatin, which of both 
have very similar values, with a difference less than 2 kcal/mol. With the addition of a 
solvent model the difference between the binding energies becomes significantly 
smaller, with an overall difference of less than 2 kcal/mol between all of them. 
Kiteplatin is still the weakest, but the trend changes with oxaliplatin becoming the most 
strongly bound, with a binding energy of 0.3 kcal/mol greater than cisplatin, although 
this difference is small and within the likely error of the calculations so it would be 
difficult to conclusively say that one has a greater binding energy than the other. 
 
5.2.3 Comparison of Single Strand Adducts 
 
A comparison between the two single strand kiteplatin DNA adducts, GpG and TGGT 
has been carried out, to ascertain whether lengthening the strand, by addition of two 
extra thymine nucleobases, has a significant effect on the geometry around the metal 
and coordinated bases and the binding energies. A comparison of selected geometrical 
parameters is reported in table 5.2.3.1 and a graphical comparison of binding energies is 
reported in figure 5.2.3.1. 
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Table 5.2.3.1 Comparison of geometrical parameters for optimised GpG and TGGT 
kiteplatin adducts in the HH1 conformation using B97-D (Å or ˚). 
Parameter GpG TGGT 
Angle between guaninesa 85.5 87.42 
1-2-3-4 dihedral angle 41.12 49.82 
N(DACH)-Pt-N(DACH) angle 97.00 97.43 
N(d(TpGpGpT))-Pt-N(d(TpGpGpT)) angle 92.02 90.27 
Pt-N(DACH) bond length2 2.08 2.07 
Pt-N(d(TpGpGpT)) bond lengthb 2.08 2.06 
a Angle between the planes of the six membered rings of the two guanines 
b Bond lengths reported are average of the two present 
 
 
 
Figure 5.2.3.1 Comparison of B97-D binding energies of kiteplatin to TGGT and the 
four GpG conformations in the gas phase and with COSMO solvent model (kcal/mol). 
 
Comparing the geometrical parameters shows that both structures are very similar 
around the coordination sites and for the guanines. This can also be confirmed from the 
structures shown in figures 5.2.1.4 and 5.2.2.1. The addition of thymines changes the 
plane angle between the guanines by an insignificant amount of 2 , this may have been 
expected to be the parameter with the greatest difference between the two structures due 
to the extra nucleobases causing the angle between the guanines to reduce through 
sterics. Although as this is only a single strand adduct, there are no interstrand 
interactions holding the structures together and therefore the thymines have more 
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freedom of movement, so form stacking interactions with the guanines, which maintain 
a similar formation as in the smaller GpG adduct. The angles and bond lengths around 
the platinum differ negligibly between the two structures; the dihedral angle 1-2-3-4 has 
the largest difference, but is still small enough to be considered negligible, especially in 
light of the small difference between the plane angles. 
 
The gas phase binding energy of kiteplatin to the TGGT strand is approximately 40 
kcal/mol more than the analogous GpG conformer, this is attributed to additional 
favourable electrostatic interactions arising from the addition of two more negatively 
charged phosphate groups. Positive sodium counter-ions have been included in the 
system, but it is assumed they will not significantly negate this extra stability due to 
their relatively long range from the platinum. Inclusion of the solvent model decreases 
this difference to approximately 9 kcal/mol, this can be expected as the electrostatic 
potential from the COSMO model will screen the favourable interactions between the 
differing charged parts of the complex. 
 
5.3 B97-D Calculations on Dual Strand DNA Platinum Adducts 
 
5.3.1 GpG·CpC Base Pair Step 
 
The original GpG adduct was also expanded on by increasing from single strand to dual 
strand DNA, to make a base pair step by the addition of CpC group. From the PDB 
entry 1PGC containing the analogous platinum drug oxaliplatin bound to a DNA 
duplex, the desired base pair step was extracted and the back bone was terminated at the 
5’ end with a hydrogen on the C4’ atom and terminated at the 3’ end with an OH group 
on the C3’ atom. The oxaliplatin group was then converted to DACH and cisplatin, by 
hand, to give starting coordinates for GpG·CpC adducts of the three platinum drugs. 
Optimisations were carried out using PM6-DH2 and the resulting structures were 
further optimised with B97-D. Instead of the geometrical parameters used for the 
adducts in section 5.2.1 and 5.2.2 above, x3DNA analysis has been carried out to get 
base pair parameters, this analysis cannot be carried out for single strand DNA, values 
are reported in table 5.3.1.1 along with corresponding B-DNA values, and optimised 
structures shown in figure 5.3.1.1. 
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Table 5.3.1.1 Base pair parameters for three platinum drug adducts with GpG·CpC, 
along with standard B-DNA values for GG base pair step (Å or ˚). 
 Shift Slide Rise Tilt Roll Twist 
Cisplatin -1.39 -1.90 3.51 1.07 28.14 30.44 
Oxaliplatin -1.37 -1.93 3.54 1.03 28.06 31.16 
Kiteplatin -1.39 -1.78 3.46 1.11 27.88 28.69 
B-DNA 0.01 0.47 3.36 -0.03 1.71 35.96 
 
 
 
 
Cisplatin Oxaliplatin 
  
Kiteplatin B-DNA 
 
Figure 5.3.1.1 B97-D optimised structures of the three platinum drug adducts with 
GpG·CpC, along with B-DNA structure obtained from w3DNA.7 Sugar phosphate 
backbone shown as wireframe for clarity. 
 
The x3DNA data in table 5.3.1.1 gives an indication of the distortion of the base pair 
step through coordination of the platinum anti-cancer drugs. The roll values are where 
the largest difference, between the B-DNA and platinum adducts lie, with a significant 
increase from 1.71 ˚ to approximately 28 ˚. Coordination of the platinum to the two N7 
sites on the adjacent guanines causes the roll angle to increase to avoid the huge strain if 
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they remained nearly co-planar, as they exist in standard B-DNA. The rise distance is 
fairly consistent across all four systems, with a slight increase for the platinum adducts, 
their large roll angle means a large increase in rise can be avoided. There are relatively 
minor differences between the platinum adducts and the B-DNA for the remaining 
parameters. All three platinum complexes give very comparable results and this shows 
that the base pair geometry is distorted by equivalent amounts for them. 
 
While the x3DNA calculations give good representations of the geometry around the 
nucleobases, it is less conclusive regarding the geometry of the sugar phosphate 
backbone. While the x3DNA values are comparative for the three platinum adducts, 
observation of the structures in figure 5.3.1.1 shows that there is some disparity between 
the backbones of the strands that have the coordinated guanines, this is most clear 
between the cisplatin and oxaliplatin optimised structures. To quantify this torsional 
parameters of the backbone were obtained, as shown in figure 5.3.1.2, values are 
reported in table 5.3.1.2 along with average values for standard B-DNA. 
 
 
 
Figure 5.3.1.2 Torsional parameters of sugar phosphate backbone.8 
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Table 5.3.1.2 Torsional parameters for coordinated strand of cisplatin, oxaliplatin, and 
kiteplatin adducts, using B97-D, along with standard values for B-DNA (˚). 
Parameter B-DNA Cisplatin Oxaliplatin Kiteplatin 
α -40.00 -75.44 -75.27 -65.52 
β -150.00 -163.29 -163.71 -175.24 
γ 30.00 47.97 47.61 56.60 
χa -95.00 -46.87 -55.40 -32.13 
χb / 9.60 -15.38 19.41 
δ 150.00 127.57 127.17 137.28 
ε 150.00 167.31 -176.55 153.66 
ζ -100.00 -86.18 -86.11 -92.63 
aThis value represents this parameter for the pentose sugar at the 3’end. 
bThis value represents this parameter for the pentose sugar at the 5’ end, due to 
distortion of the DNA adduct through coordination of platinum the two ends give 
different values, which is not seen in standard B-DNA. 
 
Table 5.3.1.2 contains the calculated torsional parameters of the sugar phosphate 
backbone of the DNA strand that also contains the coordinated platinum complexes. 
From visual observation of figure 5.3.1.1 the cisplatin and oxaliplatin structures appear 
to yield different backbone structures, comparatively the kiteplatin structure is similar to 
the cisplatin structure. The large differences between oxaliplatin and the other two 
complexes lie within the ε parameter and the second χ parameter. The difference and 
opposite sign for the ε dihedral, likely affects the second χ dihedral, as they are both 
related toward the 5’ end of the DNA strand. This difference is probably a result of the ε 
parameter having more rotational freedom in these adducts as it is close to the terminus 
of the strand. If the equivalent internal parameter was measured in larger DNA strands 
this effect might not be observed, due to increased rigidity from increasing the length of 
the backbone. The remainder of the parameters are in reasonable agreement with each 
other and with the standard B-DNA values, with the moderate differences that are a 
result of distortion through coordination of platinum.  
 
Binding energies were calculated for the three complexes, at the B97-D level, using the 
counterpoise method, to compare to the energies for the single strand adducts in table 
5.2.2.2 and to observe whether this distortion has a significant effect on the values, or in 
this case can be largely ignored. 
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Table 5.3.1.3 Binding energies calculated for cisplatin, oxaliplatin, and kiteplatin to GG 
base pair step using B97-D and corrected for BSSE using counterpoise (kcal/mol). 
 Gas Phase Binding Energy COSMO Binding Energy 
Cisplatin -283.90 -129.58 
Oxaliplatin -249.98 -122.60 
Kiteplatin -249.83 -121.97 
 
The binding energies of oxaliplatin and kiteplatin are comparable with a difference of 
0.15 kcal/mol and 0.63 kcal/mol for the gas phase and COSMO respectively. These two 
Pt drugs are isomers of each other and the binding energies show that the comparative 
distortion of the oxaliplatin has little significance. The binding energies calculated for 
TGGT are in agreement with this as in that case there is little difference between the 
binding energies of the two complexes. The trend, for all three drugs, is in clear 
agreement for both the gas phase and with solvent, with cisplatin the most strongly 
bound and kiteplatin the most weakly bound. As seen above the COSMO binding 
energies show a smaller range than gas phase, with the difference between weakest and 
strongest bound changing to 7.61 kcal/mol from 34.07 kcal/mol. The gas phase trend is 
in good agreement with those calculated for the single strand TGGT, but the COSMO 
trend differs, with this case having better agreement with gas phase. Also the cisplatin 
binding energy remains clearly the strongest for COSMO on GG, while for TGGT it is 
brought into a closer similarity with the other two drugs. 
 
5.4 ONIOM Calculations on Dual Strand DNA Adducts 
 
So far in this chapter DFT calculations have been carried out on DNA platinum adducts 
and the entire molecule in question has been treated at the same level. The calculations 
carried out using B97-D in section 5.3.1 and on the base pair steps in chapter 4 are the 
largest systems within this work that have been achieved. Even with the addition of 
resolution of identity the calculation times could take several weeks, which makes this 
approach somewhat impractical when wanting to increase the system size beyond this. 
Larger DNA fragments and systems containing explicit solvent molecules are of 
particular interest, so the route of multilayer QM/MM techniques has been approached. 
By treating the areas of the molecule that are of greatest interest with full quantum 
mechanical methods, in this case the platinum drug and the directly coordinated 
nucleobases, and treating the remainder of the molecule with lower level molecular 
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mechanics methods, calculations can be carried out on much larger and therefore more 
realistic biological systems. 
 
The chosen methodology to carry out these QM/MM calculations has recently been 
outlined by Gkionis and Platts,9 for the optimisation of analogous systems containing 
cisplatin and explicit water molecules, instead of the complex of interest here, 
kiteplatin. This was achieved using the ONIOM method, with the high layer treated 
with BHandH/6-31+G**; with SDD basis set and ECP on Pt, and the low layer with the 
AMBER forcefield. Optimisations were carried out in Gaussian 09 using the GEDIIS 
algorithm10 and micro iterations. With the entire system free to move it is difficult to 
achieve a fully optimised structure, due to large molecules with many degrees of 
freedom having relatively flat potential energy surfaces. To overcome this, 
optimisations were carried out in stages, with parts of the molecule frozen while others 
were free to move. By optimising parts at a time the forces for those can be reduced 
while maintaining the general structure from the initial construction of the coordinates. 
If the system has complete freedom from the start undesirable end points can be reached 
whereby the separate strands of the DNA move long distances apart to reduce high 
initial forces. 
 
In these calculations the QM layer is the platinum complex and the two coordinated 
guanines, while the MM layer is the remainder of the DNA fragment being studied, the 
sodium counterions, and any explicit water molecules present. For calculations on the 
QM layer the bonds the guanines form with the backbone are replaced with link atoms, 
which in this case are hydrogens. The first step is to allow just the QM layer and atoms 
in the MM layer that are part of the base pair step containing the coordinated guanines, 
including the sugar phosphate backbone; here terminated at the C4' position of the 
pentose sugar, to relax, while the remainder of the DNA and water is frozen. The second 
step is to allow just the water to relax, with the entire DNA platinum adduct frozen. The 
third step is to allow the DNA in the low layer, minus the ones contained in the base 
pair step that were not frozen in step one, to relax with the water and QM layer frozen. 
The fourth and final step is to allow the entire system to optimise freely. Step one does 
not use micro iterations while the remaining three steps do. 
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5.4.1 Optimisation of Dimer Adduct 
 
The dimer is the base pair step GpG·CpC, that was small enough to be optimised fully 
using B97-D in section 5.3. Although an optimised structure has already been obtained 
for this system, another optimisation has been carried out using the ONIOM method 
with BHandH and AMBER to allow for more accurate comparisons between the series 
of kiteplatin DNA adducts studied with this method. The optimised B97-D structure 
was used as the starting point for the optimisation, with the platinum complex and two 
guanines in the QM layer. The calculation was initially carried out in the gas phase, the 
partial optimisation steps used above were deemed unnecessary due to the relatively 
small system size, and due to the issues using microiterations for the tetramer outlined 
in section 5.4.2, these were not used. The full optimisation was carried out using 
BHandH and AMBER and the optimised structure is shown in figure 5.4.1.1. 
 
 
Figure 5.4.1.1 Optimised structure of kiteplatin dimer, optimised using ONIOM 
BHandH/AMBER. Low layer shown as wireframe for clarity. 
 
An optimisation of this system containing explicit water molecules was also attempted. 
A water soak was carried out on the gas phase optimised structure using MOE and 
several optimisation cycles were attempted, but as with the issues for the tetramer 
below, while the energy was slowly dropping the forces did not appear to be close to 
convergence, so this process was not further attempted. 
 
If the ability to carry out optimisations using full DFT is available then this is clearly 
preferable to the hybrid QM/MM approach, therefore it would be expected that the 
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equivalent system optimised using B97-D in section 5.3 is more accurate than the 
ONIOM one here. Whilst some small differences would be expected, ideally the two 
structures should not have huge deviations from each other. Table 5.4.1.1 shows the 
base pair parameters for the structures optimised using both methods, there are some 
noticeable differences especially the sign change between shift and tilt, and the 
relatively large increase of 0.28 Å in rise from the ONIOM structure to the B97-D one. 
Despite these differences and from a visual comparison between figure 5.4.1.1 and 
5.3.1.1, the two methods give broadly similar results in terms of the optimised structure 
of this system. 
 
Table 5.4.1.1 Base pair parameters of kiteplatin dimer optimised with B97-D and 
ONIOM (Å or ˚). 
 Shift Slide Rise Tilt Roll Twist 
ONIOM 1.17 -1.59 3.18 -4.03 21.65 25.37 
B97-D -1.39 -1.78 3.46 1.11 27.88 28.69 
 
5.4.2 Optimisation of Tetramer Adduct 
 
The four nucleobase sequence, the tetramer, has also been studied as an extension from 
the dimer. The sequence chosen was d(TGGT), as the single strand version was studied 
above in section 5.2.2. The starting point was constructed from the PDB entry 1AU5,11 
which is a cisplatin octamer adduct. This was truncated to the required sequence, the 
cisplatin was converted to 1,4-DACH by hand while retaining the positions of the 
platinum and nitrogen atoms, by removing one of the bound hydrogens off each 
nitrogen and adding in the cyclohexane ring in a boat like conformation. Sodium 
counterions were placed in the vicinity of each phosphate group by hand and explicit 
water molecules were added with a water soak using the MOE program12 to give 
approximately one hundred water molecules. 
 
Calculations were carried out in the order expressed above, with the initial optimisation 
of the QM layer and additional atoms in the base pair step, carried out using the smaller 
basis set, 6-31G*, with BLYP and a density fitting basis set. This combination of 
smaller basis set and pure DFT functional with density fitting was used to speed up the 
initial steps, this was deemed acceptable as any inaccuracies arising would be alleviated 
in the later steps where the full system is optimised using BHandH/6-31+G**. This step 
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was successful, but the proceeding attempt at optimising the water molecules was 
unsuccessful, with upwards of seventy five of the water molecules being ejected from 
the vicinity of the adduct. The partial optimisation steps were carried out in several 
different orders in attempt to get the water to optimise to a sensible structure, but these 
were also unsuccessful, with the same result.  
 
With the water optimisation step failing to give reasonable structures the optimisation 
was carried out in the gas phase, with all the explicit water molecules deleted. The 
initial optimisation of the QM layer and base pair step was carried out successfully but 
the optimisation of the remainder of the MM layer failed to give a sensible structure, 
with the two strands of DNA splitting. This was attributed to the microiterations as the 
same step carried out with the option for these turned off, but still using the GEDIIS 
algorithm, gave a more reasonable structure, whilst it did not fully optimise the energy 
and forces were decreasing. The attempt at optimisation of the entire system using 
microiterations failed, but with no microiterations the system fully optimised. The 
structure was then reoptimised using the desired BHandH functional with the 6-31+G** 
basis set, which is shown in figure 5.4.2.1. 
 
 
 
Figure 5.4.2.1 Optimised structure of kiteplatin tetramer, optimised using ONIOM 
BHandH/AMBER. Low layer shown as wireframe for clarity. 
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Every attempt at using microiterations for the tetramer adduct, either failed or gave 
undesirable structures, so it is reasonable to assume from this and that they have worked 
for some steps in the optimisations of the larger DNA adducts below, that 
microiterations are not suitable for the smaller systems. Knowing this another attempt at 
solvating the tetramer was carried out, the optimised structure shown in figure 5.4.2.1 
was water soaked using MOE to give one hundred and eight water molecules. The use 
of microiterations was avoided and the optimisation was attempted entirely in Cartesian 
coordinates, whilst throughout multiple optimisation steps the energy was continuously 
dropping, the forces never came close enough to consider the system converged, which 
was also observed for the dimer. Due to this, after a significant amount of computer 
time, this attempted optimisation was halted.  
 
Table 5.4.2.1 Base pair parameters for kiteplatin tetramer optimised in the gas phase (Å 
or ˚). 
 Shift Slide Rise Tilt Roll Twist 
TG/CA 0.24 -1.98 2.78 9.91 6.28 30.02 
GG/CC 0.86 -1.33 2.73 -5.52 19.26 22.89 
GT/AC 0.89 -2.50 3.63 6.98 5.65 39.91 
Average 0.66 -1.93 3.05 3.79 10.40 30.94 
 
The base pair parameters for this optimised tetramer were obtained using x3DNA and 
are reported in table 5.4.2.1. As can be seen for the parameters for the octamer in table 
5.4.3.1 below, the GG base pair step where the kiteplatin complex is coordinated shows 
a large deviation from the remaining base pair steps in several parameters. This is most 
prevalent for the roll parameter, where the platinated bases result in a roll of 19.26 °, 
significantly greater than the value of 6.28 ° and 5.65 ° for the remaining steps. The 
twist and tilt parameters also show reasonable decreases for the central base pair step 
compared to the outside steps, whilst shift, slide, and rise are more comparable across 
the entire adduct. 
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5.4.3 Optimisation of Octamer Adduct 
 
The dual strand octamer of the sequence (5'-D(CCTG*GTCC)-3') is one of the systems 
that is of interest here and is also the one that was studied by Gkionis and Platts9 when 
testing this optimisation method. Two initial structures were used for this octamer to 
test how sensitive the final structure is to the starting point. One was the NMR structure 
of the cisplatin octamer adduct, with the above sequence, with the PDB entry 1AU5, the 
second was the optimised structure from reference 9 which also used 1AU5 as its 
starting point. Both of these structures contain cisplatin, these were converted into 
kiteplatin by hand. For the starting point constructed from 1AU5, sodium counterions 
were placed in the vicinity of each phosphate group by hand and a water soak was 
carried out on the system to give a solvation shell of ninety eight water molecules, using 
the MOE program. 
 
Once again the pure DFT functional BLYP was used with a density fitting basis set as 
well as the smaller basis set 6-31G* to increase the efficiency of the initial steps. In 
some steps loose convergence criterion was also specified. The first step for optimising 
from the first starting point was the optimisation of the base pair step and the kiteplatin 
complex, this was successful. With the entire DNA platinum adduct frozen, the water 
molecules were then optimised with microiterations, an optimised structure was reached 
but the calculation caused eighteen water molecules to be moved to extreme distances 
away from the DNA, these were deleted by hand and the modified system was then 
used in the next step. The MM region was optimised, with the base pair step, QM layer, 
and water frozen. With all the separate parts relaxed while the remainder of the system 
was frozen, a full optimisation was attempted, this failed with the resulting structure one 
where the DNA had split into two strands at distance, the cause of this was thought to 
be too high forces combined with the use of microiterations. To test this, the failed step 
was rerun but with the microiterations turned off and the functional and basis set 
changed to BHandH and 6-31+G**. The resulting calculation exited due to wall time 
restrictions, but yielded a lower energy structure with lower average forces but also had 
moved an additional eight water molecules to extreme distances. The eight waters were 
removed and another optimisation of the entire system, using microiterations, was 
attempted but this time at the BHandH level and not with loose convergence criterion. 
This calculation once again failed with a similar result of "unwound" DNA. A further 
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attempt at getting a lower energy structure was carried out by using an optimisation 
within Cartesian coordinates, instead of the GEDIIS algorithm. 
 
Several cycles of Cartesian optimisations, followed by attempted optimisations using 
GEDIIS with microiterations were carried out. The lowest energy structure of the 
Cartesian optimisations was used as the starting point for the GEDIIS/micro 
optimisation, if that failed due to not converging in 25 cycles, which is the limit within 
the Gaussian 09 program, but the structure was sensible, the end point was then used for 
a further Cartesian optimisation. After three cycles of this the structure optimised fully 
using microiterations, the optimised structure is shown in figure 5.4.3.1. 
 
 
 
Figure 5.4.3.1 Optimised structure of kiteplatin octamer from 1AU5 crystal structure 
starting point, optimised using ONIOM BHandH/AMBER. Low layer and water 
molecules shown as wireframe for clarity. 
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Carrying out the same calculation but from the second starting point was slightly more 
straightforward. After the initial steps of optimising sections while freezing others with 
BLYP, the first attempt at a full optimisation failed, but one use of a BHandH 
optimisation step in Cartesian coordinates gave a structure that fully optimised using 
BHandH/AMBER with microiterations and the GEDIIS algorithm. No water molecules 
were ejected in this optimisation, presumably due to the starting point being based on a 
structure that had already been optimised with this approach, therefore the waters were 
already relaxed, so there were no instances where high initial forces caused the waters 
to move to large distances. A comparison of the extrapolated ONIOM energies for the 
two optimised structures, with the explicit waters removed, shows that the first starting 
point gives a structure that is approximately 18 kcal/mol lower in energy. The optimised 
structure from the starting point in reference 9 is shown in figure 5.4.3.2. 
 
 
Figure 5.4.3.2 Optimised structure of kiteplatin octamer from reference 9 starting point, 
optimised using ONIOM BHandH/AMBER. Low layer and water molecules shown as 
wireframe for clarity. 
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To compare the two structures in figures 5.4.3.1 and 5.4.3.2, to see how sensitive the 
optimised structure is to different starting points, base pair parameters have been 
calculated using x3DNA. These values are reported below in table 5.4.3.1, with the 
parameters from the second starting point of the optimisation in parenthesis. 
 
Table 5.4.3.1 Base pair parameters for kiteplatin octamer from 1AU5 optimisation 
starting point, values in parenthesis are from reference 9 starting point (Å or ˚). 
Step Shift Slide Rise Tilt Roll Twist 
CC/GG -0.55 
(0.30) 
-0.52 
(-0.44) 
3.03 
(3.80) 
5.38 
(2.78) 
-2.28 
(5.65) 
32.37 
(44.83) 
CT/AG 0.66 
(0.50) 
-0.90 
(-1.01) 
3.76 
(3.88) 
1.49 
(1.14) 
-1.09 
(4.43) 
41.05 
(37.53) 
TG/CA -1.33 
(-1.17) 
0.31 
(1.41) 
2.94 
(2.95) 
-0.27 
(-1.90) 
-5.24 
(5.52) 
36.34 
(33.68) 
GG/CC 1.10 
(0.44) 
-0.99 
(0.25) 
2.80 
(4.03) 
-3.04 
(-2.05) 
23.56 
(50.38) 
25.27 
(15.47) 
GT/AC 1.03 
(0.35) 
-1.14 
(-0.25) 
3.71 
(2.68) 
13.94 
(-3.88) 
5.34 
(2.97) 
47.25 
(28.10) 
TC/GA 0.39 
(0.89) 
-0.60 
(-0.14) 
3.38 
(3.13) 
-3.52 
(8.40) 
7.78 
(2.88) 
29.80 
(43.73) 
CC/GG 0.17 
(0.53) 
-1.99 
(-1.79) 
3.81 
(3.76) 
3.53 
(-3.51) 
-7.70 
(10.49) 
35.72 
(26.16) 
Average 0.21 
(0.26) 
-0.83 
(-0.28) 
3.35 
(3.46) 
2.50 
(0.14) 
2.91 
(11.76) 
35.40 
(32.79) 
 
The most important base pair step to examine is that of the central GG, to which the 
platinum is coordinated as this is likely to show the greatest differences between the two 
starting points. With platinum complexes that form 1,2-intrastrand crosslinks, as 
exhibited in the adducts of interest here, the rise and roll parameters are of particular 
interest, as the platinum attempts to retain the desired square planar geometry the roll 
angle between the platinated guanines is increased and therefore the rise is increased 
too. For the starting point from the PDB the roll is 23.56 °, in comparison the second 
starting point gives a much larger roll of 50.38 °, as can be observed from the two 
structures in figures 5.4.3.1 and 5.4.3.2. Due to this the rise for the second starting point 
is also significantly larger at 4.03 Å compared to 2.80 Å for the first starting point. 
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The structures of DNA adducts that have been elucidated from experimental NMR data, 
such as 1AU5, usually result in a family of structures that all satisfy proton distances 
found. As a result of this the base pair parameters can vary for the same adduct. For the 
PDB entry 1AU5 there is only one structure reported, so to get an experimental range of 
values Gkionis9 used the PDB entry 2NQ0,13 a dodecamer with cisplatin coordinated to 
a central GG step, which reports fifteen structures, to compare the range of the values of 
the parameters of the coordinated central step. This data is reported in table 5.4.3.2. 
 
Table 5.4.3.2 Minimum and maximum values for base pair parameters from 2NQ0 
PDB structure, from reference 9. 
 Minimum Maximum Max-Min 
Shift 0.67 1.12 0.45 
Slide -2.06 -0.94 1.12 
Rise 3.90 4.61 0.71 
Tilt -3.07 -1.39 4.46 
Roll 24.44 34.45 10.01 
Twist 19.75 28.20 8.45 
 
Although there is significant difference in the central base pair step for the two 
octamers, observation of the averages of all the base pair parameters for both starting 
points show that, with the exception of roll, they are for the most part comparable, with 
relatively small differences in the distances and angles. Along with this, the data in table 
5.4.3.2, shows that parameters can actually vary by significant amounts within different 
experimental interpretations of the same structure. Even though this is the case the part 
of greatest interest still shows some stark differences, that are greater than the range in 
experiments, between the two starting points, but as systems of this size have many 
degrees of freedom it is not necessarily surprising that using two different starting 
points can result in this. The optimisation from the PDB entry starting point will be used 
for comparison in section 5.4.5, as it results in the lowest absolute energy of the two. 
 
5.4.4 Optimisation of Dodecamer Adduct 
 
After the successful optimisations of the octamer and tetramer, the significantly larger 
dodecamer, with the sequence (5'-D(CCTCTG*GTCTCC)-3'), has also been attempted. 
The starting point was constructed from the corresponding PDB entry 3LPV,14 with the 
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desired sequence and a coordinated oxaliplatin to the central GG base pair step. The 
present cyclohexane ligand was converted into 1,4-DACH by hand and sodium 
counterions were placed in the vicinity of every phosphate moiety on the DNA 
backbone, in the place of the mixed sodium and magnesium atoms present in the PDB 
structure. To solvate the adduct, a water soak was carried out using MOE to give 
seventy-nine explicit water molecules. This amount of water molecules is perhaps not as 
many as should be present, especially as the smaller octamer has a larger number, but a 
small difference in the radii of the water soaks and the removal of close contacts 
through use of a script, meant either the small amount of water used or a significant 
amount which would have increased computational time, especially as the water 
optimisation steps had proved troublesome for the smaller complexes. 
 
The same optimisation method employed above was utilised, initially optimising just 
the platinum drug and the atoms in the coordinated base pair step, using the faster, less 
accurate BLYP with the smaller basis set. The explicit water molecules were then 
optimised, although for this system an initial step using Cartesian coordinates was 
undertaken to relax the water molecules and avoid the potential issue of the solvation 
shell ‘exploding’, as seen for the octamer and tetramer, when this step was carried out 
with microiterations. The same step using microiterations was attempted from the 
structure yielded from the Cartesian optimisation, whilst there were no issues arising 
from molecules being ejected from the solvation shell, the step did not complete due to 
the microiterations failing to converge. Another cycle of Cartesian optimisation 
followed by use of microiterations was carried out giving the same result, due to this the 
structure from the Cartesian step was taken forward to be used in further steps.  
 
The low level was then optimised but with the water molecules frozen and the base pair 
step to which the platinum is coordinated frozen also, this was initially attempted with 
microiterations but as for the water set it failed to converge within the maximum set of 
cycles. Once again optimisation within Cartesian coordinates was carried out instead, 
several iterations of using Cartesian optimisations followed by microiterations were 
carried out but every microiteration step failed to fully converge. The lowest energy 
structure, from the resultant Cartesian step, was used as the starting point for full system 
optimisation where both layers are free to move, for this step BHandH was used instead 
of BLYP, with the larger basis set 6-31+G**. The issues presented above, that plagued 
the partial optimisation steps were still present, with every attempted microiterations 
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step failing to converge, from a preceding Cartesian optimisation lowest energy 
structure. Ultimately due to the increasing time taken to carry out this optimisation, after 
seven restarted Cartesian steps the forces were deemed low enough to consider the 
structure optimised, with the RMS value of 0.000215 with the threshold at 0.000300 
Hartrees/Bohr, and the maximum value at 0.003227 with the threshold at 0.000450 
Hartrees/Bohr. The optimised structure is shown in figure 5.4.4.1. 
 
 
 
Figure 5.4.4.1 Optimised structure of kiteplatin dodecamer, optimised using ONIOM 
BHandH/AMBER. Low layer shown as wireframe for clarity. 
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Table 5.4.4.1 Base pair parameters for kiteplatin dodecamer (Å or ˚). 
 Shift Slide Rise Tilt Roll Twist 
CC/GG -0.37 -2.06 3.16 1.23 7.50 26.72 
CT/AG 0.20 -1.71 3.30 1.42 5.25 29.99 
TC/GA 0.09 -1.95 3.28 -2.12 9.94 32.30 
CT/AG -0.14 -2.01 3.14 -0.25 4.76 31.54 
TG/CA -0.38 -1.38 2.92 4.10 8.12 27.07 
GG/CC 1.16 -2.15 3.01 -2.45 34.76 30.22 
GT/AC -0.32 -1.03 3.06 3.12 8.64 33.95 
TC/GA 1.11 -0.30 3.33 3.41 10.52 40.70 
CT/AG -0.31 -0.03 2.91 2.73 13.25 22.75 
TC/GA 0.32 -1.26 4.34 -8.73 11.40 45.34 
CC/GG 0.25 -0.10 2.86 3.11 -4.96 33.03 
Average 0.15 -1.27 3.21 0.51 9.93 32.15 
 
The base pair parameters for the optimised dodecamer were calculated and are reported 
above in table 5.4.4.1. As expected the central GG/CC step, where the platinum is 
coordinated, shows the greatest distortion compared to the remainder of the helix. This 
is especially prevalent in the roll parameter, which is significantly larger, at 34.76˚, than 
the other base pair steps, this is to be expected as through coordination, the ideal angle 
of the two guanines is forced larger to meet with the square planar conformation of the 
platinum, as can be seen for the other DNA adducts. 
 
5.4.5 Comparison of ONIOM Optimised Adducts 
 
To carry out a comparison between the four adducts optimised using the QM/MM 
method, several further calculations were undertaken. The binding energy of the 
platinum complex to the DNA is a good value to compare between different size of 
DNA fragments, as well as being very important when comparing a series of different 
drugs to infer which bind the most strongly. Due to this, binding energies were 
calculated for the platinum DNA adducts in the gas phase and in the aqueous phase, as 
reported in table 5.4.5.1. 
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Table 5.4.5.1 Comparison of ONIOM binding energies of kiteplatin to DNA Adducts, 
in gas phase and with PCM model (kcal/mol). 
 Gas Phase Binding Energy PCM Binding Energya 
Dimer -271.60 -33.78 (-85.10) 
Tetramer -429.79 -186.01 (-95.96) 
Octamer -473.47 -282.42 
Dodecamer -445.50 -277.24 
aValues in parenthesis are calculated using ONIOMPCM=X, whilst all others are 
calculated using ONIOMPCM=C.15 
 
To calculate the gas phase binding energies above, the explicit water molecules were 
removed from the systems, where present and three single point energy calculations 
were carried out, on the platinum complex (1), the remainder of the DNA (2), and the 
entire adduct (3), where binding energy was calculated by (3)-(2)-(1). While a 
counterpoise correction would be ideal, in the current iteration of Gaussian it is not 
possible to do a counterpoise correction on an ONIOM calculation.  
 
An implicit solvent model was chosen, instead of the already present explicit solvent 
molecules, to avoid the issue of assigning the water molecules in close proximity to the 
platinum to one of the two fragments. Differing numbers of solvent molecules close to 
the drugs between the different adducts would mean the binding energies are not 
directly comparable. For the binding energy in the aqueous phase PCM has been used to 
model the presence of water, with the use of the ONIOMPCM=C keyword.15 This 
option calculates the reaction field for only the real system at the low level whilst all 
other sub calculations are treated in the gas phase. Whilst this is not the ideal method, it 
is most efficient for calculations on the larger systems. The ONIOMPCM=X keyword, 
which calculates the reaction field for all sub calculations, would be the ideal method 
for this, but was only obtainable for the dimer and tetramer, which are reported in the 
parenthesis in table 5.4.5.1, calculations using this on the larger fragments failed to 
complete within the available timeframes. 
 
Within the gas phase binding energies the dimer has the weakest value of -271.60 
kcal/mol, there is then a relatively large increase to -429.79 kcal/mol for the tetramer. 
There are then smaller increases to -473.47 kcal/mol and -445.50 kcal/mol for the 
octamer and dodecamer respectively. Although the binding energy decreases going 
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from the octamer to dodecamer, the values still appear to be converging, which is the 
outcome expected, as beyond a point adding further base pairs will have little effect on 
the binding energy as the distance between the additional bases and platinum drug 
increases. 
 
Binding energies in the aqueous phase have a similar pattern as the gas phase, where the 
dimer is the weakest and the values start to converge as the size of the DNA adducts 
increase, also the dodecamer in this case once again has a weaker binding energy than 
the octamer. This may be erroneous due to the dodecamer having not fully optimised, 
but without carrying out calculations on the decamer or increasing the size of the 
adducts further to create a larger series of complexes, a conclusion cannot be reached. 
Although, in this relatively short series, the energies still appear to converge with 
increasing size, which was the desired outcome. 
 
For the two smallest adducts, the dimer and tetramer, it was also possible to calculate 
the binding energies with PCM modelling the reaction field for all sub calculations. For 
the dimer the value calculated this way is significantly larger than using 
ONIOMPCM=C, increasing to -85.10 kcal/mol from -33.78 kcal/mol. The opposite is 
the case for the tetramer, where there is a significant decrease to -95.96 kcal/mol from -
186.01 kcal/mol. The use of the less accurate ONIOMPCM=C method is likely the 
cause of the initial value for the dimer, which could be considered lower than expected 
at -33.78 kcal/mol, compared to those calculated using B97-D reported in table 5.3.1.3. 
 
The exposed surface areas of the platinum and DACH ligand have been calculated using 
the Molvol program,16 in the absence of the explicit water and have been reported in 
table 5.4.5.2 below. As would be expected the dimer has the largest exposed area, at 
164.22 Å2, due to having the smallest DNA fragment. As the size of the DNA increases 
in the tetramer the exposed area decreases to 135.12 Å2, as the larger DNA helix 
reduces the area of the ligand that is exposed. The octamer has the lowest exposed area 
at 120.72 Å2, whilst the dodecamer has a slightly higher value at 124.10 Å2, similar to 
what was observed for the binding energies of these adducts. As above the values start 
to converge as the size of the DNA helix increases, which is what would be expected as 
the greater size of the DNA reduces the exposed surface of the drug. 
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Table 5.4.5.2 Exposed surface area of kiteplatin in DNA complexes (Å2). 
 Exposed Area 
Dimer 164.22 
Tetramer 135.12 
Octamer 120.72 
Dodecamer 124.10 
 
A comparison of the base pair parameters of the platinated central GG step, for each of 
the adducts is reported below in table 5.4.5.3 and represented graphically in figure 
5.4.5.1. Some differences are apparent in the parameters between adducts, specifically 
roll, which ranges from 19.26 ° to 34.76 ° for the tetramer and dodecamer respectively. 
Although this a relatively large difference the remainder of the parameters are broadly 
comparable, which concludes that changing the size of the DNA fragment still results in 
fairly comparable distortion around the coordination site of the platinum drug. 
 
 
 
Figure 5.4.5.1 Graphical representation of base pair parameters for the GG base pair 
step of kiteplatin DNA complexes (Å or ˚). 
 
 
                                               Chapter 5: Platinum (II) Anti-Cancer Drugs and their Interactions with DNA 
148 
Table 5.4.5.3 Base pair parameters for the GG base pair step of kiteplatin DNA 
complexes (Å or ˚). 
 Shift Slide Rise Tilt Roll Twist 
Dimer 1.17 -1.59 3.18 -4.03 21.65 25.37 
Tetramer 0.86 -1.33 2.73 -5.52 19.26 22.89 
Octamer 1.10 -0.99 2.80 -3.04 23.56 25.27 
Dodecamer 1.16 -2.15 3.01 -2.45 34.76 30.22 
 
5.5 NMR Calculations on Kiteplatin GpG Adducts 
 
One of the most powerful techniques of structure resolution for biological systems is the 
use of nuclear magnetic resonance (NMR) spectroscopy. Through measurement of 
chemical shifts and spin-spin coupling constants within single and multi-dimensional 
NMR, structures of large biological systems can be obtained in situations where it is 
difficult to obtain crystal structure data. Quantum chemical calculations can be used in 
conjunction with these techniques, as it is possible to calculate isotropic shielding 
values for nuclei and coupling constants using DFT and a variety of other methods. 
 
5.5.1 1H NMR Shift Calculations 
 
To aid experiments being carried out by our collaborators, the calculation of certain 
NMR values was carried out for the four conformers of the GpG adduct from section 
5.2.1. The B97-D optimised structures were used as the starting points the calculation of 
the 1H isotropic shifts, which were carried out with the BP86 functional with the TZVP 
basis sets. Calculations have also been carried out with the smaller basis sets SVP and 
PCS1, as shown by Platts and Gkionis17 to be effective in modelling changes in 1H 
NMR shifts due to intermolecular interactions despite their relatively small size: these 
values are reported in the appendix. 
 
Carrying out NMR calculations gives results as isotropic shielding values for each 
nuclei, while experimental NMR gives chemical shift values, which are relative to the 
1H shielding value of tetramethylsilane (TMS). To get comparable results, calculations 
were also carried out on TMS, the structure was optimised using B97-D with the def2-
TZVP basis set, the same as used for the optimisation of the platinum DNA adducts 
being studied here. The NMR calculation was carried out within Gaussian 09 using the 
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gauge invariant atomic orbital (GIAO) method,18-22 with the BP86 functional and an 
isotropic shielding value for the protons in TMS was found at 31.34, 31.30, and 31.60 
for the basis sets SVP, PCS1, and TZVP respectively. Using the same GIAO method, 
NMR calculations were carried out on the four GpG adducts, chemical shift values were 
obtained by subtracting the isotropic shielding values from the one calculated for TMS, 
results for the TZVP basis set are reported in table 5.5.1.1, with the shifts considered 
most significant in bold. The trends are very similar for all three basis sets, with 
differences usually no greater than 0.30 ppm across all shifts. 
 
Only the shifts for the protons located on the guanine rings and sugar phosphate 
backbone have been reported as the chemical shifts of protons on the 1,4-DACH ligand 
give little structural information of the DNA, which is the part of greater interest. Some 
difference in shift would be expected for these protons, as by changing the conformation 
the local environment changes. The maximum difference across conformers is less than 
1.10 ppm and usually significantly less, therefore structural conclusions are difficult to 
ascertain from this data. 
 
The proton shifts associated with the nitrogen and oxygen atom types can be largely 
ignored as in experimental conditions solvent exchange leads to peak broadening and it 
is difficult to get exact and consistent values. In table 5.5.1.1 below, the values that are 
considered to be most significant to the structure are the protons on the C8 atoms on the 
guanines and the protons on the C1' and C2' atoms on the pentose sugars. These shifts 
will be most affected between conformers as they are closest to the part of the complex 
that changes. A graphical representation of the difference between these shifts is shown 
for the 3' end and 5' end in figures 5.5.1.1 and 5.5.1.2 respectively. 
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Table 5.5.1.1 1H NMR shifts for the protons in the DNA for the four GpG adducts, 
calculated at BP86 level with TZVP basis set and SDD basis set and ECP on Pt (ppm). 
Atom 
Typea 
End of 
DNA 
HH1 Shift HT1 Shift HH2 Shift HT2 Shift 
Backbone      
C1' 3' 6.34 6.11 5.93 6.43 
C2' 3' 2.15 2.66 2.29 3.43 
C2' 3' 2.67 2.21 0.61 2.68 
C3' 3' 5.56 3.79 4.33 5.02 
C4' 3' 3.65 4.82 3.47 4.29 
C5' 3' 4.22 2.16 4.27 3.98 
C5' 3' 4.55 4.48 4.74 4.06 
O3' 3' 2.42 7.08 5.65 0.89 
C1' 5' 7.25 6.53 7.10 6.94 
C2' 5' 3.36 3.48 4.76 3.63 
C2' 5' 2.06 3.34 1.69 2.69 
C3' 5' 4.67 4.85 4.89 4.56 
C4' 5' 4.47 3.89 4.48 3.90 
C4' 5' 4.56 4.54 4.67 4.47 
Guanine      
C8 3' 7.83 6.48 6.33 7.54 
N1 3' 6.93 7.14 7.08 7.13 
N2 3' 4.78 4.91 4.64 4.85 
N2 3' 4.21 4.34 4.21 4.29 
C8 5' 7.96 6.70 7.95 6.44 
N1 5' 7.03 7.13 6.46 7.07 
N2 5' 4.69 4.79 4.98 4.56 
N2 5' 4.18 4.34 3.97 4.21 
aAtom type is the one which the proton of interest is bonded to, with the numbering 
system shown in figure 1.2.2.2. 
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Figure 5.5.1.1 Comparison of 1H NMR shifts at the 3' end of the four GpG 
conformations (ppm). 
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Figure 5.5.1.2 Comparison of 1H NMR shifts at the 5' end of the four GpG 
conformations (ppm). 
 
The graphs in the figures above show that there is a difference between the proton shifts 
of the conformers, as expected. At the 3' end, as shown in figure 5.5.1.1, the shift for the 
proton bonded to the C8 atom is greatest for HH1, then changes by 1.32 ppm for HT1, 
this difference is also observed at the 5' end but with a smaller change of 1.13 ppm. The 
shifts for H-C8 and H-C1' have a similar trend at the same ends of the DNA, with the 
HH2 conformer being the one that differs as at the 3' end its shifts are closer to that of 
HT1, as opposed to 5' where it is comparable to HH1. The shifts of H-C1' follow a 
similar trend to those of H-C8, however the exact difference between the conformers is 
less. 
 
For the two protons bonded to C2' there is a greater difference between the conformers 
than observed with the C1' and C8, however the trends once again are similar between 
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the ends of the DNA. To conclude on the significance of this calculated data and how 
proton shifts change between conformers, comparison to experimental data is ideal and 
this work is currently being undertaken at Università degli Studi di Bari. 
 
5.5.2 13C NMR Shift Calculations 
 
Isotropic shielding values for the carbon nuclei are also of interest and have been 
calculated using the same method as above for the proton values. The SVP basis set is 
likely too small to give reasonable accuracy for the 13C nuclei, unlike the case for the 
protons, so the larger basis set TZVP has been utilised. TZVP is still not as big a basis 
set as would be desirable, but carrying out NMR calculations is very memory intensive 
and computational costs can increase steeply with large increases in the number of basis 
functions, so a trade off between accuracy and cost has to be made. The 13C isotropic 
shielding value for TMS was calculated at 183.77 for the TZVP basis set. 13C chemical 
shifts with the TZVP basis set are reported in table 5.5.2.1, where once again bold 
indicates shifts considered most significant. 
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Table 5.5.2.1 13C NMR shifts for the carbons in the DNA for the four GpG adducts, 
calculated at BP86 level with TZVP basis set and ECP on Pt (ppm). 
Atom 
Type 
End of 
DNA 
HH1 Shift HT1 Shift HH2 Shift HT2 Shift 
Backbone      
C1' 3' 87.66 97.15 91.18 100.91 
C2' 3' 40.67 41.83 45.07 45.54 
C3' 3' 74.05 78.57 75.91 81.80 
C4' 3' 95.03 93.14 93.80 101.51 
C5' 3' 68.80 71.85 67.14 70.36 
C1' 5' 96.16 97.32 97.58 100.49 
C2' 5' 41.35 38.67 39.41 37.63 
C3' 5' 85.92 84.18 85.70 86.94 
C4' 5' 79.43 82.97 82.33 83.27 
Guanine      
C2 3' 151.84 151.51 151.86 151.65 
C2 5' 151.51 151.52 152.88 151.32 
C4 3' 152.72 153.00 150.68 151.66 
C4 5' 152.82 152.99 152.85 154.76 
C5 3' 118.85 118.61 119.41 120.25 
C5 5' 119.28 119.65 122.22 123.55 
C6 3' 155.65 156.23 155.39 156.09 
C6 5' 155.28 155.43 152.52 156.53 
C8 3' 139.64 139.70 136.40 140.67 
C8 5' 142.02 142.78 138.58 147.15 
 
Once again only the shifts of the carbon nuclei within the DNA part of the adduct have 
been reported. The 13C shifts for the carbon atoms in the DACH ring have a less 
significant difference than the associated proton shifts, with a difference no greater than 
5.00 ppm. While this value is larger than the difference for the proton NMR, the overall 
range of shifts where carbon nuclei can appear is considerably larger than protons, so a 
difference of shift of this magnitude can still be considered insignificant. The 13C shifts 
deemed most significant here are those for C1', C2', and C8, from observation of the 
other values above there seems to be very little change between the four conformers, 
with most of the atom types having a change no larger than 5 ppm. A graphical 
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representation of the difference between the important shifts is shown for the 3' end and 
5' end in figures 5.5.2.1 and 5.5.2.2 respectively. 
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Figure 5.5.2.1 Comparison of 13C NMR shifts at the 3' end of the four GpG 
conformations (ppm). 
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Figure 5.5.2.2 Comparison of 13C NMR shifts at the 5' end of the four GpG 
conformations (ppm). 
 
For the shifts of the C2' nuclei there is little difference across the four conformers, at 
both ends of the DNA, so it appears changing conformation has a relatively small effect 
on the shift at this position. This also appears to be the case for C1' shifts at the 5' end, 
however there is a greater difference at the 3' end of 13.25 ppm. C8 shifts at the 3' end 
have little difference between conformers, the 5' shifts have some more variety but there 
are still no significant changes. From this data it is clear that the shifts associated with 
carbon nuclei have a much smaller dependence on the conformation than the protons. 
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Once again to get more conclusive answers this data needs to be compared to 
corresponding experimental values, which are still in the process of being obtained. 
 
5.5.3 3JHH Coupling Constant Calculations 
 
The indirect dipole dipole coupling, or J coupling, values within 1H NMR can be of 
great use in resolving structures as they can give valuable insights into dihedral angles, 
if the coupling occurs over three bonds. There is a direct relationship between the 3J 
coupling values and the dihedral angle of the two nuclei, as shown by the Karplus 
equation.23 These values have been calculated for the four GpG adducts using the BP86 
functional with the SVP and TZVP basis sets. Results are reported for the TZVP basis 
set in tables 5.5.3.1, 5.5.3.2, 5.5.3.3, and 5.5.3.4 for HH1, HT1, HH2, and HT2 
respectively. The nomenclature H- followed by the atom type to which it is bound has 
been used, where an atom has two protons they have been labelled 1H and 2H. 
  
Table 5.5.3.1 J coupling constants for HH1 conformation, calculated at the BP86 TZVP 
level (Hz). 
3' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'        
1H-C2' 8.84       
2H-C2' 1.28       
H-C3'  9.50 7.56     
H-C4'    6.51    
1H-C5'     1.30   
2H-C5'     2.64   
        
5' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'        
1H-C2' 9.11       
2H-C2' 3.53       
H-C3'  5.80 0.35     
1H-C4'    5.74    
2H-C4'    0.96    
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Table 5.5.3.2 J coupling constants for HT1 conformation, calculated at the BP86 TZVP 
level (Hz). 
3' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'        
1H-C2' 5.21       
2H-C2' 0.12       
H-C3'  8.27 6.22     
H-C4'    4.68    
1H-C5'     6.63   
2H-C5'     8.43   
        
5' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'        
1H-C2' 3.76       
2H-C2' 8.63       
H-C3'  1.29 3.52     
1H-C4'    3.21    
2H-C4'    0.02    
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Table 5.5.3.3 J coupling constants for HH2 conformation, calculated at the BP86 TZVP 
level (Hz). 
3' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'        
1H-C2' 2.57       
2H-C2' 7.96       
H-C3'  8.77 8.64     
H-C4'    6.89    
1H-C5'     0.40   
2H-C5'     4.55   
        
5' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'        
1H-C2' 8.39       
2H-C2' 4.64       
H-C3'  6.24 0.36     
1H-C4'    5.44    
2H-C4'    0.81    
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Table 5.5.3.4 J coupling constants for HT2 conformation, calculated at the BP86 TZVP 
level (Hz). 
3' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'        
1H-C2' 4.72       
2H-C2' 7.57       
H-C3'  0.55 5.21     
H-C4'    0.04    
1H-C5'     1.62   
2H-C5'     2.02   
        
5' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'        
1H-C2' 6.33       
2H-C2' 7.44       
H-C3'  0.52 5.17     
1H-C4'    3.08    
2H-C4'    0.15    
 
The trends between the SVP and TZVP basis sets used are the same for the coupling 
constants, but the difference between the values is not consistent for the two of them. 
The values calculated using the larger basis set, TZVP, which can be assumed to give 
the more accurate results, have been reported. The coupling constants calculated using 
the SVP basis set are reported in the appendix. 
 
The coupling constants calculated above can be used to give structural insight into the 
pentose sugars of the sugar phosphate backbone of DNA. Due to steric hindrance the 
five membered rings cannot be planar, so one of the atoms moves out of the plane, 
which atom does this and in which direction has a dramatic effect on the overall 
structure of DNA, giving rise to the A and B types of DNA. For the four GpG 
complexes studied here, the C1'-O4'-C4' atoms always remain in the plane and C2' or 
C3' puckers out of the fixed plane. If the sugar puckers toward the O5' atom on the 
backbone this is endo puckering, while the opposite direction, toward O3', is exo 
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puckering. Information on which type of puckering is occurring is reported in table 
5.5.3.5 and diagrams of the pentose sugars in the four complexes are shown in figure 
5.5.3.1. 
  
HH1 3' end HH1 5' End 
  
HT1 3' End HT1 5' End 
  
HH2 3' End HH2 5' End 
  
HT2 3' End HT2 5' End 
Figure 5.5.3.1 Diagrams showing pentose sugars of kiteplatin GpG complexes along 
the plane C1'-O4'-C4', remainder of complexes shown as wireframe for clarity. 
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Table 5.5.3.5 Endo/exo puckering of pentose sugars of kiteplatin GpG complexes. 
 DNA End Atom out of Plane Geometry 
HH1 3' C3' Endo 
 5' C2' Endo 
HT1 3' C2' Exo 
 5' C2' Endo 
HH2 3' C3' Endo 
 5' C2' Endo 
HT2 3' C2' Endo 
 5' C3' Exo 
 
From the data in table 5.5.3.5 and figure 5.5.3.1, the most common type of sugar pucker 
is C2’ endo, which is present for all four conformers. This type of puckering is the one 
observed in B-DNA, so it is not unexpected to be the most common, as the original 
adduct was constructed from a PDB structure of this type of DNA. Both HH 
conformers, at the 3’ end, however have a C3’ endo pucker, which is more commonly 
observed in A-DNA.  They also have similar coupling constants for H-C4’ and H-C3’, 
with a difference of 0.38 Hz The HT conformers, at the 3’ end, have a significantly 
different corresponding coupling constant, with values of 4.68 Hz and 0.04 Hz for HT1 
and HT2 respectively. HT1 at 3’ has a C2’ exo pucker and HT2 has a C2’ endo, their 
difference in structure is the result of this change in coupling constant, also for sugars 
that pucker at the C2’ position, coupling constants between protons of C4’ and C3’ will 
be of less significance. The C3’ to C2’ coupling constants for the two HT conformers 
greatly differ, at 8.27/6.22 Hz and 0.55/5.21 Hz for HT1 and HT2 respectively, due to 
HT1 being exo and HT2 endo, a similar effect can be observed for the C1’- C2’ 
couplings. 
 
Three of the four conformers have a C2’ endo pucker at the 5’ end, with HT2 being the 
exception. The coupling between protons on C2’ - C3’ are in reasonable agreement for 
the HH conformers, with values of 5.80/0.35 Hz and 6.24/0.36 Hz for HH1 and HH2 
respectively, however the values HT1 differ at 1.29/3.52 Hz. This leads to the 
conclusion that coupling constants for protons on the carbon atom that puckers are 
comparable when the same type of puckering is occurring, but only within the same 
conformation, as can be seen by the difference in head to head and head to tail coupling 
constants when they both have C2’ endo sugar pucker. To be able to get more 
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conclusive relationships between coupling constants and DNA structure, for these cases, 
NMR data from experiments being carried out needs to accompany the data from the 
calculations in this section. 
 
5.5.4 Effect on NMR Calculations of DNA Termination 
 
For calculations regarding small DNA fragments a choice of where to terminate the 
sugar phosphate backbone has to be made while creating the starting structure for 
further optimisations. For the four GpG adducts this was carried out by terminating the 
3' end at the O3' atom with an additional hydrogen, and terminating the 5' end at the C4' 
with an additional hydrogen. The justification for terminating the 5' end this way was 
that having a relatively free moving -CH2OH moeity instead would have little structural 
effect on the rest of the backbone or the overall optimisation and as there is a CH2 
between the pentose sugar and the O5' atom, there would be negligible effects on the 
electronics of the ring. Also terminating this way reduces the number of basis functions 
and gives fewer geometrical degrees of freedom, which will lead to a slight increase in 
computational speed.  
 
The experimental results obtained for these structures were taken with the additional 
methylene at the C5' position. To check if the addition of this group has a significant 
effect on the calculated NMR values, beyond the C4' atom at the 5' end, a comparison of 
the HH1 structure has been carried out. The B97-D optimised HH1 structure was 
modified by hand to add a -CH2OH at the C4' position and the structure was then 
optimised using B97-D, the same NMR calculations as carried out above were then 
carried out on the newly optimised structure. A graphical comparison of some of the 
important 1H shifts at the BP86/SVP level is shown in figure 5.5.4.1 and 13C shifts at the 
BP86/TZVP level in figure 5.5.4.2. 
 
                                               Chapter 5: Platinum (II) Anti-Cancer Drugs and their Interactions with DNA 
162 
6
6.5
7
7.5
8
3' H-C1' 5' H-C1' 3' H-C8 5' H-C8
C4'-H Terminated
C4'-C5'-O5'-H Terminated
 
Figure 5.5.4.1 A comparison of 1H NMR shifts for HH1 terminated with -H and -
CH2OH, at the C4' position (ppm). 
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Figure 5.5.4.2 A comparison of 13C NMR shifts for HH1 terminated with -H and -
CH2OH, at the C4' position (ppm). 
 
The full list of 1H and 13C shifts are reported in the appendix, but a comparison between 
the two ways of terminating is shown in figures 5.5.4.1 and 5.5.4.2, for some of the 
shifts deemed most important, those of the C8 and C1' carbon and protons. In both 
graphs there is significant overlap of the lines, which clearly indicates that changing the 
termination site has little to no effect on these shifts, the only one with any real visible 
difference is the 5' H-C8 shift, which has a small difference of 0.19 ppm. As it is clear 
that the calculated NMR shifts at these sites have little dependence on where the 5' end 
is terminated, a similar comparison has been done for the 1H and 13C shifts on the 
pentose sugar. The comparison for the 1H shifts for the 5' pentose sugar are shown in 
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figure 5.5.4.3 and the 13C shifts in figure 5.5.4.4. A comparison for the 3J couplings of 
the protons, calculated at the BP86/TZVP level, at the 5' end is reported in table 5.5.4.1. 
 
0
1
2
3
4
5
6
7
8
5' H-C1' 5' 1H-C2' 5' 2H-C2' 5' H-C3' 5' H-C4'
C4'-H Terminated
C4'-C5'-O5'-H Terminated
 
Figure 5.5.4.3 A comparison of 1H NMR shifts of 5' pentose sugar for HH1 terminated 
with -H and -CH2OH, at the C4' position (ppm). 
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C4'-C5'-O5'-H Terminated
 
Figure 5.5.4.4 A comparison of 13C NMR shifts of 5' pentose sugar for HH1 terminated 
with -H and -CH2OH, at the C4' position (ppm). 
 
Both graphs, in figures 5.5.4.3 and 5.5.4.4, show that there is little difference in shifts 
for the protons and carbons of the C1' and C2' atoms. For the shifts of C3' some 
difference can be observed but the only significant differences on both are for the C4' 
atom. This confirms that terminating the 5' end at C4' with a hydrogen is suitable for 
calculating isotropic shieldings, with the exception of the C4' atom of which it is bound 
to.  
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Table 5.5.4.1 A comparison of the J coupling constants for 5' pentose sugar for HH1 
terminated with -H and -CH2OH, at the C4' position, calculated at the BP86/TZVP level 
(Hz). 
-C4'-C5'-O5'-H Termination      
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'        
1H-C2' 9.23       
2H-C2' 3.33       
H-C3'  6.07 0.35     
H-C4'    1.47    
1H-C5'     8.59   
2H-C5'     2.22   
        
-C4'-H Termination       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'        
1H-C2' 9.11       
2H-C2' 3.53       
H-C3'  5.80 0.35     
1H-C4'    0.96    
2H-C4'    5.74    
 
A comparison of the data in table 5.5.4.1, leads to the same conclusion as that of 
comparing the proton and carbon NMR shifts. The coupling constants for the protons on 
the pentose sugar at the 5’ end are comparable, for the values associated with C1’, C2’, 
and C3’, for the two different terminations, with the largest difference of 0.27 Hz, for 
the value between H-C3’ and 1H-C2’. The coupling constants associated with C4’ do 
differ between -H and -CH2OH, but this is expected as a proton has been removed from 
that atom in the latter case and there are additional couplings with protons on the added 
C5’ atom. This likely gives rise to the larger difference, of 0.51 Hz between H-C3’ and 
H-C4’. The effect on the sugar puckering has also been tested, with diagrams shown in 
figure 5.5.4.5. 
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-C4'-H Terminated -C4'-C5'-O5'-H Terminated 
 
Figure 5.5.4.5 Diagrams showing 5' pentose sugars of HH1 terminated with -H and -
CH2OH at C4', along the plane C1'-O4'-C4', remainder of complexes shown as 
wireframe for clarity. 
 
The pentose sugars, shown in figure 5.5.4.5, both have the same puckering, regardless 
of termination site. Both exhibit C2’ endo puckering, with some distortion causing C3’ 
to also be out of the plane, albeit by a marginal amount. This effect is slightly more 
prevalent in the sugar terminated by -CH2OH, but this can likely be attributed to the 
addition of this extra functional group. 
 
A comparison of calculated 1H and 13C NMR shifts, along with 3JHH coupling constants, 
show that by choosing to terminate the DNA at the 5’ end with a proton on the C4’ 
atom, instead of -CH2OH, has little to no effect on values associated to atoms further 
than one bond away. For the HH1 GpG 1,4-DACH Pt complex, the sugar puckering is 
also the same in both cases of termination and from visual observation of the whole 
structures in figure 5.5.4.5 it is also clear that there is little change to the overall 
geometry. As a result of this the calculations carried out on the remaining conformers 
above, all terminated with a proton at C4’, can be assumed to be accurate to those if the 
termination was changed to the more biologically correct -CH2OH, with the exception 
of value for the C4’ atom and to a much lesser extent the C3’ atom. 
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Chapter 6: Conclusions 
 
The work presented in this thesis summarises the efforts at modelling intra- and inter-
molecular non-covalent interactions of organometallic transition metal complexes. 
Several of the complexes were chosen as they have shown the potential to act as 
antitumour agents and for these interactions with differing sizes of DNA adducts have 
been explored. This was achieved using a variety of DFT and QM/MM approaches and 
where available calculations have been validated by experimental data and high level ab 
initio benchmark calculations. 
 
The interactions of two test transition metal complexes, namely ferrocene and 
6(C6H6)Cr(CO)3, with methane and benzene have been probed. Intermolecular 
complexes were constructed to represent the T-shaped methane...benzene interactions 
and several of the conformations of the benzene dimer, to model a variety of CH...π and 
π...π interactions. Two DFT methods were tested for their suitability at modelling the 
energies of non-covalent interactions in these systems, BHandH, a hybrid functional 
that has shown promise in similar applications and B97-D, a pure functional with an 
empirical dispersion correction. Both of these methods were benchmarked against two 
ab initio methods, DF-LMP2 and CBS(T), where the latter is considered the most 
accurate approach possible for systems of the size studied here. Results were in good 
agreement for all four approaches with the exception of the parallel displaced 
complexes, which had larger differences but were still in reasonable agreement. When 
testing the suitability of using both DFT functionals for optimisation of complexes 
containing non-covalent interactions, both gave comparable structures and fixed scans 
at the BHandH and DF-LMP2 levels show that this DFT method gives equilibrium 
distances comparable to the higher level method. 
 
With the suitability of BHandH and B97-D ascertained, similar intermolecular 
interactions of the ruthenium arene complex of the form [6(C6H6)Ru(en)Cl]+ with 
methane and benzene were studied. The ab initio method MP2(0.25) was also utilised 
and all three methods were in good agreement, showing that C-H...π complexes in 
which the Ru-arene acts as a hydrogen bond acceptor have binding energies and 
geometries similar to those of the free benzene. In contrast, -stacking interactions of 
the coordinated arene are found to be 7 to 8 kcal/mol stronger than those in the benzene 
dimer (ca. 2.5 kcal/mol). Similarly, the inverted-T form in which the Ru-arene acts as a 
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hydrogen bond donor to the -system of benzene is stronger again. The increased 
strength of these interactions is shown to be due to more favourable electrostatics as 
well as significantly increased dispersion forces. In the latter case, formation of N-H... 
as well as C-H... interactions plays a role in stabilisation, as demonstrated by QTAIM 
analysis. 
 
These ruthenium arene complexes of the general form [6(arene)Ru(en)Cl]+ have been 
shown to have potential anticancer activity, so were further studied with a series of 
extended aromatic and partially saturated arene ligands. Intramolecular interactions 
occurring when these complexes bond to the DNA nucleobases adenine and guanine, 
have been modelled and used to test the suitability of a variety of hybrid DFT, pure 
DFT, and post Hartree-Fock methods, with a focus on confirming whether using the 
GGA functional B97 with an empirical dispersion correction of the type D2, was 
suitable to calculate binding energies within transition metal complexes, in light of 
recent publications using the newer D3 correction. Comparing against benchmark DF-
LMP2, that has been further warranted by calculation of selected DF-LCCSD values, 
the best methods were found to be BHandH, B97-D2, and MP2(0.25), with wB97-D, 
B2PLYPD, and B97-D3 also performing adequately, but not to the desired level of 
accuracy. Through this analysis of the B97-D2 binding energies and through 
comparison to higher level methods, it been shown that this method suitably reproduces 
values of significantly more expensive calculations. 
 
The ruthenium arene guanine/adenine complexes were expanded upon by increasing 
DNA to a GpC·CpG base pair step, where the extended arenes have the potential to act 
as intercalators. Geometry optimisation using B97-D allowed the importance of these 
interactions to be determined as well as any hydrogen bonds between coordinated N-H 
groups to potential acceptors on DNA. Sensitivity of binding energies to the nature of 
the arene groups was found, such that larger and more flexible arenes are able to form 
more stabilising interactions with DNA bases. The need for flexibility to maximise 
interactions is shown by the relatively low binding energy of the anthracene complex, 
whereas dihydro- and tetrahydro-anthracene bind particularly strongly. The importance 
of non-covalent interactions between arene and DNA bases was demonstrated by 
QTAIM analysis, in which larger numbers of -stacking and C—H... hydrogen 
bonding critical points are found for the more strongly bound complexes. The 
anomalously strong binding of the benzene complex is due to the detailed electronic 
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structure of this complex, which has a much lower energy LUMO than the others 
considered. This is most evident from complexes in which DNA is in its canonical B- 
form, with the arene pointing out from the double helix. The energy difference between 
the intercalated and canonical forms also highlights the importance of non-covalent 
interactions in the former. 
 
Platinum anticancer drugs have also been explored, with a particular focus on the 
relatively new complex kiteplatin, which contains an isomeric form of the 
diaminocyclohexane ligand of oxaliplatin. Adducts of this drug with GpG were studied 
and conformational searches carried out using relaxed scans with the semi-empirical 
method PM6 to ascertain four possible conformations. These conformations were 
studied using PM6-DH2 and B97-D, and results compared against analogous 
calculations on cisplatin and oxaliplatin. To aid assignment of experimental data, 1H 
isotropic shielding values, 13C isotropic shielding values, and 3JHH coupling constants 
have been calculated at the BP86 level, for kiteplatin GpG adducts. The type of sugar 
puckering occurring on the pentose sugars of the DNA backbone was also recorded and 
related to calculated coupling constants. 
 
Larger adducts of kiteplatin, cisplatin, and oxaliplatin with DNA have also been 
modelled using B97-D, including the base pair step GpG·CpC. Base pair parameters for 
these adducts have shown that in general the nucleobases are in similar conformations, 
however torsional parameters of the sugar phosphate backbone show some disparity 
between oxaliplatin and kiteplatin/cisplatin. Binding energies show that cisplatin is most 
strongly bound in the gas phase and with an implicit solvent model, whilst oxaliplatin 
and kiteplatin are comparable and give interaction energies approximately 34 kcal/mol 
and 7 kcal/mol weaker in the gas phase and solvent phase respectively. 
 
Throughout this work the B97-D functional has been used to great effect in optimising 
relatively large systems and calculating interaction energies, but to model larger than 
the base pair steps using this method would pose major problems. For the larger systems 
studied, namely kiteplatin adducts with a tetramer, octamer, and dodecamer, the 
QM/MM approach was used. Optimisation of these adducts with explicit water 
molecules was achieved using ONIOM to combine BHandH with AMBER molecular 
mechanics. This approach was also used for the base pair step and results compared 
against those calculated using only DFT. Whilst there were some noticeable differences 
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in base pair parameters, including a sign change between shift and tilt, and a relatively 
large increase of 0.28 Å in rise, the methods do give broadly similar structures. ONIOM 
calculated binding energies for the set of adducts show that the energies converge as the 
size of the DNA fragment increases, with a large increase in strength of interaction 
between the dimer and tetramer, -271.60 kcal/mol and -429.79 kcal/mol respectively, 
while this change decreases significantly to the octamer with a binding energy of -
473.47 kcal/mol. This trend is also exhibited in the calculated exposed surface areas of 
kiteplatin in the adducts. The base pair parameters around the central platinated 
guanines for all the adducts were also compared and exhibit some differences, 
particularly in the range of values for the roll parameter. Despite this difference the 
remainder of the parameters are broadly comparable, concluding that changing the size 
of DNA fragment still results in fairly comparable distortion around the coordination 
site of the drug. 
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Chapter 7: Appendix 
 
7.1 Appendices for Chapter 3 
 
Table 7.1.1 Binding energies of ruthenium arene complexes with guanine after 
reoptimisation (kcal/mol). 
 B97-D2 BHandH MP2(0.25) DF-LMP2 
Benz -93.03 -97.50 -90.84 -94.48 
Cym -85.92 -91.62 -85.29 -89.58 
Bip -85.83 -93.13 -87.81 -93.19 
Anth -80.45 -87.08 -82.35 -87.02 
Dha -91.50 -95.43 -91.35 -96.76 
Tha -90.64 -96.80 -90.78 -96.24 
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7.2 Appendices for Chapter 5 
 
Table 7.2.1 1H NMR shifts for the protons in the DNA for the four GpG adducts, 
calculated at BP86 level with SVP basis set and ECP on Pt  (ppm). 
Atom 
Typea 
End of 
DNA 
HH1 Shift HT1 Shift HH2 Shift HT2 Shift 
Backbone      
C1' 3' 6.07 5.88 5.69 6.19 
C2' 3' 1.96 2.53 2.23 3.24 
C2' 3' 2.57 2.04 0.54 2.63 
C3' 3' 5.36 3.76 4.27 4.89 
C4' 3' 3.42 4.66 3.27 4.18 
C5' 3' 4.14 2.06 4.16 3.81 
C5' 3' 4.36 4.30 4.65 3.80 
O3' 3' 2.08 6.69 5.35 0.62 
C1' 5' 7.08 6.19 7.03 6.64 
C2' 5' 3.24 3.18 4.66 3.45 
C2' 5' 1.82 3.09 1.50 2.57 
C3' 5' 4.44 4.56 4.60 4.32 
C4' 5' 4.32 3.80 4.42 3.86 
C4' 5' 4.52 4.39 4.46 4.32 
Guanine      
C8 3' 7.60 6.28 6.04 7.23 
N1 3' 6.74 6.88 6.86 6.88 
N2 3' 4.61 4.73 4.49 4.68 
N2 3' 4.15 4.24 4.16 4.23 
C8 5' 7.59 6.46 7.57 6.16 
N1 5' 6.78 6.90 6.27 6.83 
N2 5' 4.49 4.61 4.76 4.40 
N2 5' 4.10 4.26 3.92 4.13 
aAtom type is the one which the proton of interest is bonded to 
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Table 7.2.2 1H NMR shifts for the protons in the DNA for the four GpG adducts, 
calculated at BP86 level with PCS1 basis set and ECP on Pt (ppm). 
Atom 
Typea 
End of 
DNA 
HH1 Shift HT1 Shift HH2 Shift HT2 Shift 
Backbone      
C1' 3' 6.42 6.17 5.96 6.46 
C2' 3' 2.20 2.81 2.47 3.46 
C2' 3' 2.86 2.25 0.83 2.84 
C3' 3' 5.68 3.88 4.52 5.14 
C4' 3' 3.63 4.96 3.42 4.38 
C5' 3' 4.40 2.26 4.43 4.01 
C5' 3' 4.61 4.63 4.87 3.99 
O3' 3' 2.62 7.26 5.85 1.16 
C1' 5' 7.27 6.50 7.28 6.91 
C2' 5' 3.43 3.51 4.97 3.69 
C2' 5' 2.05 3.32 1.72 2.78 
C3' 5' 4.67 4.82 4.85 4.58 
C4' 5' 4.66 4.12 4.72 4.17 
C4' 5' 4.83 4.63 4.82 4.61 
Guanine      
C8 3' 7.85 6.56 6.37 7.49 
N1 3' 6.95 7.07 7.09 7.10 
N2 3' 4.88 4.98 4.76 4.95 
N2 3' 4.46 4.55 4.47 4.54 
C8 5' 7.81 6.75 7.86 6.47 
N1 5' 6.98 7.10 6.51 7.07 
N2 5' 4.75 4.87 5.06 4.67 
N2 5' 4.41 4.57 4.25 4.46 
aAtom type is the one which the proton of interest is bonded to 
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Table 7.2.3 J coupling constants for HH1 conformation, calculated at the BP86 SVP 
level (Hz). 
3' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'               
1H-C2' 6.82       
2H-C2' 0.89       
H-C3'  7.27 5.76     
H-C4'    4.96    
1H-C5'     1.03   
2H-C5'     1.76   
        
5' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'        
1H-C2' 7.06       
2H-C2' 2.03       
H-C3'  4.43 0.23     
1H-C4'    4.32    
2H-C4'    0.54    
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Table 7.2.4 J coupling constants for HT1 conformation, calculated at the BP86 SVP 
Level (Hz). 
3' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'               
1H-C2' 4.15             
2H-C2' 0.03            
H-C3'   6.34 4.47         
H-C4'       3.59       
1H-C5'         5.04     
2H-C5'         6.33    
        
5' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'              
1H-C2' 2.41            
2H-C2' 6.56           
H-C3'   1.11 2.54        
1H-C4'       2.19      
2H-C4'       -0.15     
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Table 7.2.5 J coupling constants for HH2 conformation, calculated at the BP86 SVP 
level (Hz). 
3' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'          
1H-C2'  1.93         
2H-C2' 5.74         
H-C3'  6.63 6.62       
H-C4'    5.26      
1H-C5'     0.32     
2H-C5'     3.42    
        
5' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'        
1H-C2' 6.43       
2H-C2' 2.97       
H-C3'  4.68 0.24     
1H-C4'    3.96    
2H-C4'    0.44    
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Table 7.2.6 J coupling constants for HT2 conformation, calculated at the BP86 SVP 
level (Hz). 
3' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' H-C4' 1H-C5' 2H-C5' 
H-C1'          
1H-C2' 3.06         
2H-C2' 5.68         
H-C3'  0.45 3.70       
H-C4'    -0.11      
1H-C5'     1.03     
2H-C5'     1.55    
        
5' DNA End       
 H-C1' 1H-C2' 2H-C2' H-C3' 1H-C4' 2H-C4'  
H-C1'        
1H-C2' 4.48       
2H-C2' 5.62       
H-C3'  0.38 3.75     
1H-C4'    2.06    
2H-C4'    0.02    
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Table 7.2.7 A comparison of the 1H NMR shifts for the protons in the DNA for HH1 
terminated with a -H and -CH2OH, at the C4' position, calculated at BP86 level with 
SVP basis set and ECP on Pt (ppm). 
Atom Typea End of DNA -C4'-H Terminated 
HH1 Shift 
-C4'-C5'-O5'-H 
Terminated HH1 Shift 
Backbone    
C1' 3' 6.07 6.08 
C2' 3' 1.96 2.59 
C2' 3' 2.57 1.94 
C3' 3' 5.36 5.37 
C4' 3' 3.42 3.46 
C5' 3' 4.14 4.34 
C5' 3' 4.36 4.21 
O3' 3' 2.08 2.22 
C1' 5' 7.08 7.15 
C2' 5' 3.24 1.61 
C2' 5' 1.82 3.34 
C3' 5' 4.44 3.79 
C4' 5' 4.32 4.92 
C4' 5' 4.52  
C5' 5'  3.83 
C5' 5'  3.87 
O5' 5'  0.15 
Guanine    
C8 3' 7.60 7.62 
N1 3' 6.74 6.75 
N2 3' 4.61 4.61 
N2 3' 4.15 4.15 
C8 5' 7.59 7.78 
N1 5' 6.78 6.79 
N2 5' 4.49 4.48 
N2 5' 4.10 4.06 
aAtom type is the one which the proton of interest is bonded to 
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Table 7.2.8 A comparison of the 13C NMR shifts for the carbons in the DNA for HH1 
terminated with a -H and -CH2OH, at the C4' position, calculated at BP86 level with 
TZVP basis set and ECP on Pt (ppm). 
Atom Type End of DNA -C4'-H Terminated 
HH1 Shift 
-C4'-C5'-O5'-H 
Terminated HH1 
Shift 
Backbone    
C1' 3' 87.66 87.50 
C2' 3' 40.67 41.17 
C3' 3' 74.05 73.86 
C4' 3' 95.03 94.48 
C5' 3' 68.80 68.73 
C1' 5' 96.16 96.38 
C2' 5' 41.35 42.04 
C3' 5' 85.92 87.80 
C4' 5' 79.43 92.36 
C5' 5'  71.52 
Guanine    
C2 3' 151.84 152.19 
C2 5' 151.51 151.60 
C4 3' 152.72 156.04 
C4 5' 152.82 155.25 
C5 3' 118.85 118.39 
C5 5' 119.28 119.18 
C6 3' 155.65 152.36 
C6 5' 155.28 152.78 
C8 3' 139.64 139.41 
C8 5' 142.02 141.39 
 
 
 
